 
 
 
 
 
 
Phase I/II Trial of Ruxolitinib in Combination with Trastuzumab in 
Metastatic HER2 Positive Breast Cancer  
 
 
 
Version: September 19, 2019  
National Clinical Trial Identifier : [STUDY_ID_REMOVED]   
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 1 of 96 
 Local Protocol#:  AAAM1906   
TITLE:   Phase I/II Trial of Ruxolitinib in Combination with 
Trastuzumab in Metastatic HER2 Positive Breast Cancer   
Coordinating Center:    Columbia University Medical Center   
Principal Investigator:     Kevin Kalinsky, MD  
                                                 161 Fort Washington Avenue, Room 1069  
               New York, NY 10032  
               Phone 212 -305-1945/Fax 212 -305-0178 
               E-mail: kk2693@columbia.edu   
 
Site Principal Investigator and Contact Information:  
Columbia Presbyterian Medical Center  
Kevin Kalinsky, MD, MS  
161 Fort Washington Ave, NY, NY 10032  
Phone: 212 -305-1945  
Email: kk2693@columbia.edu ; mm2058@columbia.edu  
Montefiore Medical Center  
Della Makower, MD  
1695 Eastchester Rd, Bronx, NY 10461  
Phone: 718-405-8529  Email: dmakower@montefiore.org  
Mount Sinai Medical Center  
Amy Tiersten, MD  
1 Gustave L. Levy Place, Box 1079, NY, NY 10029  
Phone: 212 -241-2299 Email: amy.tiersten@mssm.edu   
New York Hospital  
Tessa Cigler , MD  
Weill Medical College -Cornell, 425 E. 61st Street, 8th Floor, 
NY, NY 10065  
Phone 212-821-0644 Email: elc2007@med.cornell.edu   
Statistician:  
Shing Lee, PhD  
Department of Biostatistics   
Mailman School of Public Health   
722 West 168th Street, 6th Floor  
New York, New York 10032  
Tel: 212-305-9398  
Email: sml2114@columbia.edu     
Incyte-Supplied Agent(s):  Ruxolitinib (Jakafi), INCB018424, INC424 , Incyte  
Other Agent(s):  Trastuzumab (Herceptin), NSC 688097, Commercial   
  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 2 of 96 
 SYNOPSIS  
 
Phase I/II Trial of Ruxolitinib in Combination with Trastuzumab in Metastatic HER2 
Positive Breast Cancer (32 -40 patients)  
 
Patient Selection (see section 3 for complete eligibility criteria)  
1. HER2+ Metastatic Breast Cancer  
2. Patients must have received at least two lines of HER2 -directed t herapy in the metastatic 
setting, and prior therapy for metastatic disease should include both pertuzumab and ado -
trastuzumab unless contraindicated or declined by the patient.  
3. ECOG performance status 0 -2 
4. Measurable or non -measurable disease  
5. Adequate bone marrow and organ function  
6. Left Ventricular Ejection Fraction > 50%   
7. No prior history of IL -6, JAK or STAT inhibitor, such as ruxolitinib  
8. No HIV+ or active infection  
9. No concurrent medications that are potent CYP3A4 inhibitors or inducers  
 
Phase I (n=10: Section 5) : The dose of t rastuzumab will be fixed at 6 mg/kg every 3 weeks 
(with 8 mg/kg initial re -load if no trastuzumab in > 28 days). The dose levels of r uxolinitib:  
 
Dose Level  Ruxolitinib Dose  
1 25 mg bid  
0 20 mg bid  
-1 15 mg bid  
-2 10 mg bid  
The maximum tolerated dose (MTD) combination is defined as the dose combination associated 
with a target probability of dose limiting toxicity of 0.25. The MTD will be estimated using the 
time-to-event continual reassessment method (TITE -CRM) as detailed in Section 13.  
 
Phase II (n=30 evaluable pts: Section 5):  Recommended phase II dose of r uxolitinib (oral bid 
dosing) plus t rastuzumab 6 mg/kg every 3 w eeks (cycle = 21 days).  If no t rastuzumab > 28 days, 
patients will be initially re -loaded at 8 mg/kg, then 6 mg/kg . Pts treated in Phase I at recommended 
Phase II dose will be considered evaluable.  
Design: Non-randomized, open -label trial  
Stratification:  Hormone Receptor Status (+/ -) 
 
Evaluations  
Disease Assessment:  
CT chest, abdomen, and pelvis plus (OR) PET/CT will be obtained every 3 cycles ( 9 weeks of 
treatment +/- 4 days, allowing for protocol specified dose delays ).  Baseline bone scan required in 
all patients and will be performed every 3 cycles as clinically indicated . If patients have known 
brain metastases and are eligible for this trial, a head CT or brain MRI MUST be performed along 
with systemic imaging.  If a patient does not have known brain metastases and is asymptomatic, no 
baseline brain imaging is required.  
Blood: Samples  will be obtained for biomarker analysis  pre-treatment, on -treatment on cycle 2 day 
1, and then at progression  
Tumor Tissue: Pre -treatment biopsies from archival tissue or new biopsy, prior to cycle 2 day 1, 
and upon progression of disease will be discuss ed with pts with accessible disease (Optional)  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 3 of 96 
 Table of Contents  
1. OBJECTIVES  ................................ ................................ ................................ ..........6 
1.1 Primary Objectives  ................................ ................................ .................  6 
1.2 Secondary Objectives  ................................ ................................ ............. 6 
1.3 Exploratory Objectives  ................................ ................................ .......... 6 
2. BACKGROUND  ................................ ................................ ................................ .....6 
2.1 HER2 Overexp ressed Breast Cancer  ................................ .....................  6 
2.2 Trastuzumab  ................................ ................................ ...........................  6 
2.3 Incyte-Supplied Investigational Drug  ................................ ....................  7 
2.3.1  Ruxolitinib  ................................ ................................ .................  7 
b. Non-Clinical Pharmacology  ................................ ....................  7 
c. Animal Toxicity  ................................ ................................ ........ 8 
2.4 Rationale  ................................ ................................ ..............................  13 
2.5 Preliminary Results  ................................ ................................ .............. 14 
2.5.1  Target Validation  ................................ ................................ ..... 14 
Target Modulation  ................................ ................................ ............. 15 
2.6 Correlative Studies Background  ................................ ..........................  17 
2.6.1  Transcriptional Profiling  ................................ ..........................  17 
2.6.2  Reverse Phase Proteomic Array (RPPA)  ................................ . 17 
3. PATIENT SELECTION  ................................ ................................ ........................ 18 
3.1 Inclusion Criteria  ................................ ................................ .................  18 
3.2 Exclusion Criteria  ................................ ................................ ................  19 
4. REGISTRATION PROCEDURES  ................................ ................................ .......20 
5. TREATMENT PLAN  ................................ ................................ ............................ 24 
5.1 Agent Administration  ................................ ................................ ........... 24 
5.2 General Concomitant Medication and Supportive Care Gui delines .... 25 
5.3 Duration of Therapy  ................................ ................................ ............. 25 
5.4 Duration of Follow Up  ................................ ................................ ......... 26 
5.5 Criteria for Removal from Study  ................................ .........................  26 
6. DOSING DELAYS/DOSE MODIFICATIONS ................................ .................... 26 
6.1 Management of Cardiac Toxicity  ................................ ........................  28 
6.2 Asymptomatic Decrease in LVEF (Left Ventricular Ejection 
Fraction) ................................ ................................ ...............................  29 
6.3 Symptomatic Decrease in LVEF  ................................ .........................  29 
6.4 Cardiac Ischemia/ Infarction  ................................ ................................  29 
6.5 Arrhythmia  ................................ ................................ ...........................  30 
6.6 Management of Corrected QTc Prolongation  ................................ ...... 30 
6.7 Management of Trastuzumab Infusion Reaction  ................................ . 30 
7. ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS  ................ 30 
7.1 Comprehensive Adverse Events and Potential  Risks List  ...................  31 
7.2 Definitions and Reporting  ................................ ................................ .... 36 
7.2.1  Dose Limiting Toxicity (DLT)  ................................ ................  36 
7.2.2  Adverse Event (AE)  ................................ ................................ . 36 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 4 of 96 
 7.2.3  Serious adverse event (SAE)  ................................ ...................  37 
7.2.4  Unanticipated Problem ................................ .............................  38 
7.2.5  Suspected Adverse Reaction  ................................ ....................  38 
7.2.6  Expectedness  ................................ ................................ ............ 39 
7.2.7  Attribution  ................................ ................................ ................  39 
7.2.8  Expedited Adverse Event Reporting  ................................ ........ 39 
7.2.9  Serious Adverse Event Reporting  ................................ ............ 40 
7.2.10  Pregnancy  ................................ ................................ .................  41 
7.2.11  Non-Serious Adverse Event Reporting  ................................ .... 42 
7.2.12  Reporting to the Institutional Review  Board (IRB) .................  42 
7.2.13  Reporting to the Food and Drug Administration (FDA)  ......... 42 
7.2.14  Reporting to Incyte Corporation  ................................ .............. 43 
7.2.15  Guidelines for Processing IND Safety Reports  ...................  44 
7.2.16  Reporting to Hospital Risk Management  ................................ . 44 
7.2.17  Monitoring of Adverse Events and Period of Observation  ...... 44 
7.3 Secondary Malignancy  ................................ ................................ ......... 44 
8. PHARMACEUTICAL INFORMATION  ................................ .............................. 44 
8.1 Investigational Agent(s)  ................................ ................................ ....... 44 
8.1.1  Ruxolitinib  ................................ ................................ ............... 45 
8.1.2  Trastuzumab  ................................ ................................ ............. 45 
9. BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES  ............................ 46 
10. STUDY CALENDAR  ................................ ................................ ........................... 49 
11. MEASUREMENT OF EFFECT ................................ ................................ ............51 
11.1  Antitumor Effect â€“ Solid Tumors  ................................ ........................  51 
11.1.1  Definitions ................................ ................................ ................  51 
11.1.2  Disease Parameters  ................................ ................................ .. 51 
11.1.3  Methods for Evaluation of Measurable Disease  ......................  52 
11.1.4  Response Criteria  ................................ ................................ ..... 54 
11.1.5  Duration of Response  ................................ ...............................  56 
11.1.6  Progression -Free Survival  ................................ ........................  56 
11.1.7  Response Review  ................................ ................................ ..... 56 
12. DATA REPORTING / REGULATORY REQUIREMENTS  ............................... 57 
12.1  Data Collection  ................................ ................................ ....................  57 
12.2  Data Reporting  ................................ ................................ .....................  57 
Responsibility for Data Submission ................................ .....................  57 
12.3  Data and Safety Monitoring Committee  ................................ .............. 64 
12.4  Quality Control and Quality Assurance  ................................ ............... 64 
12.5  Confidentiality  ................................ ................................ .....................  65 
12.6  Source Documents  ................................ ................................ ............... 65 
12.7 Reporting to Incyte Corporation  ................................ ..........................  66 
12.8  Records Retention  ................................ ................................ ................  66 
13. STATISTICAL CONSIDERATIONS ................................ ................................ ...66 
13.1  Study Design/Primary Endpoint (Sample Size)  ................................ ... 67 
13.2  Accrual Rate ................................ ................................ .........................  69 
13.3  Stratification Factors  ................................ ................................ ............ 69 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 5 of 96 
 13.4  Analysis of Secondary Endpoints  ................................ ........................  69 
13.4.1  Clinical Benefit Rate, Percent Progression -Free at 24 
weeks, Objective Response Rate:  ................................ .......... 69 
13.4.2  Toxicity Evaluation  ................................ ................................  70 
13.4.3  Correlative Studies  ................................ ................................ . 70 
13.5  Reporting and Exclusions  ................................ ................................ .... 70 
13.5.1  Evaluation of toxicity.  ................................ ............................  70 
14. Protection of Human Subjects  ................................ ................................ ...............70 
15. REFERENCES  ................................ ................................ ................................ ......71 
APPENDIX A:  PERFORMANCE STATUS CRITERIA  ................................ ............................ 74 
APPENDIX B: PATIENTâ€™S Medication Diary  ................................ ................................ ............75 
APPENDIX C: Strong KNOWN CYP 3A4 INHIBITORS AND INDUCERS.  ........................... 76 
APPENDIX D: Archived Tissue and Biopsy Collection and Shipment  ................................ ........77 
APPENDIX E:  BLOOD BIOMARKER C OLLECTION  ................................ ............................ 79 
APPENDIX G: GUIDELEINES FOR AFFILIATE INSTITUTIONS IN MULTICENTER STUDIES
................................ ................................ ................................ ................................ ........................ 90 
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 6 of 96 
 1. OBJECTIVES  
Refer to Section 13: Statistical Considerations for definition of the endpoints below.  
1.1 Primary Objectives   
â€¢ To evaluate the safety  and tolerability of ruxolitinib  in combination with 
trastuzumab  
â€¢ To determine the MTD of r uxolitinib with a fixed dose of t rastuzumab ( Phase 1)  
â€¢ To estimate the efficacy end point of progression free survival (PFS) of the 
combination of r uxolitinib and trastuzumab in patients with HER2+ metastatic 
breast cancer who have progressed on a t rastuzumab -containing regimen  (Phase 2)  
 
1.2 Secondary Objectives  
â€¢ To assess the pharmacokinetics (PK) and pharmacodynamics (PD) of combination 
ruxolitinib and t rastuzumab (Phase 1)  
â€¢ To assess the objective response r ate (ORR) and clinical benefit r ate (CBR) in the 
study population  (Phase 2)  
 
1.3 Exploratory Objectives  
â€¢ To explore differences in clinical outcome (PFS, ORR, and CBR) based on 
clinicopathologic features, such as hormone receptor status  
â€¢ To explore the characteristics of the tumor and peripheral blood as potential 
pharmacod ynamic or predictive biomarkers.  Potential biomarkers will inclu de 
tumor evaluation of pSTAT3 expression, serum IL-6, IL-8, and C-reactive protein .   
â€¢ To conduct genomic pro filing of seria l tumor samples of subjects through RNA -
Seq to explore mechanisms of acquired resistance  and response  
 
2. BACKGROUND  
2.1 HER2 Overexpressed Breast Cancer  
Breast cancer is the most common female cancer and the second most common cause  of 
cancer death in women.  Approximately 1,150,000 cases and 410,000 deaths from  breast 
cancer occur annually worldwide (Parkin et al, 2005), and , in the U.S. , there are an  estimated 
184,450 new cases and 40,480 deaths from breast cancer every year  (Jemal et al, 2008).   The 
vast majority of patients who die from breast cancer succumb  to metastatic disease.  The 
human epidermal growth factor receptor type 2 gene (HER2)  is amplified in 20% to 30% of 
breast cancers  (Revillion et al. 1998).  
 
HER2+ breast cance rs are associated with earlier recurrence and shorter overall survival and 
are associated with other adverse prognostic markers, such as high tumor grade, high rates of 
cell proliferation, increased nodal metastases, and relative resistance to certain type s of 
chemotherapy (Slamon et al. 1987; Paik et al. 1990).  The HER family of receptors, HER1, 
HER2, HER3, HER4 (also referred to as epidermal growth factor receptors ErbB -1, ErbB-2, 
ErbB-3, ErbB-4), is a group of related transmembrane receptor tyrosine kin ases that regulate 
normal cell survival, proliferation, differentiation, and migration (Hudis, 2007).  
 
2.2 Trastuzumab  
Trastuzumab, a recombinant humanized monoclonal antibody  against the extracellular 
domain of HER2, prevents cell proliferation and has greatly improved the treatment of  
HER2+ breast cancer.  Clinical studies demonstrate that t rastuzumab can  dramatically 
improve disease -free and overall -survival in HER2 + patients in both  the curable  and 
advanced disease settings (Slamon et al. 2001; Romond et a l. 2005).   
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 7 of 96 
 A single arm, 222 p atient, multinational study of t rastuzumab monothe rapy in HER2+  
metastatic breast cancer patients w ho had progressed after one or two  treatment regimens 
showed a 14% response rate (2% complete responses) and a median duration of response of 
13 months (Cobleigh et al,1999; Herceptin (T rastuzumab) USPI, 2008).  Although response 
rates of HER2+  metastatic breast cancer  to trastuzumab monot herapy are low ( 11 - 34%), the 
combination of  chemotherapy, including taxanes and vinorelbine,  plus trastuzumab yield 
response rates  which approach 70% in the first line setting (Slamon et al. 1987; Seidman et 
al. 2001; Esteva et al. 2002; Burstein et al. 2007).   
 
In a pivotal trial in which women with  previously untreated HER2 + MBC were randomized 
to chemotherapy versus  chemotherapy wit h trastuzumab, the addition of t rastuzumab 
increased time to  progression from 4.6 months to 7.4 months (Slamon et al. 200 5).  
Trastuzumab as a single  agent is approved for treatment of HER2 -overexpressing breast 
cancer in patients who  have received one or more chemotherapy regimens (U .S. approval) or 
at least two  chemotherapy regimens (European approval) for metastatic disease.  
Trastuzumab received approval in the U.S. for HER2+ metastatic breast cancer either as 
monotherapy or in combination with paclitaxel . Trastuzumab is also  approved for the 
adjuvant treatment  of HER2-overexpressing, node  positive or node negative breast cancer.   
While the treatment effects  of trastuzumab were seen in patients treated with anthracycline 
plus cyclophosphamide (AC) or paclitaxel, the size of the treatment effect was greater in th e 
paclitaxel subgroup, with less cardiotoxicity.  The incidence of New York Heart Association 
class III or IV cardiac dysfunction was 16% i n patients treated with AC and t rastuzumab 
compared with 2 % among those wh o had received paclitaxel and t rastuzumab (Herceptin 
(Trastuzumab)  USPI, 2008; Slamon et al, 2001).  
 
2.3 Incyte-Supplied Investigational Drug  
2.3.1 Ruxolitinib    
 
a. Mechanism of Action  
Ruxolitinib (INCB018424 phosphate, INC424, ruxolitinib  phosphate) represents a potent, and 
selective inhibitor of JAK1 (Janus kinase 1) (inhibition concentration 50% [IC50]=3.3 Â± 1.2 
nM) and JAK2 (IC50=2.8 Â± 1.2 nM) with modest to marked selectivity against TYK2 
(tyrosine kinase 2) (IC50=19 Â± 3.2 nM) and JAK3  (IC50=428 Â± 243 nM), respectively. 
Ruxolitinib interferes with the signaling of a number of cytokines and growth factors that are 
important for hematopoiesis and immune function. JAK signaling involves recruitment of 
signal transducers and activators of t ranscription (STATs) to cytokine receptors, activation, 
and subsequent localization of STATs to the nucleus leading to modulation of gene 
expression. Dysregulation of the JAK -STAT pathway has been associated with several types 
of cancer and increased proli feration and survival of  malignant cells.  
 
b. Non-Clinical Pharmacology  
Ruxolitinib has high aqueous solubility and high permeability in vitro based on Caco -2 cell 
culture study .  In single oral dose PK studies, ruxolitinib  was absorbed rapidly with mean 
Tmax values ranging from 0.5 to 2 h. In mice,  dogs, minipigs and humans, there were 
minimal gender differences in the exposure of  ruxolitinib  and its metabolites. In rats, the 
Cmax and AUC (area under the concentration -time curve) values were several -fold higher in 
females compared to males, due to metabolism by  male rat specific isozymes 2C11, 2C13 
and CYP3A2. The terminal half -life, routes and rate  of excretion for ruxolitinib -derived 
radioactivity and metabolites observed between male and  female rats wer e similar. The oral 
bioavailability was variable across species, ranging from  22% in male monkeys to virtually 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 8 of 96 
 complete in female rats consistent with the species  dependent  clearance observed following 
IV dosing.  
 
Following IV administration of ruxolitinib, the plasma clea rance was species -dependent and 
ranged from moderate in male dogs (0.48 L/h/kg) to very  high in male rats (9.4 L/h/kg) . 
Based on the apparent steady -state volume of distribution, ruxolitinib  was not distributed 
extensively beyond body wat er in dogs  (1.1 L/kg) and monkeys (0.81 L/kg), but may be 
distributed to a greater degree in rats (1.6 -3.8 L/kg) and minipigs (6.4 L/kg). The terminal 
elimination half -life ranged from 0.4 h (rat) to 2.5  h (dog). In monkeys, the PK parameters of 
ruxolitinib were comparable with and without the  pretreatment of agents that increase gastric 
pH, indicating that elevated gastric pH is not likely  to affect t he oral exposure of ruxolitinib . 
 
c. Animal Toxicity  
Ruxolitinib was evaluated in several in animal based toxicology studies and did not exhibit 
significant toxicities at target concentrations.  Cardiovascular evaluation in dogs 
demonstrated lowered blood pressure and increased hea rt rate at the highest dose of 
ruxolitinib  (30 mg/kg).  Effects noted in multipl e-dose toxicity studies in mice (up to 4 
weeks), rats (up to 6 months), and dogs (up to 12 months) were primarily those associated 
with the mechanism of action of ruxolitinib , a potent and reversible inhibitor of JAK -STAT 
signaling. Decreases in red blood cells, reticulocytes, eosinophils and lymphocytes have been 
observed along with lymphoid depletion in bone marrow and lymphoid organs. In addition, in 
dogs, demodectic mange, bacterial pneumonia and viral -induced papillomas, expected 
consequences of the ph armacology of JAK inhibition, were noted.  
 
Embyro-fetal assessments in rat and rabbit, maternal toxicity and minimal embryo -fetal 
toxicity were noted at the highest doses.  No teratogenicity was noted in rat or rabbit animal 
models.  There were no reported  effects on fertility  or early embryonic development.  In an 
evaluation of fertility and early embryonic development, no effects were noted on 
reproductive performance or fertility in male or female rats. Increases in post -implantation 
loss were noted at t he higher doses. In a pre - and post-natal development and maternal 
function study in rats there were no adverse findings for fertility indices or for maternal and 
embryo-fetal survival, growth, and developmental parameters. Ruxolitinib passed into the 
milk of lactating rats with an exposure that was 13 -fold higher than maternal plasma 
exposure.   
 
d. Absorption, bioavailability, and pharmacokinetics  
Ruxolitinib is a potent and selective inhibitor of the JAKs with selectivity for JAK1 and 
JAK2 (QuintÃ¡s -Cardama e t al, 2010). Ruxolitinib potently inhibits JAK1 and JAK2 
(IC50<5nM), yet it does not significantly inhibit a broad panel of 28 kinases (<30% 
inhibition) when tested at 200 nM (approximately 100 Ã— the average IC50 value for JAK1 
and JAK2 enzyme inhibition).  In cell-based assays relevant to the pathogenesis of MPNs  
(myeloproliferative neoplasms) , such as JAK/STAT signaling and the growth of cytoki ne-
dependent tumor cell lines, r uxolitinib demonstrates IC50 values of 80 -300 nM. This effect is 
not due to genera l cytotoxicity, because ruxolitinib  (up to 25 Î¼M) had no significant effect on 
the growth of a cytokine -independent, BCR -ABL-driven cell line. In addition, ruxolitinib  
inhibited JAK/STAT signaling and growth of a cell line expressing the constitutively act ive 
JAK2 mutant (JAK2V617F) that has been implicated in the pathogenesis of the majority of 
Philadelphia chromosome negative MPNs. Ruxolitinib was also tested in cell -based assays 
relevant to the increased inflammatory cytokine levels observed in MPNs that  contribute to 
MPN-related systemic symptoms. Ruxolitinib potently inhibited IL -23 stimulated IL -22 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 9 of 96 
 production in human T cells (IC50=50 nM), as well as IL -6, GM-CSF and TPO induced 
STAT3 phosphorylation in human peripheral blood mononuclear cells with IC5 0 values < 
100 nM. Ruxolitinib also inhibited GCSF stimulated STAT3 phosphorylation in human 
neutrophils (IC50=28 Â± 9 nM), as well as TPO induced STAT3 phosphorylation in human 
whole blood (IC50=281 Â± 62 nM).  Finally, ruxolitinib  inhibited the production of IL-17 in 
response to IL -23 in T cells, and the production of monocyte chemotactic protein -1 in 
response to IL -6 in peripheral blood mononuclear cells with IC50 values of â‰¤120 nM 
(Fridman et al, 2011).  
 
Ruxolitinib inhibited splenomegaly in mice resulti ng from intravenous (IV) inoculation of 
cells expressing the clinically relevant JAK2V617F mutation (QuintÃ¡s -Cardama et al, 2010). 
After 3 weeks of treatment, more than 90% of vehicle -treated mice had succumbed to disease 
while more than 90% of ruxolitinib  -treated mice survived. Treatment with ruxolitinib  also 
reduced inflammatory cytokine levels in these mice. The effects of ruxolitinib  were also 
tested in a mouse disease model of polycythemia vera -like disease, based on transplantation 
of a 1:1 ratio of JAK2 wild type green fluorescent protein (GFP) -expressing murine bone 
marrow cells with JAK2V617F -positive murine bone marrow cells, which have a 
repopulation advantage. In this model, oral ruxolitinib  treatment at doses of 30 or 90 mg/kg 
twice a day for 2 1 consecutive days reduced levels of phosphorylated STAT5 (pSTAT5) in 
the spleen, as well as the spleen size. Ruxolitinib also effectively reduced the red cell 
parameters (RBC count, Hgb, Hct and reticulocyte count) and neutrophil count. The 
treatment was well tolerated as assessed by monitoring body weight, and histological 
assessments of spleen and bone marrow samples post -therapy revealed a decrease of 
hypercellularity (erythroid and myeloid lineages) in ruxolitinib  treated groups as compared to 
vehicle treated animals. However, no significant decrease in the mutant allele burden 
surrogate readout (percentage of GFP -negative cells, i.e. cells expressing JAK2V617F) was 
observed, as assessed by flow cytometry. Treatment of mice with ruxolitinib  in a cytokin e-
dependent multiple myeloma ( MM) xenograft model resulted in a dose -dependent 
suppression of phosphorylated STAT3 (pSTAT3) and tumor growth. Efficacy was also 
observed in additional preclinical tumor models representing both hematologic and solid 
tumors. Taken together, these data indicate that ruxolitinib  will be able to inhibit wild -type 
and mutant JAKs in the clinical setting and are consistent with its observed efficacy in 
patients with MPNs.  
 
e. Clinical Trials  
The clinical database (safety set) in solid  tumor and hematolog ic malignancies consists of 
787 patients treated in 6 studies evaluating patients with myelofibrosis ( MF) (n=679), 
prostate cancer (n=22), MM  (n=13), essential thrombocythemia ( ET), and polycythemia vera 
(PV) (n=73), of whom 61 7 patients received ruxolitinib .  Hematologic events are the most 
frequently reported adverse events (AE s) and include  thrombocytopenia and anemia. The 
majority of these AEs are of Grades 1 -2, seldom led to  study drug discontinuation (<1% of 
patients), and  can be usually managed through dose  reduction or interruption.  Increased rates 
of anemia resulted in an increase in packed red blood cell (PRBC)  transfusion requirements 
for some ruxolitinib -treated patients. Platelet transfusions while  on ruxolitinib  were rare. 
Biochemistry laboratory abnormalities of alanine aminotransferase (ALT), aspartate  
aminotransferase (AST) and cholesterol were reported. The majority of these increases  were 
Grade 1 or 2. No Grade 4 events were reported.  
 
Safety in clinical pharmac ology studies  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 10 of 96 
 The safety profile for ruxolitinib  in the Phase I development program was assessed in 
over145 healthy subjects for single doses from 5 mg to 200 mg, and in 53 healthy subjects for 
repeat doses from 15 mg to 50 mg b.i.d. and 50 to 100 mg q.d. Ruxolitinib has also been 
administered to 32 subjects with various degrees of renal impairment, 24 subjects with 
various degrees of hepatic impairment, and 50 subjects with RA (rheumatoid arthritis). AEs 
were, in general, mild and resolved without interven tions. In the first in human study one 
subject had hyponatremia after receiving 5 mg  ruxolitinib . The hyponatremia was assessed as 
severe in intensity, unrelated to study medication, reversed within 5 days, and was reported as 
a serious adverse event (SAE) . A Phase I dose escalation study and a study to evaluate food 
effect in Japanese healthy volunteers showed that administration of ruxolitinib with a high -fat 
meal led to results that were in line with results from the North American study.   A Phase I 
dose escalation study in Chinese healthy volunteers showed similar overall results over a 
dose range of 10 -50 mg.  The pharmacokinetics of ruxolitinib was linear in the dose range 
studied, with a short half -life of 2-4 hours resulting in no notable drug accumu lation 
following multiple doses.  
 
In the repeat -dose study in healthy subjects, the intensity of an adverse event was graded 
according to the protocol -defined toxicity criteria based on Rheumatology Common Toxicity 
Criteria V 1.0. The dose -limiting AE was neutropenia, which occurred at a dose of 50 mg 
b.i.d. Neutropenia as an AE was noted in three subjects, all receiving the highest dose of 
ruxolitinib , 50 mg b.i.d. Neutropenia at the Grade 4 level, assessed as severe, led to study 
drug discontinuation on D ay 5 in one subject, and was reported as a SAE. Neutrophil count 
returned to a normal level 12 days after the final dose of study medication. In two other 
subjects, neutropenia was Grade 1 or 2, and resolved with dose interruption or during 
continued dosin g. The AE profile was similar for single - and multiple -dose studies, and no 
differences were observed between males and females. The most frequent (â‰¥2 subjects) 
treatment -emergent AEs (TEAEs) occurring in the Phase I multiple -dose study were: 
neutropenia ( 4.2%), dizziness (2.8%), headache (2.8%) and nausea (2.8%). Overall, in 
healthy volunteer studies where frequent sampling of the neutrophil count was performed, a 
transient, reversible decrease in neutrophil count was frequently seen following dosing, 
which reversed after 12 -24 hours off drug. 
 
Two clinical pharmacology studies are ongoing to evaluate the effect of ruxolitinib on the 
pharmacokinetics of orally administered midazolam in healthy males subjects and of 
monophasic oral contraceptives in health f emale subjects.   
 
The first Periodic Safety Update Report (PSUR) for ruxolitinib covered the reporting period 
from 16 Nov 2011 to 22 Feb 2013.  A critical analysis of the efficacy and safety data revealed 
that the overall benefit -risk assessment of ruxoli tinib remains favorable.  Based on a single 
confirmed case of PML in an MF patient treated with ruxolitinib, this condition has been 
identified as an important potential risk.  Reports of tuberculosis continue to be received in 
ruxolitinib -treated subjects  in clinical trials.  While the cumulative incidence of these 
tuberculosis reports appears to decline since the original Phase III trials, given the potential 
impact of JAK1/JAK2 inhibition upon immune defense, the risk tuberculosis will be 
monitored close ly in subsequent PSURs.  
 
 
 
 
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 11 of 96 
 Phase III studies in patients with myelofibrosis  
The Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment I, (COMFORT -I) 
was a randomized, double -blind, placebo -controlled, multicenter study compar ing the 
efficacy and safety of ruxolitinib  tablets to a matched placebo in 309 patients with MF. The 
primary objective was to evaluate the effica cy, safety and tolerability of ruxolitinib  given 
b.i.d. compared to placebo in patients with MF. Patients wer e randomized in a 1:1 ratio of 
ruxolitinib : placebo with no stratification. Ruxolitinib starting dose was based on baseline 
platelet count as follows: patients with baseline platelet count >200 x109/L started at 20 mg 
b.i.d. and patients with baseline plat elet count >100 x 109/L to â‰¤200 x 109/L started at 15 mg 
b.i.d. The primary endpoint for this study was the percentage of patients with â‰¥35% reduction 
in spleen volume assessed by imaging (MRI or CT) from baseline, at Week 24.   The 
Controlled Myelofibrosis  Study with Oral JAK Inhibitor Treatment II ( COMFORT II) was an 
open-label, randomized, active -comparator, multicenter study comparing the efficacy and 
safety of ruxolitinib  tablets versus best available therapy  as selected by the investigators in 
219 adults patients with myelofibrosis.  Key eligibility criteria were as follows: adult MF 
patients, not candidates for stem cell transplantation, with two or more risk factors identified 
by IPSS, palpable spleen length â‰¥5 cm below the left costal margin, periphe ral blast count 
<10%. The primary endpoint for this study was the percentage of patients with â‰¥35% 
reduction in spleen volume assessed by imaging (MRI or CT) from baseline, at Week 48. 
These trials iden tified statistically significantly larger proportion o f patients randomized to 
ruxolitinib  achieved a â‰¥35% reduction from baseline in spleen volume  compared to patients 
randomized to control. This effect was seen at both Week 24 (primary  endpoint in 
COMFORT -I) and Week 48 (primary endpoint in COMFORT -II). For patients who remained 
on study, the median percent re duction from baseline in spleen volume in both ruxolitinib  
arms was approximately 30%, was reached as early as Week 12 and was maintained 
throughout the study. The control arms had a median percent incr ease from baseline in spleen 
volume throughout the study.  
 
For additional information see the ruxolitinib Investigatorâ€™s Brochure, Edition 12, dated 11 
September, 2013.  
 
Phase III study in patients with polycythemia vera  
The RESPONSE Trial is a global, randomized, open label pha se III pivotal study comparing 
ruxolitinib  (starting dose of 10 mg b.i.d.) with best available therapy (HU, pipobroman, 
immunomodulatory drugs, pegylated interferon or interferon, anagrelide, observation only) in 
PV patients. The protocol is designed for patients with evidence of need for phlebotomy and 
splenomegaly, either resistant or intolerant to HU. The primary endpoint is a composite one 
with phlebotomy control (absence of phlebotomy from Week 8 to 32) and reduction in spleen  
volume by MRI (or CT if MRI is clinically contraindicated) of at least 35% measured at 32 
weeks. Two key secondary endpoints include durability of the primary endpoint and 
complete hematologic remission. There are multiple, non -key secondary endpoints inc luding 
modified clinico -hematologic response (overall response rate, durability and duration), as 
defined by the European Leukemia Net (ELN). The study is ongoing and 147 patients have 
been enrolled so far (as of 1 August 2012).  
 
Phase I/II study in patients with multiple myeloma  
Ruxolitinib is being evaluated in a phase II, multicenter, Simon -two-stage, open label, 
clinical trial to) in patients with relapsed or refractory MM. This was a multi -center, Simon 2 -
stage, open -label clinical t rial. Patients were  to receive ruxolitinib  25 mg orally b.i.d. on each 
day of each 28 -day cycle. Tumor responses were assessed every cycle. Respond ing patients 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 12 of 96 
 could continue on ruxolitinib  monotherapy. The patients who were assessed to have 
progressed at any time or were as sessed to have st able disease after 3 cycles of ruxolitinib  
monotherapy had the addition of 40 mg oral dexamethasone daily on Days 1 -4, 9-12, and 17 -
20 of each 28 -day cycle (combination phase of the trial). Each cycle of dexamethasone was 
repeated every 28  days for 4 cycles. After the fourth cycle, 40 mg of dexamethasone was to 
be administered only on Days 1 -4 of subsequent cycles. Treatment could be continued until 
occurrence of progressive disease or unacceptable toxicity. A total of 13 MM patients have 
been enrolled in Stage 1 to receive ruxolitinib  as monotherapy (11 were evaluable for 
response). Seven of these subjec ts received ruxolitinib  in combination with high dose 
dexamethasone after their disease progressed or afte r having had stable disease on ruxolitinib 
monotherapy. No MM patient has been enrolled in stage 2. None of the 11 MM evaluable 
subjects achieved a response according to the IRC (International uniform Respon se Criteria) 
when treated with ruxolitinib  monotherapy. However, with combination therapy of hig h dose 
dexamethasone added to ruxolitinib , two out of seven subjects achieved a partial response 
and one subject had long -term stable disease.  
 
Phase I/II study in patients with prostate cancer  
A Phase II, open label study of ruxolitinib  administered orally to  patients with androgen 
independent metastatic prostate cancer (AIPC)  was performed. The primary endpoint was 
PSA50 (prostate -specific antigen) response rate, a clinically validated  endpoint associated 
with clinical benefit in patients wi th metastatic prostate cancer. This  endpoint is defined as a 
PSA decline from baseline of 50% or greater, confirmed by  measurement on two occasions at 
least 4 weeks apart.  The study used a Simon 2 -stage optimal design. The first stage of the 
trial (Part 1)  was designed to enroll 21 patients. If fewer than two PSA50 responses were 
observed in the first  
21 patients (no later than 10 weeks after the last patient in the firs t stage is enrolled), the trial 
would be closed and the agent will be declared inactive as a monotherapy. If two or more  
PSA50 responses are seen in the first stage, an additional 20 pa tients would be enrolled in the 
second stage (Part 2) for a total of 41 patients.  The study in patients with advanced prostate 
cancer completed enrollment of 2 2 subjects in  the first stage of the study. The study endpoint 
permitting advancement to a second stage of  the study was not reached. Seventeen of 22 
subjects enrolled experienced death or protocol -defined progressive disease while on study.  
 
Given that a ll patients discontinued the study due to protocol -specified lack of efficacy, the 
primary efficacy endpoint of PSA50 response rate was not assessed. Similarly, the secondary 
endpoints of median time to progression and tumor response rates were not assesse d. All 
patients provided samples for the secondary endpoints of evaluating population PK and 
plasma PD markers; however, the samples were not assessed as part of this analysis.  
The primary endpoint of safety and tolerability was assessed in this analysis. All patients 
experienced at least one TEAE, and the majority of patients (16 patients; 72.7%) experienced 
treatment -related TEAEs. The events associated with ruxolitinib treatment included anemia, 
fatigue, diarrhea, nausea, leukopenia and peripheral edema,  all of which were not unexpected 
events in this patient population of metastatic androgen AIPC, as were the most frequently 
reported severe or life -threatening TEAEs (anemia, thrombocytopenia, peripheral edema, 
increased blood alkaline phosphatase, bone p ain). 
Treatment with ruxolitinib was generally well -tolerated. Among the 11 SAEs reported by 
nine patients, the only SAE that was reported by more than one patient was anemia (two 
patients), and only two SAEs were considered to be possibly or definitely re lated to study 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 13 of 96 
 medication by the investigator (cardiac arrest and anemia, respectively). Further, only one 
patient discontinued treatment as a result of an AE (anemia). Among the four deaths, cardiac 
arrest was deemed by the investigator as possibly relate d to study medication in one patient, 
but the patient had other risk factors that may have also contributed to the event; the other 
three deaths were likely associated with medical history and metastatic AIPC.  
Eight patients had laboratory abnormalities th at resulted in serious, severe, or life -threatening 
AEs, which included the following events: anemia, increased blood alkaline phosphatase, 
increased Î³GT, thrombocytopenia, hyperuricemia, and leukopenia. There was no specific 
trend among patients with rega rds to laboratory abnormalities or ECG values out of the 
normal range. Overall, there were no specific safety concerns associated with ruxolitinib.  
Phase IIa study in patients with rheumatoid arthritis (RA)  
A total of 50 patients were enrolled to a double -blind, placebo -controlled study exploring the 
safety, tolerability, and efficacy of a 4 -week course of ruxolitinib  in subjects with active 
RA.This trial consisted of Cohort 1: 16 patients (12 received 15 mg b.i.d. of  ruxolitinib , and 
four received placebo) , Cohort 2: 34 patients  (nine received 5 mg b.i.d. of ruxolitinib , 10 
received 25 mg b.i.d. of ruxolitinib , 10 received 50 mg q.d. of ruxolitinib , and five received 
placebo).  Efficacy demonstrated in this study has been notable. Efficacy greater than plac ebo 
was demonstrated in the top three doses in this study, with ACR20 (American College of  
Rheumatology 20% improvement response criteria) responses ranging from 50 -83% of 
subjects, ACR50 responses in 40 -50% of subjects, ACR70 responses in 25 -30% of subjec ts, 
and ACR90 responses in 10 -17% of subjects, while the placebo group and 5 mg b.i.d. group 
exhibited ACR20 responses of 33% and ACR50 responses of 11% with no ACR70 or 90 
responses.  
 
Ruxolitinib was well tolerated in RA patients dosed for 28 days with re gimens including 5 
mg b.i.d, 15 mg b.i.d., 25 mg b.i.d., and 50 mg q.d. AEs were seen in similar frequency in 
patients receiving ruxolitinib as in patients receiving placebo. The intensity of AEs was 
graded according to the protocol -defined toxicity criter ia based on the Rheumatology 
Common Toxicity Criteria (Version 1.0). In general, AEs were mild and self -limited usually 
resolving with continued dosing. There were no clinically significant changes in mean Hgb or 
platelet counts, and mean neutrophil counts  remained within the normal range. One patient 
dosed with 25 mg b.i.d. exhibited Grade 3 neutropenia, which improved with continued 
dosing, and one patient, who had a prior history of thrombocytopenia, probably immune -
mediated thrombocytopenia, exhibited G rade 3 thrombocytopenia. SAEs of interstitial lung 
disease and congestive heart failure occurred with onset 20 days following the last dose of 
study medication (50 mg q.d.) in a patient taking methotrexate with coronary artery disease. 
The SAE resolved wit h treatment and was assessed as possibly related to study medication.  
2.4 Rationale  
In addition to t rastuzumab, other HER2 therapies that specifically target upstream HER2 
activity have been approved in HER2+ metastatic breast cancer, including pertuzumab, 
lapatinib, and T-DM1.  Unfortunately,  the control of tumor progression is only temporary and 
the majority of the patientsâ€™ tumors eventually acquire resistance and progress (Hynes et al, 
2005). Thus, there is the need to find alternative tumor targets to d evelop specific, more 
efficient, treatments for patients with ErbB2+ breast cancer. By combining RNAi loss -of-
function screens with system biology interactome models, we completed a genome -wide 
screen searching for gene/pathways that are essential for the survival of ErbB2 
overexpressing breast tumor cells but dispensable for normal cells (synthetic lethal 
/RFDO3URWRFRO$$$0
9HUVLRQ'DWH6HSWHPEHU
3DJHRILQWHUDFWLRQV:HLGHQWLILHGWKD WWKH-$.67$7SDWKZD\LVDFWL YDWHGLQ+(5EUHDVW
FDQFHUDQGWKDWEORFNLQJWKLVSD WKZD\VWURQJO\UHGXFHVWKHYLDE LOLW\RI+(5FHOOV
,QDWXPRUFHOOE\YLUWXHRIWKHLU DFFXPXODWHGDOWHUDWLRQVPX OWLSOHUHJXODWRU\QHWZRUNVKDYH
EHHQUHDUUDQJHGLQRUGHUWRDGDSWWRVSHFLILFJHQRPLFDEQRUPDOL WLHV&RQVHTXHQWO\WXPRU
FHOOVDFTXLUHVSHFLILFYXOQHUDELOLWLHV WKDWFUHDWHRSSRUWXQLWLH VIRUWKHUDSHXWLFLQWHUYHQWLRQ
'XULQJWKHWUDQVIRUPDWLRQPHGLDWHGE\RYHUH[SUHVVLRQRIWKHRQF RJHQH(UE%ZH
K\SRWKHVL]HWKDWEUHDVWFDQFHUFHOOVE HFRPHDGGLFWHGWRWKHDFW LYDWLRQRI6WDW'LVUXSWLRQRI
WKHSDWKZD\GHILQHGE\WKHVLJQDOLQJÂµ,/-$.67$7GRZQVWUHDP WDUJHWVÂ¶FRPSURPLVHV
WKHYLDELOLW\RI(UE%FDQFHUF HOOVZLWKRXWDIIHFWLQJQRQWUDQ VIRUPHGRQHV7KXVNH\
FRPSRQHQWVRIWKLVSDWKZD\UHSUHVHQWDQRYHOVWUDWHJ\WRVHOHFW UDWLRQDOSXWDWLYHWDUJHWVIRU
WKHWUHDWPHQWRI+(5EUHDVWFDQFHU
&RPSXWDWLRQDOELRORJ\DOJRULWKP VKDYHEHHQVXFFHVVIXOLQUHYHUV HHQJLQHHULQJWKHUHJXODWRU\
QHWZRUNVRIQRUPDODQGQHRSODVWL FKXPDQFHOOVIURPODUJHJHQHH [SUHVVLRQSURILOH*(3
FROOHFWLRQV%DVVRH WDO&DUURHWDO0DUJROLQHW DO:DQJHWDO
7KHVHPHWKRGVKDYHSURGXFHGWKHILUVWFHOOFRQWH[WVSHFLILFJH QRPHZLGHPDSVRI
WUDQVFULSWLRQDODQGSRVW WUDQVODWLRQDOLQWHUDFWLRQVLQKXPDQFH OOVÂ³LQWHUDFWRPHVÂ´%\XVLQJ
WZRRIWKHVHDOJRULWKPV$5$&1HDQG0,1'\ZHKDYHUHFRQVWUXFWH GWKHLQWHUDFWRPHRI
KXPDQPDPPDU\HSLW KHOLDOFHOOVWUDQVIRUPHGZLWKWKH(UE%RQFRJ HQH7KLVKDVSURYLGHGXV
ZLWKDOLVWRIJHQHIXQFWLRQVWKDWDUH GLIIHUHQWLDOO\DFWLYHEH WZHHQ(UE%WUDQVIRUPHGDQG
QRQWUDQVIRUPHGPDP PDU\HSLWKHOLDOFHOOV:HSUHGLFWWKDWSUHYH QWLQJWKHDFWLYDWLRQRIVRPH
RIWKHVHIXQFWLRQVZLOOLPSDFWWKHWUDQVIRUPDWLRQPHGLDWHGE\( UE%$OWKRXJKWKHYDOXHRI
WKHPHQWLRQHGFRPSXWDWLRQDOPHWKRGV WRVWXG\KXPDQFDQFHUIURP DQXQELDVHGJOREDO
SHUVSHFWLYHLVXQTXHVWLRQDEOHWKHVHPHWKRGVDUHK\SRWKHVLVJHQ HUDWLQJVWUDWHJLHVDQGPXVW
EHYDOLGDWHG,PSRUWDQWO\WKHL PSDFWRIWKHVHDOJRULWKPVLVVH YHUHO\FRPSURPLVHGE\WKHORZ
WKURXJKSXWDSSURDFKHVQHFHVVD U\WRIXQFWLRQDOO\YDOLGDWHWKHL QVLOLFDSUHGLFWLRQV51$
LQWHUIHUHQFH51$LKDVHP HUJHGDVDSRZHUIXOJHQHWLFVWUDWHJ\ WRLQWHUURJDWHJHQHIXQFWLRQ
E\ORVVRIIXQFWLRQVWXGLHV6LOYDHWDO:HKDYHSLRQHH UHGWKHGHVLJQFRQVWUXFWLRQ
DQGYDOLGDWLRQ51$LEDVHGJHQHWLFDSSURDFKHVWRSHUIRUPKLJKWK URXJKSXW+73VFUHHQVLQ
PDPPDOLDQV\VWHPV6LOYDHWDO6LOYDHWDO6LOYD HWDO6LOYDHWDO
3DGGLVRQHWDO8VLQJWKLVWHFKQRORJ\ZHKDYHSHUIRUPHG JHQRPHZLGH51$LVFUHHQV
LQKXPDQQRUPDOPDPPDU\HSLWKHOLDO0&)$FHOOVDQGLQDQLVRJ HQLFYDULDQWWUDQVIRUPHG
ZLWKRQFRJHQLF(UE%0&)$(UE%7KHFRPELQDWLRQRIWKHFRP SXWDWLRQDOSUHGLFWLRQV
DQGWKHORVVRIIXQFWLRQVWXGLHVKDYHDOORZHGXVWRLGHQWLI\WK HDFWLYDWLRQRIWKH-$.67$7
SDWKZD\DVHVVHQWLDOIRU(UE%PHGLDWHGWUDQVIRUPDWLRQ )LJ


3UHOLPLQDU\5HVXOWV
7DUJHW9DOLGDWLRQ
:HREVHUYHGWKDWNH\PHPEHUVRIWKH67$7IDPLO\6WDWDQG ZHUHSKRVSKRU\ODWHG
XSRQ(UE%RYHUH[SUHVVLRQ )LJ$7KH-$.67$7SDWKZD\KDVEHHQSUHYLRXVO\
LGHQWLILHGDVDNH\FRPSRQHQWRIWKHWUDQVIRUPDWLRQRIPXOWLSOH WXPRUW\SHVHVSHFLDOO\LQ
OXQJFDQFHU$NFDHWDO%\HUVHWDO)XUWKHUPRUHD QLQFUHDVLQJDPRXQWRI
HYLGHQFHSRLQWVWRWKLVSDWKZD\DVDQHVVHQWLDOKXERIFDQFHUF HOOKRPHRVWDVLV:HHUDVLQJKH
)LJ7KHJHQHWLF
FRPSXWDWLRQDOVFUHHQVWUDWHJ\
/RFDO3URWRFRO$$$0
9HUVLRQ'DWH6HSWHPEHU
3DJHRIHWDO=KDQJHWDO'DUQHOOHWDO,PSRUWDQWO \JHQHWLFVL51$NQRFNGRZQ
DQGFKHPLFDOVPDOOPROHFXOH LQKLELWRU6WDWWLFLQKLELWLRQR I6WDWUHGXFHGWKHYLDELOLW\RI
(UE%FHOOVZLWKRXWDIIHFWLQJQRQ WUDQVIRUPHGFHOOV )LJ%DQG& $QQH[LQ9VWDLQLQJ
UHYHDOHGWKDWWKLVHIIHFWZDVPHGLDWHGE\LQGXFWLRQRIDSRSWRVL V)LJ&7KHGHSHQGHQF\RQ
6WDWKDGDSURIRXQGHIIHFWLQWKHJURZWKRI(UE%FHOOVQRW RQO\LQYLWUREXWDOVRLQYLYR
DQGNQRFNGRZQRI6WDWGUDPDWLFDOO\UHGXFHGWKHJURZWKRI(UE %FHOOVLQPRXVH
[HQRJUDIWV )LJ'2QFHZHYDOLGDWHGWKDW6WDWDFW LYDWLRQLVHVVHQWLDOWRPDL QWDLQWKH
KRPHRVWDVLVRIWKH(UE%FHOOVZHGHFLGHGWRLQYHVWLJDWHWKH PHFKDQLVPWKDWPHGLDWHVLWV
DFWLYDWLRQ%\FRPSDULQJWKHH[SUHVVLRQSURILOHRISDUHQWDODQG (UE%DFWLYDWHGFHOOVZH
IRXQGDVWURQJXSUHJXODWLRQRIPXOWLSOHLQWHUOHXNLQPROHFXOHVD QGLPSRUWDQWO\WKHLU
UHFHSWRUV7KHPRVWXSUHJXODWHGLQWHUO HXNLQ!WLPHVZDVLQ WHUHXNLQ,/DZHOO
FKDUDFWHUL]HGERQDILGHDFWLYDWRU RI6WDW)XUWKHUPRUHWKHF DQRQLFDO,/UHFHSWRU,/5
ZDVDOVRIRXQGWREHXSUHJXODWHG,PSRUWDQWO\WKHKLJKOHYHOV RI,/P51$GHWHFWHGZHUH
DOVRDVVRFLDWHGZLWKKLJKHUOHYHOVRIV HFUHWHG,/LQWRWKHFX OWXUHPHGLD )LJ(DQG) 

7DUJHW0RGXODWLRQ
7KHVHGDWDVXJJHVWDPRGHOZKHUHFHOOVZLWKDFWLYDWHG(UE%SUR GXFHKLJKOHYHOVRI,/DQG
XSUHJXODWHVLWVUHFHSWRU6HFU HWLRQRIWKLVLQWHUOHXNLQJHQHUDW HVDQDXWRFULQHORRSWKDW
DFWLYDWHVWKH-DN6WDWSDWKZD\LQGXFLQJWKHSKRVSKRU\ODWLRQRI 6WDWWKDWLVQHFHVVDU\IRU
WKHWUDQVIRUPDWLRQSURFHVV
,QRUGHUWRWUDQVODWHRXUUHVXOWV WRWKHFOLQLFDOVHWWLQJZHV HDUFKHGIRUFRPSRXQGVWKDWFRXOG
LQKLELW67$7DFWLYLW\ LQYLYR%HFDXVH67$7PDLQO\PHGLDWHV LWVDFWLRQWKURXJKSURWHLQ
$ % &
)('
)LJ$FWLYDWLRQRI6WDWLVQH FHVVDU\IRUWUDQVIRUPDWLRQRIP DPPDU\HSLWKHOLDOFHO OVLQGXFHGE\(UE% $3KRVSKRU\ODWLRQOHYHOVRI
6WDWPHPEHUVLQ SDUHQWDODQGKXPDQPDPPDU\HSLWKHOLDO0&)$FHOOVWUDQVIRUPHG ZLWKZLOGW\SH(UE%R UDQDFWLYDWHGIRUP(UE%
%
7KHXSSHUSDQHOVKRZ VWKHHIILFLHQF\RIWZ RVK51$DJDLQVW6WDW 7KHORZHUSDQHOVKRZVWKH LPSDFWWKDWNQRFN GRZQRI6WDWXVLQJWKH
VK51$VIURPXSSHUSDQHOKDVRQFHOOYLDEL OLW\LQSDUHQWDODQG(UEEW UDQVIRUP0&)$FHOOV&$QQH[LQ 9VWDLQLQJVKRZLQJWKDW
UHGXFWLRQLQFHOOYLDELOLW\ LVDVVRFLDWHG WRDSRSWRVLV')457 3&5GDWDVKRZLQJLQFUHDVH GOHYHOVRI,/DQGLWVUHFHSWRU,/5LQ(UE%
WUDQVIRUPHG0&) $FHOOV)&\WRNLQHVHFUHWL RQRI0&)$DQG0&)$(UE%FH OOVPHDVXUHGE\&\WRNLQHDUUD\6HFUHWHG&\WRNLQHV
/RFDO3URWRFRO$$$0
9HUVLRQ'DWH6HSWHPEHU
3DJHRISURWHLQRUSURWHLQ'1$LQWHUDFWLRQVLQVWHDGRIDQHQ]\PDWLFDFW LYLW\LWKDVEHHQFRQVLGHUHG
GLIILFXOWWRWDUJHWE\FODVVLF DOPHFKDQLVPV6HYHUDODSSURDFKHV KDYHEHHQSURSRVHGWRLQKLELW
,/-$.67$7SDWKZD\EHLQJWKHPRVWXVHGRQHVEDVHGRQWKHLQK LELWLRQRIWKHUHFHSWRU
DFWLYDWLRQYLDEORFNLQJDQWLERGL HVVXFKDV7RFLOL]XPDE67$7E LQGLQJPROHFXOHVZKLFK
VKRZSRRUVXFFHVVDQGLQKLELWRUV RI-$.NLQDVHDFWLYLW\6DQVR QH
)LUVWZHLQFXEDWHG0&)$(UE%FHO OVZLWKDVLQJOHGRVHRI X0RIUX[ROLWLQLEIRU
LQFUHDVLQJWLPHVDQGDQDO\]HGWKHHIIHFWRQGLIIHUHQWFRPSRQHQW VRIWKHSDWKZD\E\ZHVWHUQ
EORW)LJ$2XUUHVXOWVVKRZHGWKDWUX[ROLWLQLEWUHD WPHQWGHFUHDVHVWKH SKRVSKRU\ODWLRQRI
67$7LQDWLPHGHSHQGHQWPDQQHUZLWKWKHFRQFRPLWDQWWULJJHUR IDSRSWRVLVLQ0&)
$(UE%DVVKRZQE\WKHFOHDYDJHRI3$537KHVHUHVXOWVFRQIL UPHGWKHHVVHQWLDOUROHRI
67$7DFWLYDWLRQLQFHOOVWKDWRYHUH[SUHVV(UE%
6HFRQGZHVWXGLHGE\VRIWDJDUDVVD\VWKHHIIHFWRIUX[ROLWLQLE RQWUDQVIRUPDWLRQGULYHQE\
(UE%RYHUH[SUHVVLRQ$VVKRZQLQ )LJ%WUHDWPHQWZLWKLQFUHDVLQJGRVHVLPSDLUHGWKH
DQFKRUDJHLQGHSHQGHQWJURZWKRI0&)$(UE%FHOOV7KHQZHI ROORZHGWKHIRUPDWLRQ
RIDFLQLLQPDWULJHOZKHQWUHDWL QJZLWKUX[ROLWLQLE$VVKRZQ LQFXEDWLRQZLWKX0RI
UX[ROLWLQLEDIIHFWVWKHJURZWKRI0&)$(UE%FHOOVLQ'IR UPLQJVPDOOHUVWUXFWXUHV
ZLWKDQRUPDOOLNHVKDSHZKLOH0&) $FHOOILWQHVVLVDOPRVW QRWDIIHFWHG )LJ&
,QYLYRZHLQMHFWHG0&)$(UE%FHOOVLQWRWKHPDPPDU\IDWSDGRI6 &,'PLFHDQG
RUDOO\DGPLQLVWHUHGPJNJRIUX[ROLWLQLEWZLFHDGD\7UHDWPH QWGHFUHDVHGWXPRUJURZWK
ZKLOHZDVQRWWR[LFIRUWKHPLFHDVLQGLFDWHGLQQRVLJQLILFDQW ZHLJKWORVV )LJ')LQDOO\
ZHWHVWHGLIFRPELQLQJUX[ROLWLQLEZLWKVWDQGDUGDQWL(UE%WKH UDS\SURYLGHGDGGLWLRQDO
EHQHILWV,PSRUWDQWO\ZHIRXQGWKDWFRPELQDWLRQRIUX[ROLWLQLE SOXVWUDVWX]XPDEVLJQLILFDQWO\
LQKLELWHGWXPRUJURZWKFRPSDU HGWRHLWKHUWUHDWPHQWDORQH )LJ(,QVXPPDU\ZHKDYH
GHPRQVWUDWHGWKDWWKH-$ .67$7SDWKZD\LVDPDVWHUUHJXODWRURI (5%%EUHDVWFDQFHU
DQGUHSUHVHQWVDQRYHORUWKRJRQDODSSURDFKWRWUHDWLQJWKHVHWX PRUV$OOWRJHWKHUWKHVHGDWD
SURYLGHDVWURQJUDWLRQDOHIRUWHVWLQJ WKHHIILFDF\RIUX[ROLWL QLEWUHDWPHQWRI(5%%
DPSOLILHGEUHDVWFDQFHULQFRPELQDWLRQZLWKWUDVWX]XPDE

Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 17 of 96 
  
 
 
2.6 Correlative Studies Background  
Patientâ€™s tumor tissues will be collected including archived tissue as well as optional biopsy 
before treatment, C2D1, and after treatment metastatic biopsies.  RNAseq will be p erformed 
on all tumor tissues to assess intrinsic molecular subtype, mutations, and interactome 
modeling for JAK/SAT pathway dependence. Metastatic biopsies will also be sent for 150 
protein reverse phase protein analysis (RPPA). These unbiased approaches will allow for 
integrated exploration of candidate resistance and sensitivity biomarkers.  In addition, 
specific candidate biomarkers will be assessed including IHC for pSTAT3 (Cell Signaling), 
serum IL-6 and IL-8 (Immulite 1000, Siemens Healthcare Diagnos tics), and serum C -reactive 
protein (Cobas Integra 400 Plus, Roche Dx).  
2.6.1 Transcriptional Profiling  
RNA sequencing [RNA -seq] has emerged as the single most powerful genomic profiling 
technology.  It can be performed from less tissue [requires only 100-200ng RNA] and at 
lower cost than whole genome sequencing and delivers identification of both mutational 
events and gene expression. Unlike traditional RNA microarray analysis, RNA -seq is 
unbiased with respect to potential content, so it can detect pre viously unidentified genes or 
transcripts which may be involved in the phenotype of interest.  One of the biggest 
advantages of RNA -seq over microarray analysis is the ability to detect single nucleotide 
variants, small insertions and deletions (InDels) an d transcript isoforms. RNA -seq also offers 
improved specificity than microarrays, so it can detect different isoforms of a transcript, and 
offers increased dynamic range of expression over microarray analysis.  Given the power of 
RNA-seq it is our chosen m ethod of transcriptional profiling.  The quality of RNA isolated 
from FFPE samples is potentially compromised by loss in poly -A tails, fragmentized, and 
chemical modification, with possible additional deterioration from prolonged storage times.  
However, e ven with these limitations, RNAseq from FFPE breast cancers has been successful 
[PMID: 22808097].  In addition, the Columbia University genome center has compared RNA 
sequencing from the same samples, fresh frozen and PPFE, and found highly concordant 
sequencing. 
 
2.6.2 Reverse Phase Proteomic Array (RPPA)  
Reverse phase protein array (RPPA) is a high -throughput antibody -based technique developed 
for functional proteomics studies to evaluate protein activities in signaling networks. RPPA 
has been developed and val idated as a quantitative, sensitive, and reproducible proteomic 
technology. It is inexpensive, automated, and only requires 30 micrograms of sample.  Over 
150 total and phosphospecific antibodies can be assessed. RPPA study has major strengths in 
identification and validation of cellular targets, characterization of signaling pathways and 
networks, as well as determination of on and off target activity of novel drugs. Among the 
cancer pathways represented in the RPPA data are the pathways most important for  analysis of 
the combined treatment with trastuzumab and ruxolitinib, including the JAK/STAT, PI3K, and 
MAPK pathways. Each sample is analyzed for cell cycle progression, apoptosis, functional 
proteomics, and signaling network activity. RPPA is the current  technology being used for 
proteomic profiling in the cancer genome atlas (TCGA) project.  Importantly, RPPA has 
recently been validated using FFPE tissues  (Guo, Wang et al. 2007 , Guo, Liu et al. 2012 ).   In 
addition, the molecular pathology core at Columbia University Medical Center has experience 
preparing RPPA samples and analyzing the results [unpublished results].   
 Fig 3. Ruxolitinib treatment impairs transformation of MCF -10A/ErbB2 cells. (A) Western blot showing the effect of  
incubation with ruxolitinib 10u M in phosphorylation of STAT3. Treatment with the JAK inhibitor affects the expression 
of S100A8 and S100A9 while promoting PARP and caspase3 cleavage. (B) and (C) Soft agar and matrigel assays in MCF -
10A/ErbB2 cells treated with increasing doses of ruxolitinib . (D) Growth of MCF -10A/ErbB2 tumors in 
immunocompromised mice when treated with ruxolitinib . The right graph shows the final weight of the extracted tumors. 
(E) Growth of MCF -10A/ErbB2 tumors when mice wer e treated with different drug combin ations. 
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 18 of 96 
 3. PATIENT SELECTION  
 
3.1 Inclusion  Criteria  
A subject must meet all of the following criter ia to be eligible for the study.  
 
1. Subjects must have histologically or cytologically confirmed adenocarcinoma of the 
breast with locally recurrent or metastatic disease.  Locally recurrent disease must not 
be amenable to any local treatment  with curative intent .  Metastatic disease must be 
demonstrated either radiographically or histologically.   
2. Primary tumors and/or metastatic lesions must demonstrate HER2 -neu 
overexpression, per the 2013 recommendations (Wolff, Hammond et al. JCO 2013 ), 
i.e.  immunohistochemis try (IHC 3+) or amplification by in situ hybridization based 
on the following:  
a. Single-probe average HER2 copy number â‰¥6.0 signals/cell  
b. Dual-probe HER2/CEP17 ratio â‰¥2.0 with an average HER2 copy number â‰¥4.0 
signals/cell  
C. Dual-probe HER2/CEP17 ratio â‰¥2.0 with an average HER2 copy number <4.0 
signals/cell  
d.  Dual-probe HER2/CEP17 ratio < 2.0 with an average HER2 copy number > 
6.0 signals/cell  
 
Patients may be estrogen and/or progesterone positive ( >1%) or negative (<1%).  
Hormone receptor  status will be a stratification factor . 
 
3. Patients must have received at least two lines of HER2 -directed therapy in the 
inoperable locally advanced and/or metastatic setting.  Prior therapy for inoperable 
locally advanced/metastatic disease should include  trastuzumab plus pertuzumab as 
well as  ado -trastuzumab.  Pertuzumab and ado -trastuzumab should have been 
previously used, unless for reasons that include, but are not limited, to the following: 
intolerance to pertuzumab and/or ado -trastuzumab, medical co ntraindication, regimen 
declined by patient, treating investigator discretion, or medical insurance coverage 
issues which prevented administration of pertuzumab or ado -trastuzumab.  These 
reasons must be reviewed with the study chairs and documented in the  medical record 
and care report form.   Patients who relapse within 12 months of completing 
neoadjuvant/adjuvant pertuzumab or ado -trastuzumab would be considered as having 
progressed on that regimen.  
 
Patients may have measurable disease only, non -measurable disease only, or both (RECIST 
1.1).   Concomitant treatment with bone-targeted therapies such as RANKL in hibitors or 
bisphosphonates is allowed.  It is anticipated that most patients will have measurable disease, 
given the behavior of HER2+ metastatic breast cancer.  
 
4. Because no dosing or adverse event data are currently available on the use of 
ruxolitinib  in combination with trastuzumab in patients <18 years of age, children are 
excluded from this study.  
 
5. Women and men of all races and ethnic groups are eligible for this trial.  
 
6. ECOG performance status 0-2 (Karnofsky â‰¥60%, see Appendix A ). 
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 19 of 96 
 7. Left ventricular ejection fraction > 50% by transthoracic echocardiography or mult i-
gated acquisition scan (MUGA) within 28 days prior to the first dose of the study 
drug. 
 
8. The subject has a baseline corrected QT interval < 480ms.  
 
9. Patients must have normal organ and marrow function as defined below:  
ï€­ leukocytes  â‰¥ 3,000/mcL 
ï€­ absolute neutrophil count  â‰¥ 1,500/mcL 
ï€­ platelets â‰¥ 100,000/mcL 
ï€­ hemoglobin  â‰¥ 9 g/dL 
ï€­ total bilirubin  â‰¤ 1.5 Ã— the upper limit of normal  
ï€­ AST(SGOT)/ALT(SGPT)  â‰¤ 2.5 Ã— institutional upper limit of normal  
ï€­ Serum creatinine    â‰¤ 1.5 Ã— the upper limit of normal or  
        calculated creatinine  clearance â‰¥ 60 mL/min  
 
10. Women of childbearing potential  and men m ust use adequate contraception prior to 
study entry and for the duration of study participation.  Contraception should continue 
to be used for a minimum of 5 mean half -lives after the last dose of study drugs (mean 
Trastuzumab half -life at 6 mg/k g 16 days; mean half -life Ruxolitinib: 3 hours)  
 
11. Patient is able to swallow, retain, and absorb oral medication.  
 
12. Life expectancy of at least 12 weeks  
 
13. Informed Consent.  Ability to understand and the willingness to sign a written  
            informed consent document.  
 
3.2 Exclusion Criteria  
A subject who meets any of the following crite ria is ineligible for the study:  
 
1. Patients who have had chemotherapy, hormonal therapy, or radiotherapy within 2 
weeks prior to entering the study or those who have not recovered from adverse 
events due to agents administered more than 2 weeks earlier.  
 
2. Patients who are receiving a ny other investigational agents or have received other  
investigational agents within 2  weeks or 5 half-lives of the compound or active 
metabolites, whichever is longer  before the first dose of the study treatment.  
 
3. Patients who have previously been treated w ith an IL-6, JAK or STAT inhibit or for 
any indication, such as ruxolitinib or tocilizumab.   
 
4. Symptomatic or unstable brain metastases. (Note:  Asymptomatic patients wit h 
metastatic  brain disease who have been on a stable dose of corticosteroids for 
treatment of brain  metastases for at least 14 days prior to randomization are eligible to 
participate in the study).  
 
5. History of allergic reactions a ttributed to compounds of similar chemical or biologic 
composition to ruxolitinib or trastuzumab.   
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 20 of 96 
 6. The effects of ruxolitinib  on the developing human fetus are unknown.  For this 
reason and because JAK2 inhibitor agents as well as other therapeutic agents used in 
this trial are known to be teratogenic, women of child -bearing potential and men must 
agree to use adequate contracep tion (hormonal or barrier method of birth control; 
abstinence) prior to study entry and for the duration of study participation.  Should a 
woman become pregnant or suspect she is pregnant while she or her partner is 
participating in this study, she should inform the principal investigator  immediately.  
   
7. Patients receiving any medications or substances that are strong inhibitors of CYP450 
3A4 isoenzyme are ineligible.  Please refer to Appendix C  for list of common strong 
inhibitors  of the CYP 3A4 isoenzyme.  This list is not meant to be comprehensive, but 
provides an example of medications. If there it remains unclear as whether the 
medication is a strong inhibitor, check the prescribing information of the medication 
for accurate details.  Patients must be off the strong inhibitor for at least 1 week prior 
to being deemed eligible.  
 
8. Patients may not have an u ncontrolled intercurrent illness including, but not limited 
to, ongoing or active infection, symptomatic congestive heart failure, unst able angina 
pectoris, cardiac arrhythmia, or psych iatric illness  that would limit compliance with 
study requirements.  
 
9. Patients must not have c linically significant cardiovascular disease (New York Heart 
Association Cl ass III or IV heart failure), u ncontrolled clinically significant atrial or 
ventricular cardiac arrhythmias, o r any of the following within the past 6 months: 
myocardial infarction, new evidence of transmural infarction on ECG, unstabl e 
angina, coronary angioplasty.   
 
10. Pregnant women are ex cluded from this study because ruxolitinib  is a Class C agent 
with the potential for teratogenic or abortifacient effects.  Because there is an 
unknown but potential risk for adverse events in nursing infants secondary t o 
treatment of the mother with r uxolitinib, breastfeeding must be discontinued  if the 
mother is treated with r uxolitinib.  These potential risks also apply to t rastuzumab, 
which can cause fetal harm when administered to a pregnant woman.   
 
11. Active Infections.  Patients with known active infections with human 
immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis B (HBV), and 
hepatitis C virus (HCV) infections will not be considered for this trial.  HIV+ patients 
on combination antiretroviral therapy are ineligible because  of the potential for 
pharmacokinetic interactions with  ruxolitinib .  In addition, these patients are at 
increased risk of lethal infections when treated with marrow -suppressive therapy.  
Testing for HIV or hepatitis is not required.  
 
4. REGISTRATION PROCEDU RES 
 
CUMC Research Participant Registration  
Confirm eligibility as defined in the section entitled Criteria for Subject Eligibility.  
 
Obtain informed consent, by following procedures defined in section entitled Informed 
Consent Procedures, along with applicable institutional policies and federal regulations.  
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 21 of 96 
 Only Investigators/Research personnel properly trained and delegated to consent subjects for 
this protocol will participate in the consenting process. Furthermore, properly 
delegated/trained Physi cian Investigators (i.e., MD, MD PhD) are required to sign/verify a 
protocol specific Eligibility Checklist for each subject enrolled on the study, in addition to 
providing the relevant source documentation to confirm subject eligibility.  
 
All participants  must be centrally registered through the Central Registration Office 
within Herbert Irving Comprehensive Cancer Center at CUMC prior to initiation of 
study treatment.  
 
Registration hours are available Monday through Friday from 9:00am â€“ 5:00pm EST 
(excluding holidays and weekends). Same day patient registrations (and after hour 
registrations) will be accommodated on a case -by-case basis provided that the study team has 
expressed all time sensitive registration concerns/cases in a timely manner to the Centr al 
Registration Office.  
 
CPDM Central Registration Procedures:  
Within 48 hours of obtaining consent (excluding holidays and weekends), a completed/signed 
IRB approved informed consent HIPAA form, and demographics forms must be submitted to 
the CPDM Central Registration Office via an email to CPDMRegistration@columbia.edu  or 
fax to 212.305.5292,  with the subject line â€œAAA M1906 Pending Subject Registration 
Request (PHI)â€.  Upon receipt, applicable subject information as well as a â€œpending 
eligibilityâ€ status will be entered into HICCCâ€™s institutional database.  This status will remain 
until further source documentation is made available to confirm overall patient eligibility. 
Required materials for all pend ing registration submissions are as follows:  
 
ï‚· Completed/signed IRB approved/stamped Informed Consent Forms, including 
additional study ICFs (i.e. tissue, DNA, etc.) as applicable  
ï‚· The completed/signed IRB approved HIPAA Authorization form  
ï‚· Completed/signed CPDM ICF checklist  
ï‚· Completed/signed HICCC personal census form  
ï‚· Completed/signed CPDM Demographics Note to File  
In order to confirm eligibility status, Investigators/designees (i.e., study specific Clinical 
Research Coordinator/Research Nurse, etc.) must sub mit the following documentation to the 
Central Registration Office via email or fax:  
 
ï‚· The completed/signed study specific Eligibility Checklist  (signed by a  Physician 
level Investigator)  
ï‚· Copies of source documentation necessary for each item to be verified on the CUMC 
specific Eligibility Checklist, including but not limited to:  
o Copy of required laboratory test and procedure reports (i.e., hematology, 
serum chemistry, pregnancy test when applicable, MRI reports, CT/bone scans  
or PET/CT , etc.) 
o Copy of pathology and surgical reports  
o Copy of clinic note(s) or other appropriate medical records capturing the 
consent process information, along with providing source documentation of 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 22 of 96 
 any other items needed for screening/eligibility that are not captured in o ther 
source document forms (e.g., positive investigator statements of unique 
eligibility items not captured via other direct source documentation, 
concomitant medication lists, etc)  
o Protocol deviation/waiver approvals (if applicable)  
ï‚· Please note : subject line of email or fax should include the following: â€œAAA M1906 
Complete Subject Registration Request (PHI) .â€ 
Upon Receipt of the above -mentioned documentation, participant eligibility information will 
be verified by a qualified Central Registration Registrar . If any questions arise during the 
review process, queries in the form of emails will be addressed to the applicable study team 
personnel for clarification prior to enrollment .  All applicable finalized registration/eligibility 
information will then be en tered into HICCCâ€™s institutional database by the Central 
Registration Registrar.  Upon completion, an official subject registration notification email 
will be sent to the PI/research team , which will include eligibility/enrollment status, as well 
as subject ID information.  Protocol therapy may not be initiated prior to receipt of this 
notification from the Central Registration Office.  
 
All screenfail/ineligible subjects, as well as subjects who withdraw consent prior to 
enrollment/initiation of protocol th erapy must be submitted to the Central Registration office 
in a manner analogous to the procedures noted above. Applicable source documentation will 
be required within the corresponding submissions.  
 
Central Registration Procedures - Affiliate Institution R esearch Participant Registration 
Process:  
 
All Affiliate Institutions must register subjects with the coordinating center (CUMC) prior to 
any administration of study drug/intervention/local institution registration.  Please see 
instructions below:  
 
Within 48 hours of obtaining consent (excluding holidays and weekends), the Affiliate 
Institution CRN and/or CRC is required to submit the following documents to the 
coordinating centerâ€™s designee  (CUMCâ€™s Multicenter Core ) via the study email at 
m1906@columbia.edu .  The coordinating centerâ€™s designee will review the documents for 
accurateness, and subsequently submit the documents to the CPDM Central Registration 
Office via email at CPDMRegistration@columbia.edu  (or via fax at 212.305.5292), with a 
request to register the patient â€œpending eligibility.â€ The title of the email should read, 
â€œAAAM1906 Pending Subject Registration Request (PHI)â€.  The following documents 
should be submitted with the pending registration request:  
ï‚· Redacted Completed/signed IRB approved/stamped Informed Consent Forms, 
including additional study ICFs (i.e. tissue, DNA, etc.) as applicable  
ï‚· Redacted Signed HIPAA (or institutional equivalent)  
ï‚· MCT CPDM Demographics Note to File form  
 
The Affiliate Institutionâ€™s investigator/research nurse/data manager/coordinator must contact 
the coordinating centerâ€™s designee (CUMC Multicenter Core ) via telephone or email at 
m1906@columbia.edu  to communicate the following:  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 23 of 96 
 ï‚· Notify of pending registration request  
ï‚· Confirm method of registration request submission (email or fax)  
ï‚· Communicate expected time -line of registration request submission (i.e., same 
day, next day, within the h our, etc.) 
 
To complete registration, the Affiliate Institutionâ€™s investigator/research nurse/data 
manager/coordinator should then submit the following documents to the CUMC study 
specific designee:  
ï‚· A signed Affiliate Site Eligibility Checklist (signed by the investigator)  
ï‚· Copies of redacted source documentation necessary for each item to be verified on 
the CUMC specific Eligibility Checklist, including but not limited to:  
o Copy of required laboratory test and procedure reports (i.e., hematology, 
serum chemi stry, pregnancy test when applicable, MRI reports, CT/bone 
scans, etc.)  
o Copy of pathology and surgical reports  
o Copy of clinic note(s) capturing the consent process information, along with 
providing source documentation of any other items needed for 
screening/eligibility that are not captured in other source document forms. 
(e.g., positive investigator statements of unique eligibility items not captured 
via other direct source documentation, concomitant medication lists, etc.)  
o Protocol deviation/waiver appro vals (if applicable)  
 
Please note : subject line of email or fax should include the following: â€œAAAM1906 
Complete Subject Registration Request (PHI)â€.  
 
Upon receipt of the above mentioned documents, the designated study specific Clinical 
Research Coordinato r will review all documents and verify patient eligibility.  If any 
questions arise during the review process, queries in the form of emails will be addressed to 
the applicable affiliate site study team personnel for clarification prior to enrollment.  Upo n 
verification, the CUMC study specific designee will then forward all documents to the 
CPDM Central Registration Office for central registration (as described above). The CPDM 
Central Registration Registrar will review all applicable documents and communi cate to the 
CUMC study specific designee in order to clarify any items.  The CUMC study specific 
designee will communicate with the applicable site study team personnel for additional 
clarifications necessary prior to enrollment.  
 
Upon receipt of the subje ct registration notification email, the CUMC study specific designee 
will forward the notification email (which will include the study specific patient ID) to the 
affiliate siteâ€™s Principal Investigator, Consenting Professional, and applicable research 
personnel.  This notification should be filed in the patient research binder accordingly. 
Protocol therapy may not be initiated prior to receipt of this notification from the 
coordinating center.  
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 24 of 96 
 All screenfail/ineligible subjects, as well as subjectâ€™s who withdraw consent prior to 
enrollment/initiation of protocol therapy must be submitted to the Central Registration office 
in a manner analogous to the procedures noted above. Applicable source documentation will 
be required within the corresponding submissi ons. 
 
5. TREATMENT PLAN  
 
5.1 Agent Administration  
Treatment will be administered on an outpatient basis.  Expected adverse events and potential 
risks are described in Secti on 7.  Appropriate dose modifications  are described in Section 6 .  
No investigational or co mmercial agents or therapies other than those described below may 
be administered with the intent to treat the patient's malignancy.  
 
Table 1: Regimen Description  
Agent Premedications; 
Precautions  Dose Route Schedule  Cycle 
Length 
Ruxolitinib  None 
 Phase I (assigned): 
BID dosing ( 10 mg, 
15 mg, 20 mg , or 25 
mg) 
Phase II: Based upon 
MTD from phase I  PO Days 1-
21  
21 days  
(3 weeks) 
 
 
 Trastuzumab  None (unless 
prior reaction)  6 mg/kg in 250 cc NS 
(8 mg/kg initial re -
load if no 
trastuzumab > 28 
days) IV over 90 
minutes for 
initial dose.  
IV over 3 0-90 
minutes for 
subsequent 
doses Day 1, 
Week 1 
 
 
Treatment Cycle  
The duration of a treatment cycle will be 21 days.  Ruxolitinib will be taken orally twice 
daily, every day for 21 days.  Trastuzumab will be administered IV on Day 1 out of a 21 -day 
cycle.  The initial d ose of trastuzumab  will be 8 mg/ kg (loading dose)  if the patient has  not 
received t rastuzumab in > 28 days .  If the patient has received a dose of trastuzumab within 
the prior 28 days then the initial dose will be 6 mg/kg. Subsequent doses will b e 6 mg/kg 
(maintenance dose).  
 
If the patient has a history of infusion re action to t rastuzumab, the pre -medications wi ll be 
administered 30 minu tes prior to administration of t rastuzumab .  Pre-medications  are allowed 
and should be followed by institutional standards.  These can include acetaminophen 650mg 
po once, diphenhydramine 25-50mg po/IV once 30 minutes prior to adm inistration of drug, 
and/or a H2 receptor antagonist (such as famotidine 20 mg po/IV).  
 
Patient compliance with ruxolitinib  will be assess ed by medication diary.  The patient will be 
requested to record each dose of medication.  The medication diary will b e returned to 
research staff at the end of each cycle.  
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 25 of 96 
 Ruxolitinib  
Ruxolitinib is an FDA -approved treatment for intermediate to high-risk myelofibrosis, 
including primary myelofibrosis, post -polycythemia vera myelofibrosis and post -
essential thrombocythemia myelofibrosis. I t does not require specific prophylactic or 
supportive regimens.  It is an oral therapy and can be administered with or without 
food according to manufacturerâ€™s recommendations.  Subjects in the phase I study 
will be given a  3-week supply of medication.  Dosing will start at 20 mg b.i.d. for the 
phase I. 
 
Trastuzumab  
Trastuzumab  is FDA-approved for  HER2+ breast cancer and gastric cancer.  It does 
not require specific prophylactic or supportive regimens.  It is an intravenous therapy 
that should be prepared according to manufacturerâ€™s recommendations.  It can be 
administered with or without food.  
 
5.2 General Concomitant Medication an d Supportive Care Guidelines  
Ruxolitinib is a n FDA approved treatment for myelofibrosis  and is commercially available.  
Per manufacturer Prescribing  Information (PI), there are no concurrent supportive or 
prophylactic regimen s recommended . 
 
Ruxolitinib is predominantly metabolized by CYP3A4. When administering ruxolitinib  with 
strong CYP3A4 inhibitors, a dose reduction is recommended.  Thus, co -administration of 
ruxolitinib  with strong CYP3A4 inhibitors will not be allowed.  Patients should b e closely 
monitored and the dose titrated based on safety and efficacy. No dose adjustment is 
recommended when ruxolitinib  is co-administered with mild or moderate CYP3A4 inhibitors 
(i.e. erythromycin) or a CYP3A4 inducer â€“ and patients on these medication s will not be 
excluded.  Appendix C  presents guidelines for identifying medications/substances that could 
potentially interact with the study agent(s).  
 
If a subject requires additional anti -cancer therapy,  the subject must be withdrawn from study 
treatment, with the exception of palliative radiotherapy (ie, to bone metastasis or for subjects 
who have disease progression limited to the CNS but who are otherwise benefiting from 
study treatment), which may be allowed during the study but must be discussed wit h the 
overall principal investigator . Study treatment should be withheld until palliative 
radiotherapy is terminated. This treatment break should not be considered as treatment 
interruption in determining the DLT. Palliative radiotherapy to metastatic dise ase sites is 
allowed provided there are other sites of disease and â‰¥ 1 week has elapsed since the 
completion of radiotherapy and all treatment -related toxicities have resolved or are at a new 
stable baseline. Subjects who have received radiation to the spi ne, pelvis, ribs, or femur 
should be discussed and approved by one of the overall principal  investigator prior to study 
re-entry.  If anti-cancer treatment follows discontinuation of study treatment due to clinical 
progression determined by the investigato r, the basis for this determination should be 
documented.  
5.3 Duration of Therapy  
In the absence of treatment delays due to adverse event (s), treatment may continue  until one 
of the following criteria applies:  
ï‚· Disease progression  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 26 of 96 
 ï‚· Intercurrent illness that prevents furt her administration of treatment  
ï‚· Unacceptable adverse event(s)  
ï‚· Patient decide s to withdraw from the study  
ï‚· General or specific changes in the patient's condition render the patient 
unacceptable for further treatment in the judgment of the inves tigator. OR 
ï‚· Pregnancy  
 
In the absence of one of the events listed above, there is no pre -defined limit on the number 
of potential cycles.  
 
5.4 Duration of Follow Up  
Patients will no longer be followed after removal unless adverse event (s) occur.  All  adverse 
events, both serious and non-serious, and deaths that are encountered  during the study and  
within 30 days of the  last study inter vention should be followed.  See Section 7.4.7.  
 
5.5 Criteria for Removal from Study  
Patients will be removed from study when any of the criteria listed in Section 5. 3 applies.  
The reason for study removal and the date the patient was removed must be documented in 
source documentation and the Case Report Form.  
 
6. DOSING DELAYS/DOSE M ODIFICATIONS  
The most common adverse events are list ed below.  Definitions of grading of each Adverse 
Events are defined per CTCAE 4.0 .  Doses of ruxolitinib  that are missed wil l not be made up, 
and upon resump tion of dosing, the cycle will stay on schedule.  If the dose is reduced for 
hematologic toxicities, a repeat complete blood count with differenti al should be performed 
within 7 days (+/ - 2 days) of dose reduction.  Management for each grade of AE is outlined 
below.   
 
Dosing delays/ dose  modification s should occur only if adverse event is deemed possibly, 
probably, or definitely related to study drug.  
 
Table 2: Dose Levels  
Dose Level  Ruxolitinib  Dose 
1 25 mg bid  
0 20 mg bid  
-1 15 mg bid 
-2 10 mg bid 
 
Table 3: Neutropenia  
Neutrophil Count 
Decreased  Management/Next Dose for 
Ruxolitinib  Management/Next Dose for 
Trastuzumab  
Grade 1 
<LLN â€“ 1500 No change in dose  No change in dose  
Grade 2 
<1500 â€“ 1000 No change in dose  No change in dose  
Grade 3 
<1000 â€“ 500 Hold* until â‰¤ Grade 2.  Resume at 
one dose level lower, per 
investigator discretion** No change in dose  
Grade 4 Hold* until â‰¤ Grade 2. Resume at No change in dose  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 27 of 96 
 Neutrophil Count 
Decreased  Management/Next Dose for 
Ruxolitinib  Management/Next Dose for 
Trastuzumab  
<500 one dose level lo wer** 
*Patients requiring a ruxolitinib  delay of > 28 days should go off protocol therapy.  Growth 
factor support is allowed, per investigator discretion.  
**Patients requiring > 2 dose reductions of ruxolitinib  should go off protocol therapy.  
 
Table 4: Thrombocytopenia  
Platelet Count 
Decreased  Management/Next Dose for 
Ruxolitinib  Management/Next Dose for 
Trastuzumab  
Grade 1 
<LLN - 75,000 No change in dose  No change in dose  
Grade 2 
<75,000 â€“ 50,000 No change in dose  No change in dose  
Grade 3 
<50,000 - 25,000 Hold* until â‰¤ Grade 2.  Resume at 
one dose level lower , per 
investigator discretion** No change in dose  
Grade 4 
<25,000 Hold* until â‰¤ Grade 2.  Resume at 
one dose level lower** No change in dose  
*Patients requiring a ruxolitinib  delay of > 28 days should go off protocol therapy.  
**Patients requiring > 2 dose reductions of ruxolitinib  should go off protocol therapy.  
 
Table 5: Anemia  
Hemoglobin 
Decreased  Management/Next Dose for 
Ruxolitinib  Management/Next Dose for 
Trastuzumab  
Grade 1 
<LLN â€“ 10 No change in dose  No change in dose  
Grade 2 
<10 â€“ 8 No change in dose  No change in dose  
Grade 3 
<8 Transfuse PRBC as clinically 
indicated.  Hold* until â‰¤ Grade 2.  
Resume at one dose level lower, 
per investigator discretion** No change in dose  
Grade 4 Transfuse PRBC as clinically 
indicated.  Hold* until â‰¤ Grade 2.  
Work up for alternative causes of 
blood loss.  First occurrence: 
Resume at one dose level lower.  
Second occurrence: off therapy.  No change in dose  
*Patients requiring a ruxolitinib  delay of > 28 days  should go off prot ocol therapy.   Growth 
factor support is allowed, per investigator discretion.  
**Patients requiring > 2  dose reductions of ruxolitinib  should go off protocol therapy.  
 
Table 6: Febrile Neutropenia  
Febrile Neutropenia  Management/Next Dose for 
Ruxolitinib  Management/Next Dose for 
Trastuzumab  
Grade 1 N/A N/A 
Grade 2 N/A N/A 
Grade 3 Hold* until â‰¤ Grade 2 .  Resume at No change in dose  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 28 of 96 
 Febrile Neutropenia  Management/Next Dose for 
Ruxolitinib  Management/Next Dose for 
Trastuzumab  
one dose level lower ** 
Grade 4 Hold* until â‰¤ Grade 2.  First 
occurrence: Resume at one dose 
level lower.  Second occurrence: 
off therapy.  No change in dose  
*Patients requiring a ruxolitinib  delay of > 28  weeks should go off protocol therapy.   Growth 
factors support is allowed, per investigator discretion.  
**Patients requiring > 2 dose reductions should go off protocol therapy.  
 
Table 7: Non -Hematologic Toxicities  
Non-Hematologic 
Toxicities   
(non-Cardiac)  Management/Next Dose for 
Ruxolitinib  Management/Next Dose for 
Trastuzumab  
Grade 1 No change in dose  No change in dose  
Grade 2 Hold* until â‰¤ Grade 1.  
Recommend resume at same dose 
level, but per investigator 
discretion.  If the toxicity is 
deemed possibly, probably, or 
definitely related to ruxolitinib  â€“ 
and not reduced after the first 
occurrence - a dose reduction 
should be considered after a second 
recurrence, if still deemed  
possibly, probably, or definitely 
related. No change in dose  
Grade 3 Hold* until â‰¤ Grade 1.  Resume at 
one dose level lower** No change in dose  
Grade 4 Off protocol therapy  Off protocol therapy  
*Patients requiring a delay of >2 weeks should go off protocol therapy.  
**Patients requiring > two dose reductions should go off protocol therapy.  
Recommended management  if diarrhea :  loperamide  antidiarrheal therapy  
Dosage schedule:  4 mg at first onset, followed by 2 mg with each loose motion until diarrhea -
free for 12 hours (maximum dosage:  16 mg/24 hours)  
Adjunct anti -diarrheal therapy is permit ted and should be recorded when used.  
Recommended management if nausea/vomiting: anti -emetics 
 
6.1 Management of Cardiac Toxicity  
Frequent cardiac evaluations will be performed in this study because cardiotoxicity has been 
reported in pati ents treated with single-agent trastuzumab and in combination with targ eted 
therapies.  Initiation of t rastuzumab will depend on review of the initial multiple -gated 
acquisition (MUGA) scan/echocardiogram (ECHO) results. It is recommended patients have 
their MUGA scans/ECHO s performed at the same radiology facility to eliminate variability 
between facilities. The same method for assessment should be used throughout the study.  A 
MUGA/ECHO should be performed at baseline, prior to cycle 2 (during phase I), and then 
every 3 cycles (~9 weeks+/ - 1 week) from the last MUGA/ECHO while on study treatment.  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 29 of 96 
 The cardioprotective drug de xrazoxane may not be taken by subjects  participating in this 
trial. 
 
6.2 Asymptomatic Decrease in LVEF  (Left Ventricular Ejection Fraction)  
Decision to cont inue or stop t rastuzumab treatment is based on the measured ejection fraction 
as it relates to the radiology facilityâ€™s lower limit of normal (LLN) and change in ejection 
fraction from baseline. Guidelines for performing MUGA scan/ECHO and management of 
patients who have an asymptomatic decrease in LVEF from baseline are provided below:  
 
Table 8: Guidelines for Trastuzumab Suspension  
Relationship of 
LVEF to Radiology 
Facilityâ€™s LLN  Decrease of < 10  
Percentage Points  
From Baseline  Decrease of 10 to  
15 Percentage Points  
From Baseline  Decrease of  
â‰¥ 16 Percentage  
Points From Baseline  
Within normal limits  Continue 
Trastuzumab  Continue 
Trastuzumab  Hold Trastuzumaba,b 
1-5 percentage points 
below 
LLN Continue 
Trastuzumab  Hold Trastuzumaba,b Hold Trastuzumaba,b 
â‰¥ 6 percentage points 
below 
LLN Continue 
Trastuzumaba Hold Trastuzumaba,b Hold Trastuzumaba,b 
LLN, lower limit of normal; LVEF, left ventricular ejection fraction; MUGA, multiple gated 
acquisition scan.  Source: Card iac management during adjuvant t rastuzumab therapy (Mackey et 
al. 2008).  
a Repeat MUGA/ECHO after 4 weeks.  
b After two consecutive  holds permanently discontinue t rastuzumab.  
 
If trastuzumab is held or discontinued during therapy, treatment with ruxolitinib may be 
continued , per the investigator . Trastuzumab must be permanently discontinued if withheld 
for more than 9 weeks or  earlier per discretion of the investigator. If LVEF is maintained at a 
â€œcontinue and repeat MUGA/ECHOâ€ or improves from a  â€œholdâ€ to a â€œcontinue and repeat 
MUGA/ECHOâ€ category, additional MUGA scans/ECHO prior to the next scheduled 
MUGA scan/ECHO will be at the discretion of the  investigator.  
 
6.3 Symptomati c Decrease in LVEF  
For symptomatic Grade 3 and Grade 4 congestive hear t failure (CHF), hold treatment with 
study drugs. A cardiology consult should be obtained and treatment per institutional  
standards should be initiated. Confirm diagnosis of CHF with either a MUGA  scan/ECHO. A 
chest x-ray is also required. Once a diagnosis of CHF is confirmed,  treatment with study 
drugs must be permanently discontinued and reported as an AE.   
 
6.4 Cardiac Ischemia/ Infarction  
Grade 1: Continue trea tment with frequent monitoring.  
 
Grade 2: Hold treatment with study drugs and conduct ca rdiac evaluation. Based on this 
evaluation, tr eatment may be continued at the discretion of the investigator.  
 
Grade 3 or 4: Discontinue treatment with study drugs.  
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 30 of 96 
 6.5 Arrhythmia  
Grade 1: Continue treatment with study drugs with caref ul monitoring OR hold treatment and 
conduct cardiac evaluation. Based  on cardiac evaluation, treatment with study drugs  may 
continue or discontinue at the discretion of the investigator.  
 
Grade 2: Hold treatment with study drugs and conduct cardiac evaluation. Based on  cardiac 
evaluation, treatment with study drugs may cont inue or discontinue at the  discretion of the 
investigator.  
 
Grade 3 or 4: Discontinue treatment with study drugs.  
 
6.6 Management of Corrected QTc Prolongation  
At any time point, if there is an increase in the QTc intervals (using Bazett or Fridericia 
correction formula) to > 500 msec (ie, Grade 3 QTc prolongation), an additional ECG should 
be performed. If the average QTc is > 500 msec, study treatment should be withheld.  If the 
subject is asymptomatic (ie, does not have palpitations, dizziness, syncope, orth ostatic 
hypotension, a significant ventricular arrhythmia on ECG, or a change in vital signs), the 
following actions should be taken:  
â€¢ Hold ruxolitinib .  Can continue t rastuzumab.  
â€¢ Check electrolytes, especially magnesium and potassium; correct abnormalities  as 
clinically indicated  
â€¢ Modify th e dose as a Grade 3, N on-hematologic AE as described in  Table 7 after 
the QTc elevation has resolved . 
 
Subjects with QTc prolongation and symptoms must b e monitored closely. Cardiology 
consultation is recommended for evalu ation and subject management. No additional study 
treatment will be given to the  subject unti l after the event has resolved.   
 
6.7 Management of Trastuzumab Infusion Reaction  
Infusion reactions consist of a symptom complex, such as fever and chills, and on oc casion 
nausea, vomiting, pain (in some cases at tumor sites), headache, dizziness, dyspnea, 
hypotension, rash, and asthenia. Infusion reactions should be managed by standard clinical 
practice. Stop infusion and give antipyretics if f ever occurs within 24 h ours of trastuzumab 
infusion. Once the temperature is < 38Â°C, resume infusion at a slower rate and monitor the 
patient according to institutional standard practice. Chill s triggered by t rastuzumab infusion 
can be treated with acetaminophen and/or diphenhyd ramine hydrochloride. Meperidine may 
be given at the investigatorâ€™s discretion.  
 
Pulmonary toxicity including dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural 
effusions, non -cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia,  acute 
respiratory distress syndrome, and pulmonary fibrosis can occur as sequelae of infusion 
reactions. Management of pulmonary toxicity should follow clinical standard practice.  
 
7. ADVERSE EVENTS:  LIS T AND REPORTING REQU IREMENTS  
 
An Adverse Event ( AE) is any undesirable sign, symptom or medical condition or experience 
that develops or worsens in severity after starting the first dose of study treatment or any 
procedure specified in the protocol, even if the event is not considered to be related to the 
study. 
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 31 of 96 
 Abnormal laboratory values or diagnostic test results constitute adverse events only if they 
induce clinical signs or symptoms or require treatment or further diagnostic tests.  
 
Adverse events will be monitored from the time the subject signs infor med consent. Subjects 
will be instructed to report all AEs during the study and subjects will be assessed for the 
occurrence of AEs throughout the study. All AEs (serious and nonserious) must be recorded 
on the source documents and case report forms regard less of the assumption of a causal 
relationship with the study drug.  
 
Adverse Events that begin or worsen after informed consent should be recorded in the 
Adverse Events section of the case report form  (CRF). Conditions that were already present 
at the time of informed consent should be recorded in the baseline symptoms section of the 
CRF. Adverse Event monitoring should be continued for at least 30 days following the last 
dose of study treatment. Adver se Events (including lab abnormalities that constitute AEs) 
should be described using a diagnosis whenever possible, rather than individual underlying 
signs and symptoms. When a clear diagnosis cannot be identified, each sign or symptom 
should be reported as a separate AE.  
 
The following list of AEs (Section 7.1) and the characteristics of an observed AE (Section 
7.2) will determine whether the event requires expedited  reporting in addition  to routine 
reporting.  
 
7.1 Comprehensive Adverse Events and Potential R isks List 
 
Adverse Event List  for Ruxolitinib  
Adverse Events with Possible Relationship to Ruxolitinib  
(CTCAE 4.0 Term)  
Likely (> 20%)  Less Likely ( â‰¤ 20%)  Rare but Serious ( <3%)  
BLOOD AND LYMPHATIC SYSTEM DISORDERS  
 
1. Anemia  1. Febrile neutropenia  
  
CARDIAC DISORDERS  
 1. Atrial Flutter  
2. Atrial Fibrillation  
 Cardiac Failure  
GASTROINTESTINAL DISORDERS  
 
1. Diarrhea  
 1. Abdominal pain  
2. Abd Distension  
3. Constipation  
4. Dyspepsia  
5. Flatulence  
6. Nausea  
 1. Colitis 
2. Gastrointestinal hemorrhage  
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS  
 1. Fatigue   
2. Fever   
3. Pain  
4. Edema limb  
  
INFECTIONS AND INFESTATIONS  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 32 of 96 
     1. Infection  1.  Posterior multifocal 
leukoencephalopathy  
INJURY, POISONING, AND PROCEDURAL COMPLICATIONS  
1. Bruising    
INVESTIGATIONS  
1. Platelet count decreased  1. Aspartate aminotransferase 
increased  
2. Bilirubin increased  
3. GGT increased  
4. Neutrophil count decreased2  
5. Weight Gain  
  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS  
 1. Arthralgia  
2. Back pain  
  
NERVOUS SYSTEM DISORDERS  
 1. Headache  
2. Dizziness   
  
PSYCHIATRIC DISORDERS  
   1. Confusion  
  2. Insomnia   
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS  
 
 1. Cough  
2. Dyspnea  
3. Epistaxis  1. Pleural Effusion  
  
  
SKIN AND SUBCUTANEOUS TISSUE DISORDERS  
 1. Rash  Rash acneiform (Gr. 3)  
  
VASCULAR DISORDERS  
  1. Hematoma  
 
The compariso n of the control groups to the ruxolitinib  patients showed that headache was 
more frequent in ruxolitinib -treated patients (13.6% vs. 6.0% on placebo and 5.5% on best 
available therapy: BAT). Most AEs of headache were Grade 1 or 2. Similarly, dizziness 
(12.0% vs. 6.6% on placebo and 6.8 % on BAT) w as more frequent in ruxolitinib -treated 
patients, again mostly Grade 1 or 2. When adjusted for patient -year exposure, the differences 
are still present for headache and dizziness.  
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 33 of 96 
 Weight increase was also more frequent in ruxolitinib -treated patients than  in the control 
groups (9.6% vs. 1.3% on placebo and 1.4% on BAT). Although some of these patients had 
co-reported AEs of edema, many had a past medical history of weight loss and the weight 
gain usually gradually accumulated over the course of one year of  treatment. The majority of 
weight gain AEs were Grade 1 and 2. It is worth noting that weight gain may be a beneficial 
effect in patients with MF, given the catabolic nature of the disease and the frequency of 
weight loss reported as a constitutional symp tom. Other preferred terms w ith increased 
frequency in the ruxolitinib  arms included bruising (2.6% vs. 1.3% on placebo), contusion 
(8.6% vs. 5.3% on placebo and 1.4% on BAT), urinary tract infection (7.3% vs. 4.6% on 
placebo and 2.7% on BAT), herpes zoste r (4.0% vs. 0.7% on placebo and 0% on BAT) and 
flatulence (3.3% vs. 1.3% on placebo and 0% on BAT).  
 
Abdominal pain was more frequent in the control groups than in the ruxolitinib  group (43% 
on placebo and 13.7% on BAT vs. 12% on ruxolitinib ), as were weig ht decrease (8.6% on 
placebo and 8.2% on BAT vs. 1% on ruxolitinib ), early satiety (8.6% on pla cebo and 0% on 
BAT vs. 0.3% on ruxolitinib ) and splenic infarction (6.0% on placebo and 0% on BAT vs. 
1.0% on ruxolitinib ). 
 
A total of 13 reports of tuberculosis (TB) during ruxolitinib treatment had been received from 
all clinical trials, as of February 2013.  The cumulative incidence of TB reported in subjects 
treated with ruxolitinib (13/4755; 0.27%) is less than that originally observed in the Phas e III 
clinical trials (3/301; 1.0%), possibly due to differences in time of exposure to ruxolitinib and 
a more heterogeneous study population.  The Phase III clinical trial sample size did not allow 
detection of a statistically significant difference in th e incidence of tuberculosis between the 
treatment and control arms.  The cumulative incidence of these TB reports appears to have 
declined since the original Phase III trials.  
 
Progressive multifocal leukoencephalopathy (PML) was reported in a myelofibrosi s patient 
receiving ruxolitinib, with an atypical feature of a short time to onset (approximately 1 
month) after initiation of ruxolitinib treatment.  Because of its mechanism of action, 
ruxolitinib may be associated with a higher risk of infections.  Howe ver, infections are also 
well known complications of myelofibrosis and the occurrence of PML has been described in 
myeloproliferative diseases in the absence of ruxolitinib treatment.  Whereas a contribution 
of ruxolitinib therapy cannot be formally ruled out, the available information with the 
observation of a single case of PML is currently insufficient to formally establish a causal 
association of PML with the drug therapy.  Based on this report and provided the potentially 
disabling outcome of this cond ition, the potential risk of PML is closely monitored.  
 
Non-melanoma skin cancers (NMSC) have been reported in patients treated with ruxolitinib. 
These are highly uncommon.  Most of these patients had histories of extended treatment with 
hydroxyurea (a che motherapy associated with skin cancer) and prior NMSC or pre -malignant 
skin lesions.  Hydroxyurea is not a standard chemotherapy given to patients with breast 
cancer. A causal relationship to ruxolitinib has not been established . 
 
Updated Risk Section, inc luding update on NMSC and the following statement: â€œ Ruxolitinib 
is currently und er clinical development for the treatment of solid tumors in combination with 
cytotoxic chemotherapy.  To date there have been no specific adverse drug reactions have 
been identified that are  unique to ruxolitinib combination therapies under study, and the  
relative strength index derived primarily from treatment of myeloproliferative  neoplasms is 
appropriate for these ongoing studies in solid  tumors. 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 34 of 96 
  
Adverse Event List for Trastuzumab  
Adverse Events with Possible Relationship to Trastuzumab  
(CTCAE 4.0 Term)   
Likely (> 20%)  Less Likely ( â‰¤ 20%)  Rare but Serious ( <3%)  
BLOOD AND LYMPHATIC SYSTEM DISORDERS  
 
 1. Anemia   
2. Febrile neutropenia2  
  
CARDIAC DISORDERS  
 1. Cardiomyopathy  
2. Left ventricular systolic 
dysfunction   
3. Pericardial effusion  
4. Pericarditis  
5. Sinus tachycardia   
6. Supraventricular tachycardia  
  
GASTROINTESTINAL DISORDERS  
 
 1. Abdominal pain  
2. Diarrhea  
3. Mucositis oral  
4. Nausea  
5. Vomiting  
  
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS  
 1. Chills   
2. Fatigue   
3. Fever   
4. Flu like symptoms   
5. Infusion related reaction  
6. Non-cardiac chest pain   
7. Pain  
  
IMMUNE SYSTEM DISORDERS  
 1. Allergic reaction3  
2. Anaphylaxis  
  
INFECTIONS AND INFESTATIONS  
    1. Infection4   
INVESTIGATIONS  
 1. Alkaline phosphatase 
increased  
2. Aspartate 
aminotransferase increased  
3. GGT increased  
4. Neutrophil count 
decreased2  
  
METABOLISM AND NUTRITION DISORDERS  
 1. Anorexia   
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS  
 1. Arthralgia  
2. Back pain  
3. Bone pain  
4. Myalgia  
  
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)  
 1. Tumor pain   
NERVOUS SYSTEM DISORDERS  
 1. Headache   
2. Peripheral sensory  
 neuropathy  
  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 35 of 96 
 RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS  
 
 1. Allergic rhinitis   
2. Cough   
3. Dyspnea3   
4. Hypoxia3   
5. Pneumonitis3  
6. Pulmonary edema  
7. Pulmonary fibrosis  
   1. Adult respiratory   distress syndrome3 
  2. Bronchospasm3 
3. Pneumonitis3  
4. Pulmonary edema  
5. Pulmonary fibrosis  
  
SKIN AND SUBCUTANEOUS TISSUE DISORDERS  
 1. Rash acneiform  Rash acneiform (Gr. 3)  
2. Rash maculo -papular  Rash maculo -papular (Gr. 3)  
3. Urticaria  Urticaria (Gr. 3)  
  
VASCULAR DISORDERS  
 1. Hypertension5  
2. Hypotension5  
  
1This table will be updated as the toxicity profile of the agent is revised.  
2Fatal event when given in combination with XelodaÂ® (capecitabine) and TaxotereÂ® (docetaxel).  
3Severe hypersensitivity reactions including angioedema and pulmonary adverse events (e.g., hypoxia, dyspnea, 
pulmonary infiltrates, pleural effusion, and acute r espiratory distress syndrome) have been reported.  
4Infection may include any of the 75 sites of infection under the INFECTIONS AND INFESTATIONS SOC.  
5Associated with infusion reactions.  
 
Additional adverse events:  
The following are adverse events which have been repo rted on trastuzumab trials; however, 
the relationship to t rastuzumab is currently undetermined .  
ï‚· Cardiac Disorders â€“ acute coronary syndrome, atrial fibrillation, cardiac arrest, 
myocardial infarction; ventricular ar rhythmia; ventricular fibrillation; ventricular 
tachycardia  
ï‚· Ear and Labyrinth Disorders - hearing impaired  
ï‚· Endocrine Disorders â€“ hypothyroidism  
ï‚· Eye Disorders - blurred vision; extraocular muscle paresis  
ï‚· Gastrointestinal Disorders - colitis; dyspepsia; enterocolitis; esophageal ulcer; 
gastritis; pancreatitis; upper gastrointestinal hemorrhage  
ï‚· General Disorders and Administration Site Conditions - sudden death NOS  
ï‚· Immune System Disorders - immune system disorders - Other (autoimmune 
thyroiditis)  
ï‚· Investigations - alanine aminotransferase increased; blood bilirubin increased; cardiac 
troponin-I; creatinine increased; platelet count decreased  
ï‚· Metabolism and Nutrition Disorders - hypomagnesemia; hyponatremia  
ï‚· Musculoskeletal and Connective Tissue Dis orders - avascular necrosis; generalized 
muscle weakness; muscle weakness left -sided; muscle weakness lower limb; muscle 
weakness right -sided; muscle weakness trunk; muscle weakness upper limb; 
musculoskeletal and connective tissue disorder - Other (myopat hy)  
ï‚· Nervous System Disorders - ataxia; cognitive disturbance; depressed level of 
consciousness; dizziness; hydrocephalus; ischemia cerebrovascular; neuralgia; 
seizure; syncope  
ï‚· Psychiatric Disorders - anxiety; confusion; depression; psychosis  
ï‚· Renal and U rinary Disorders - acute kidney injury; hematuria; proteinuria; urinary 
tract obstruction  
ï‚· Reproductive System and Breast Disorders - fallopian tube obstruction; prostatic 
obstruction; spermatic cord obstruction; uterine obstruction; vaginal obstruction  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 36 of 96 
 ï‚· Respiratory, Thoracic and Mediastinal Disorders - apnea; laryngeal edema; 
pharyngolaryngeal pain; pleural effusion; pneumothorax; pulmonary hypertension; 
voice alteration  
ï‚· Skin and Subcutaneous Tissue Disorders - nail loss; pruritus; skin ulceration  
ï‚· Vascular Disorders - thromboembolic event  
 
Note: Trastuzumab in combination with other agents could cause an exacerbation of any 
adverse event currently known to be caused by the other agent, or the combination may result 
in events never previously associated w ith either agent.  
Additional adverse events from the FDA -approved October 2010 Prescribi ng 
Information for HerceptinÂ® (T rastuzumab)  
General Disorders â€“ edema limbs, edema trunk  
Infections and Infestations â€“ pharyngitis  
Nervous System Disorders â€“ dizziness  
Psychiatric Disorders â€“ depression, insomnia  
Renal and Urinary Disorders â€“ other (glomerulopathy)  
 
7.2 Definitions  and Reporting  
 
7.2.1 Dose Limiting Toxicity (DLT)  
A dose-limiting toxicity is defined as any grade 3 non -hematologic toxicities despite maximal 
supportive care or any grade 4 hematologic toxicity directly related to study drug.  In order 
for a patient to be completely evaluable for DLT, the patient must incur a DLT during the 
first 21 days of actively taking ruxolitinib plus trastuzumab.  If, for instance, the patient 
temporarily stops ruxolitinib due to uncomplicated hematologic toxicities, the patient can 
resume ruxolitinib at the same dose and the DLT period will remain defined as the first 21 
days of actively taking the study medication.  In or der to be considered completely followed, 
the DLT period (i.e. 21 days of actively taking ruxolitinib plus trastuzumab) must be 
completed within 30 days of the first dose of ruxolitinib.  If a patient is not compl etely 
followed due to dropout, treatment di scontinuation, or death which is unrelated to study drug, 
we will replace that patient so that the sample size refers to those with complete DLT follow -
up.  However, patients with partial follow -up will be included up to their last assessment 
while on trea tment. 
 
7.2.2 Adverse Event (AE)  
AEs will be assessed according to the Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.0. The occurrence of AEs should be sought by non -directive questioning 
of the subject during the screening process after signi ng informed consent and at each visit 
during the study. As far as possible, each AE should be evaluated to determine:  
â€¢ The severity grade (CTCAE Grade 1 -5) 
â€¢ Reasonable possibility that AE is related to the study treatment: Definite, Probable, 
Possible, U nlikely, Unrelated (Section 7.3.4) 
â€¢ Start and end dates, unless unresolved at final exam  
 
Action take n with respect to study drug (i.e. , none, dose adjusted, temporarily interrupted, 
permanently discontinued, unknown, not applicable)  
â€¢ Outcome (eg, not re covered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequelae, fatal, unknown)  
â€¢ Whether it is serious, as per Serious Adverse Event (SAE) definition provided in Section 
7.2.2. 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 37 of 96 
  
Unlike routine safety assessments, SAEs are  monitored continuously and have special 
reporting requirements, see Section 7.2.2. 
 
All AEs should be treated appropriately. If a concomitant medication or non -drug therapy is 
given, this action should be recorded on the AE CRF as well as the Prior/Concom itant 
medications CRF.  
 
Once an AE is detected, it should be followed until its resolution or until it is judged to be 
permanent; assessment should be made at each visit (or more frequently if necessary) of any 
changes in severity, the suspected relationsh ip to the study drug, the interventions required to 
treat it, and the outcome.  
 
Disease progression should not be regarded or reported as an AE itself, unless it is associated 
with a separate AE.  
 
Laboratory abnormalities that constitute an AE in its own r ight (are considered clinically 
meaningful, induce clinical signs or symptoms, require concomitant therapy or require 
changes in study treatment), should be recorded on the AE CRF. Whenever possible, a 
diagnosis, rather than a symptom should be provided (i .e., anemia instead of low 
hemoglobin). Laboratory abnormalities that meet the criteria for AEs should be followed 
until they have returned to normal or an adequate explanation of the abnormality is found.  
 
When an abnormal laboratory or test result corres ponds to a sign or symptom of a previously 
reported AE, it is not necessary to separately record the lab/test result as an additional event.  
 
Laboratory abnormalities that do not meet the definition of an AE should not be reported as 
AEs. A Grade 3 or 4 (severe) event, as per CTCAE, does not automatically indicate a SAE 
unless it meets the definition of serious, as defined below, and/or as per the investigatorâ€™s 
discretion.  
 
7.2.3 Serious adverse event (SAE)  
A serious adverse event (SAE) is any adverse event, o ccurring at any dose and  
Regardless of causality that:  
 
â€¢ Results in death . 
 
â€¢ Is life-threatening. Life -threatening means that the person was at immediate risk of death 
from the reaction as it occurred, i.e., it does not  include a reaction which hypotheti cally might 
have caused death had it  occurred in a more severe form. 
 
â€¢ Requires or prolongs inpatient hospitalizati on (i.e., the event required at least a 24 -hour 
hospitalization or prolonged a hospitalization beyon d the expected length of stay). 
Hospitalization admissions and/or surgical operations scheduled to occur during the study 
period, but planned prior to study entry are not considered SAEs if the illness or disease 
existed before the person was enrolled in the trial, provided that it did not deter iorate in an 
unexpected manner during the trial (e.g., surgery performed earlier than planned).  
 
â€¢ Results in persistent or significant disability/incapacity. Disability is defined as a substantial 
disruption of a personâ€™s ability to conduct normal life fu nctions. 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 38 of 96 
  
â€¢ Is a congenital anomaly or birth defect; or  
 
â€¢ Is an important medical event when,  based upon appropriate medical judgment, it may 
jeopardize the participant and require medical or surgical  intervention to prevent one of the 
outcomes listed above. Examples of  such medical events include allergic bronchospasm 
requiring intensive  treatment in an emergency room or at home; blood dyscrasias or  
convulsions that do not result in inpatient hospitalization, or the  development of drug 
dependency or dr ug abuse.   
 
Events not considered to be serious adverse events are hospitalizations for:  
 
â€¢ Routine treatment or monitoring of the stu died indication, not associated with any 
deterioration in condition, or for elective procedures . 
 
â€¢ Elective or pre -planned treatment for a pre -existing condition that did not w orsen. 
 
â€¢ Emergency outpatient treatment for an event not fulfilling the serious  criteria outlined above 
and not resulting in inpatient admission . 
 
â€¢ Respite care  
 
7.2.4 Unanticipated Problem  
An Unanticipated Problem (UP) is any incident, experience or outcome involving risk to 
subjects or others in any human subjects research that meets all of the following criteria:  
ï‚· Unexpected (in terms of nature, severity or frequency) given (a) the research 
procedures that are described in the IRB -approval protocol and informed consent 
document, and (b) the characteristics of the subject population being studied;  
ï‚· Related or possibly related to participation in such research (i.e., there is a reasonable 
possibility that the incident, experience or outcome may have been caused by the 
procedures involved in such research); and  
ï‚· Suggests that the research places subjects or others at a greater risk of harm (including 
physical, psychological, economic or social har m) than was previously known or 
recognized .   
 
7.2.5 Suspected Adverse Reaction  
A Suspected Adverse Reaction (SAR) is any AE for which there is a reasonable possibility 
that it was caused by the drug.  
Reasonable possibility means that there is evidence to suggest a causal relationship between 
the drug and the AE.  Examples of reasonable possibility are:  
ï‚· A single occurrence of an event that is uncommon and known to be strongly 
associated with drug exposure.  
ï‚· One or more occurrences of an event that is not com monly associated with drug 
exposure, but is otherwise uncommon in the population exposed to the drug.  
ï‚· An aggregate analysis of specific events observed in a clinical trial that indicates that 
those events occur more frequently in the drug treatment group t han in a concurrent or 
historical control group.  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 39 of 96 
 7.2.6 Expectedness  
Adverse events can be 'Expected' or 'Unexpected.'  
 
Expected adverse events are those that have been previously identified as resulting from 
administration of the agent. For the purposes of this  study, an adverse event is considered 
expected when it appears in the current adverse event list, the Investigatorâ€™s Brochure, the 
package insert or is included in the informed consent document as a potential risk.  
 
For the purposes of this study, an adve rse event is considered unexpected when it varies in 
nature, intensity or frequency from information provided in the current adverse event list, the 
Investigatorâ€™s Brochure, the package insert or when it is not included in the informed consent 
document as a potential risk.  
 
7.2.7 Attribution  
Attribution is the relationship between an adverse event or serious adverse event and the 
study treatment. Attribution will be assigned as follows:  
 
â€¢ Definite â€“ The AE is clearly related to the study treatment.  
â€¢ Probable â€“ The AE is likely related to the study treatment.  
â€¢ Possible â€“ The AE may be related to the study treatment.  
â€¢ Unlikely - The AE is doubtfully related to the study treatment.  
â€¢ Unrelated - The AE is clearly NOT related to the study treatment.  
 
7.2.8 Expedited Adv erse Event Reporting  
Participating investigators will assess the occurrence of AEs and SAEs at all participant 
evaluation time points during the study.  
 
All AEs and SAEs whether reported by the participant,  discovered during questioning, 
directly observed,  or detected by physical examination, laboratory test or other means,  will be 
recorded in the participantâ€™s medical record and on the appropriate study specific  case report 
forms. 
 
The descriptions and grading scales found in the revised NCI Common Termino logy 
Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE reporting.  A copy 
of the CTCAE version 4.0 can be downloaded from the CTEP website at:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . 
 
For multi -site trials where a Columbia University Medical Center investigator is serving as 
the principal investigator, each participating investigator is required to abide by the  reporting 
requirements set by Columbia University Medical Center. The study must be conducted in 
compliance with FDA regulations, local safety reporting requirements, and reporting 
requirements of the principal investigator.  
 
Each investigative site will be responsible to report SAEs that occur at that institution to their 
respective IRB. It is the responsibility of each participating investigator to report serious 
adverse events to the study sponsor (i.e. Kevin Kalinsky, MD, MS and Incyte representative) 
as described below.  
 
In addition to the reporting requirements for SAEs, a se parate case report form will be made 
for reporting of any grade adverse eve nts attributable to  research biopsies. These events will 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 40 of 96 
 not require expedited reporting unless they als o meet the requirements for SAE reporting, as 
detailed below.  
 
Copies of all IND safety reports submitted to the FDA and/or institutional IRB by the 
institution under the institutionâ€™s IND will be shared with Incyte Pharmacovigilance  
representative, so tha t these reports can be evaluated and included in the Investigator  
Brochure and future Incyte IND safety submissions per regulations.  
 
7.2.9 Serious Adverse Event Reporting  
All serious adverse  events that occur after the initial dose of study  treatment, during 
treatment, or within 30 days of the  last dose of treat ment must be reported to Columbia 
University Medical Center Overall Principal Investigator on the local institutional SAE form. 
This includes events meeting the criteria outlined in Section 7.2.2, as well as the following:  
 
â€¢   All Grade 4 (life-threatening  or disabling) Events â€“ Unless expected  AND 
specifically listed in the protocol as not requiring reporting.  
 
â€¢   All Grade 5 (fatal) Events â€“ When the participant is enrolled and actively 
participating in the trial OR when the  event occurs within 30 days of the  last study 
intervention.  
 
Note: If the participant  is in long term follow up, report  the death at the time of 
continuing  review.  
 
Participating  investigat ors must report each serious adverse event to the Columbia University 
Medical Center Overall Principal Investigator  within 24 hours of learning  of the occurrence.  
In the event that the participating investigator  does not become aware of the serious adverse  
event immediately (e.g., participant sought treatment elsewhere),  the participating  
investigator  is to report the event within 24 hours after  learning of it and document the time of 
his or her first awareness of the  adverse event. Report serious adverse  events by telephone,  
email or facsimile to: 
 
Name of Contact:   Kevin Kalinsky, MD  
Address:   Columbia University Medical Center  
Herbert Irving Comprehensive Cancer Center  
161 Fort Washington Avenue  
New York, NY 10032  
Email:    M1906@columbia.edu  
Phone:    212-305-1945 
Fax:   212-305-0178 
 
 
Within the following  24-48 hours, the  participating investigator  must provide follow-up 
information on the serious adver se event. Follow-up information should describe whether the 
event has resolved or continues,  if and how the event was treated,  and whether the participant 
will continue or discontinue study particip ation. 
 
Follow-up information is sent to the same person to whom the original SAE 
Report Form was sent, using a new SAE Report  Form stating that this is a follow- up to the 
previously  reported SAE and giving the date of the original report. Each re-occurrence, 
complication,  or progression of the original event should be reported as a follow-up to that 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 41 of 96 
 event regardless  of when it  occurs. The follow-up information should describe whether the 
event has resolved  or continues,  if and how it was treated,  and whether the subject continued 
or withdrew  from study participation  or if study drug was interrupted  or discontinued.   
If the SAE is not previously  documented in the Investigatorâ€™s  Brochure for the study drug 
(new occurrence)  and is thought to be related to the Sponsorâ€™s  study drug, a Sponsorâ€™s 
associate may urgently require further information from the Investigator  for reporting  to 
Health Authorities.   
The Sponsor may need to issue an Investigator Notification  (IN) to inform all Investigators 
involved in any study with the same drug that this SAE has been  reported. Suspected 
Unexpected Serious Adverse Reactions  (SUSARs) will  be collected and reported to the 
competent authorities and relevant ethics committees in accordance with Directive 
2001/20/EC or as per  national regulatory requirements in participating  countries.  If the study 
is open-label, no special  unblinding  procedures  are needed for exceptional  circumstances or 
medical emergencies.  
 
7.2.10  Pregnancy  
Pregnancy,  in and of itself, is not regarded as an AE, unless there  is suspicion  that study drug 
may have interfered  with the effectiveness  of a contraceptive  medication or method.  The 
procedures  that will be followed based on whether  a pregnancy  is confirmed by a positive  
serum or urine test result are listed below:  
â€¢ Investigator  and subject must notify each other immediately .   
o Investigator  must notify the Principal Investigator  and Incyte within 24 
hours of learning  of the occurrence   
â€¢ Study drug must  be discontinued immediately.   
â€¢ Subject must be withdrawn  from the study.  
 
â€¢ Investigator  must complete and submit the Pregnancy  Initial and Follow-up report  
forms to the Principal Investigator  and to Incyte.  
 
â€¢ A serum pregnancy test must be performed to confirm the urine test result. (The 
serum test should be performed at the investigative  site to ensure the test will be 
performed promptly and the result available immediately for review.) 
  
If a negative serum test does not confirm the urine test result, then:  
â€¢   The Investigator  will use his/her  expert judgment, based on an assessment  
of the pote ntial benefit/risk to the subject, to determine if it is in the subjectâ€™s 
best interest to resume study drug and continue participation  in the study.  
To ensure subject safety, each pregnancy in a subject during mater nal or paternal 
exposures to study drug must be re ported within 24 hours of lear ning of its 
occurrence.  Data on fetal outcome and breast-feeding are collected for regulatory  reporting 
and drug safety evaluation.  The pregnancy should be followed- up to determine  outcome, 
including spontan eous or voluntary  termination, details of the birth, and the presence or 
absence of any birth defects, congenital abnormalities, or maternal and/or newborn 
complications  by following  until the first well-baby visit. Pregnancy should be recorded on 
a Clinical Study Pregnancy  Form and reported by the Investigator  to the Incyte. Pregnancy  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 42 of 96 
 follow-up should be  recorded on the same form and should include an assessment of the 
possible relationship  to the study drug of any  pregnancy  outcome and follow-up to the first 
well-baby visit. Any SAE experienced during pregnancy must be reported on the SAE 
Report Form and to Incyte Corporation.  
 
7.2.11  Non-Serious Adverse Event Reporting  
 
Non-serious adverse events will be reported to the Columbia University Medical Center 
Overall Principal Investigator  on the toxicity Case Report Forms. 
 
7.2.12  Reporting to the Institutional Review  Board (IRB) 
Unanticipated Problems (Ups) are to be reported to the IRB.  SAEs not constituting UPs are 
to be reported to the HICCC DSMC.   
 
Other investigative  sites should report serious adverse events to their respective  IRB 
according to the local IRBâ€™s policies  and procedures in reporting adverse events. A copy 
of the submitted institutional SAE form should be forwarded  to: 
 
Name of Contact:   Kevin Kalinsky, MD  
Address:   Columbia University Medical Center  
Herbert Irving Comprehensive Cancer Center  
161 Fort Washington Avenue  
New York, NY 10032  
Email:    M1906@columbia.edu  
Phone:    212-305-1945 
Fax:   212-305-0178 
 
SAEs are to be reported to the HICCC DSMC, if th ey are considered UPs, then they must be 
submitted to CUMC IRB per institutional policies.  
 
Unanticipated Problems must be reported promptly, but not later than 7 calendar days 
following the occurrence of the UP or the Principalâ€™s Investigatorâ€™s acquiring knowledge of 
the UP. 
 
Expected AEs must be reported at the time of continuing review of a protocol.  
 
7.2.13  Reporting to the Food and Drug Administration (FDA)  
Columbia University Medical Center Overall Principal Investigator  (Sponsor-Investigator) , as 
holder of the IND, will  be responsible for all communication with the FDA. Columbia 
University Medical Center Principal Investigator will report to the FDA, regardless  of the site 
of occurrence, any adverse event that is serious, unexpected  and reasonably  related (i.e., 
possible, probable, definite) to the study treatment. 
 
The Columbia University Medical Center Sponsor Investigator must report the following 
SARs: 
â€¢ To the FDA, as soon as possible, but no later than 7 calendar days after the S -I's 
initial receipt of the information, any unexpected fatal or life -threatening SAR.  
â€¢ To the FDA and all participating investigators, as soon as possible but no later 
than 15 calendar days after the S -I determines that information qualifies for 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 43 of 96 
 reporting, in an IND safety report , any SAR that is both serious and unexpected.  
â€¢ To the FDA and all participating investigators, as soon as possible but no later 
than 15 calendar days after the S -I determines that the information qualifies for 
reporting, any findings from epidemiological s tudies, pooled analysis of multiple 
studies or clinical studies, whether or not conducted under an IND or by the S -I, 
that suggest a significant risk in humans exposed to the drug.  
â€¢ To the FDA and all participating investigators, as soon as possible, but n o later 
than 15 calendar days after the S -I determines that the information qualifies for 
reporting, any findings from animal or in vitro testing, whether or not conducted 
by the S-I, that suggest a significant risk in humans exposed to the drug.  
â€¢ To the FDA and all participating investigators, as soon as possible, but no later 
than 15 calendar days after the S -I determines that the information qualifies for 
reporting, any clinically important increase in the rate of a Serious SAR over that 
listed in the pr otocol or Investigator Brochure.  
â€¢ Expected SAEs and AEs should be included in the IND Annual Reports.  
 
Follow-up information to a safety report should be submitted as soon as the relevant 
information is available.  However, if the results of a sponsorâ€™s inv estigation show that an 
adverse drug experience not initially determined to be reportable are so reportable, the 
sponsor must report such experience as soon as possible, but no later than 15 calendar days 
after the determination is made.  
 
All other serious unexpected  experiences  associated with the use of the  study treatment will 
be reported to FDA as soon as possible but in no event later than 15 calendar  days after 
initial receipt of the information. 
 
Events will be reported to the FDA by telephone  (1-800-FDA-1088) or by fax  (1-800- 
FDA-0178) using  Form FDA 3500A (Mandatory  Reporting  Form for investigational  
agents) or FDA Form 3500 (Voluntary  Reporting Form for commercial  agents). Forms are 
available at http://www.fda.gov /medwatch/getfo rms.htm. 
 
7.2.14  Reporting to Incyte Corporation  
The Overall Principal Investigator will report to Incyte Corporation any serious adverse 
events within 24 hours of learning of  the event. Reporting will occur by emailing the 
completed Serious Adverse Event Reporting Form to IncytePhVOpsIST@incyte.com .  
 
The Overall Principal Investigator send copies of any IND Safety reports subm itted to the 
FDA will be sent to Incyte so that these reports can be evaluated and included in the 
Investigatorâ€™s Brochure or Incye IND safety submissions. These will be sent via email to 
IncytePhVOpsIST@in cyte.com. 
 
,Every six months, the overall Principal Investigator will submit copies of IND safety reports 
in the format of a lie listing with details regarding the reports that were submitted to the FDA. 
These will be inclusive of all sites  to they will be sent via email to 
IncytePhVOpsIST@incyte.com .  
 
The Overall Principal investigator will provide complete data transfers for AEs listings, 
including AEs, on labs, on a quarterly basis for the d uration of the study. The data transfer 
will not include any Protected Health Information as defined by HIPAA.  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 44 of 96 
  
7.2.15  Guidelines for Processing IND Safety Reports  
The U.S. Food and Drug Administration (FDA) regulations require sponsors of clinical 
studies to n otify the FDA and all participating investigators of any serious and unexpected 
adverse experiences that are possibly related to the investigational agent. The CUMC 
Principal Investigator will review all applicable IND Safety Reports and has the responsibl y 
for forwarding the IND Safety Reports to the Affiliate Institutions. The Affiliate Institution 
investigators are to review, send a copy to their IRB according to their local IRBâ€™s policies 
and procedures, and file a copy with their regulatory documents. All Affiliate site INDSR 
submissions, along with IRB acknowledgment (per local policies and procedures) are to be 
forwarded to CUMC for placement within the trial master file.  
 
 
7.2.16  Reporting to Hospital Risk Management  
Participating investigat ors will report to their local Risk Management office any subject 
safety reports or sentinel  events that require reporting according to institutional policy. 
 
7.2.17  Monitoring of Adverse Events and Period of Observation  
All adverse events, both serious and non-serious, and deaths that are encountered  from 
initiation of study intervention,  throughout  the study, and within 30 days of the  last study 
intervention should be followed to their resolution, or until the participating  investigat or 
assesses them  as stable, or the participating  investigator  determines the event to be 
irreversible,  or the participant  is lost to follow-up. The presence and resolution  of AEs and 
SAEs (with  dates) should be documented on the appropriate  case report form and recorded  in 
the participant â€™s medical record and subject binder to facilitate source data verification.  
 
For some SAEs, the  study sponsor or designee  may follow-up by telephone,  fax, and/or 
monitoring  visit to obtain additional  case details deemed necessary  to appropriately evaluate  
the SAE report  (e.g., hospital discharge summary, consultant  report, or autopsy  report). 
 
Participants  should be instructed  to report any serious po st-study event(s) that might 
reasonably be related to participation in this study. Participating  investigators  should noti fy 
Columbia University Medical Center Overall Principal Investigator and their respective IRB 
of any unanticipated  death or adverse  event occurring  after a participant  has discontinued  
or terminated study participation  that may reasonably  be related to the study. 
 
7.3 Secondary Malignanc y 
A secondary malignancy is a cancer caused by treatment for a previous malignancy ( e.g., 
treatment with investigational agent/intervention, radiation or chemotherapy). A secondary 
malignancy is not considered a metastasis of the initial neoplasm.   Second malignancies 
require ONLY routine reporting unless otherwise specified .  
 
8. PHARMACEUTICA L INFORMATION  
 
A list of the adverse events and potential risks associated with the investigational or 
commercial agents administered in this study can be found in Section 7. 
 
8.1 Investigational  Agent(s) 
This study will evaluate the effects of a novel combina tion of two commercially available, 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 45 of 96 
 FDA-available medications.  Ruxolitinib has been approved by the FDA for treatment of 
intermediate and high risk myelofibrosis .  Trastuzumab has been approved by th e FDA for 
the treatment of HER2+ breast cancer.  Both me dications have been widely used and have 
considerable safety data.  To our knowledge, this combination has been not been evaluated in 
patients with breast cancer.   
 
8.1.1 Ruxolitinib  
8.1.1.1  Product Description  
Ruxolitinib (INCB018424 phosphate, INC424, ruxolitinib phosphate) represents a novel, 
potent, and selective inhibitor of JAK1 (Janus kinase 1 ) (inhibition concentration 50% 
[IC50]=3.3 Â± 1.2 nM) and JAK2 (IC50=2.8 Â± 1.2 nM) wi th modest to marked selectivity 
against TYK2 (tyrosine kinase 2) (IC50=19 Â± 3.2 nM) and JAK3 (IC50=428 Â± 243 nM), 
respectively. Ruxolitinib interferes with the signaling of a  number of cytokines and growth 
factors that are important for hematopoiesis and immune function.  
 
Ruxolitinib phosphate is a kinase inhibitor with the chem ical name ( R)-3-(4-(7H-pyrrolo[2,3 - 
d]pyrimidin -4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and a molecular 
weight of 404.36. Ruxolitinib phosphate is a white to off -white to light pink powder and is 
soluble in aqueous buffers across a pH range of 1 to 8.  
 
8.1.1.2  Product Formulation  
Ruxolitinib is an oral medication supplied as 5 mg tablets for this study.   
 
8.1.1.3  Route of Administration  
Tablets are for oral admin istration. Each tablet contains ruxolitinib  phosphate equivalent to 5 
mg of ruxolitinib  free base together with microcrystalline cellulose, lactose monohydrate, 
magnesium stearate, colloidal silicon dioxide, sodium starch glycolate, povidone and 
hydroxypropyl cellulose.  
 
8.1.1.4  Agent Ordering  
Ruxolitinib is an investigational agent supplied to inv estigators by Incyte Pharmaceuticals. 
Ruxolitinib supplied for this protocol is intended for clinical trial use only and is not 
commercially available. Ruxolitinib is shipped directly from the company to the participating 
institution  (see Appendix H for Dr ug Order Form) . For further details molecule 
characterization, see the ruxolitinib  Investigatorâ€™s Brochure.  
 
8.1.2 Trastuzumab  
8.1.2.1  Product Description  
Trastuzumab is a recombinant DNA -derived humanized monoclonal antibody that selectively 
binds with high affinity i n a cell-based assay (Kd=5 nM) to the extracellular domain of the 
human epidermal growth factor receptor 2 protein, HER2. The antibody is an IgG1 kappa that 
contains human framework regions with the complementarity -determining regions of a 
murine antibody (4D5) that binds to HER2.  
The humanized antibody against HER2 is produced by a mammalian cell (Chinese Hamster 
Ovary [CHO]) suspension culture in a nutrient medium containing the antibiotic gentamicin. 
Gentamicin is not detectable in the final product.  
 
Trastuzumab is a sterile, white to pale yellow, preservative -free lyophilized powder for 
intravenous (IV) administration. The nominal content of e ach trastuzumab vial is 440 mg 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 46 of 96 
 trastuzumab, 400 mg Î±,Î± -trehalose dihydrate, 9.9 mg L -histidine HCl, 6.4 mg L -histidine, 
and 1.8 mg polysorbate 20, USP. Reconstitution with 20 mL of the supplied Bacteriostatic 
Water for Injection (BWFI), USP, containing 1.1% benzyl alcohol as a preservative, yields a 
multi-dose solution containing 21 mg/mL t rastuzumab, at a pH of a pproximately 6.  
 
8.1.2.2  Solution Preparation  
Vials of trastuzumab are stable at 2Â° â€“8Â°C (36Â°â€“46Â°F) prior to reconstitution. Do not use 
beyond the expiration date stamped on the vial. A  vial of trastuzumab reconstituted with 
BWFI, as supplied, is stable for 28 days after reconstitution when stored refrigerated at 2Â° â€“
8Â°C (36Â°â€“46Â°F), and the solution is preserved for multiple use. Discard any remaining multi -
dose reconstituted solution after 28 days. If unpreserved SWFI (not suppli ed) is used, the 
reconstituted t rastuzumab solution should be used immediately and any unused portion must 
be discarded. Do not freeze trastuzumab that has been reconstituted. The solution of 
trastuzumab for infusion diluted in polyvinylchloride or polyethylene bags containing 0.9% 
Sodium Chloride Injection, USP, may be stored at 2Â° â€“8Â°C (36Â°â€“46Â°F) for up to 24 hours 
prior to use. Diluted t rastuzumab has been shown to be stable for up to 24 hours at room 
temperature 2Â° â€“25Â°C. However, because diluted t rastuzumab contains no effective 
preservative, the reconstituted and diluted solution should be stored refrigerated 2Â° â€“8Â°C. 
 
8.1.2.3  Route of Administration  
Trastuzumab is administered intravenously. When administering t rastuzumab to a patient 
with a known hyper sensitivity to benzyl alcohol, t rastuzuma b must be reconstituted with 
SWFI, and only one dose per trastuzumab vial should be used. Trastuzumab, which has been 
reconstituted,  with SWFI must be used immediately and any unused portion must be 
discarded. Use of other reconstitution diluents should be  avoided.  
Shaking the reconstituted t rastuzumab or causing excessive foaming during the addition of 
diluent may result in problems with dissolution and the amount of t rastuzumab that can be 
withdrawn from the vial. Use appropriate aseptic technique when p erforming the following 
reconstitution steps:  
âˆ’ Using a sterile syringe, slowly inject the 20 mL of diluent into the vial cont aining the 
lyophilized cake of t rastuzumab. The stream of diluent should be directed into the lyophilized 
cake.  
âˆ’ Swirl the vial  gently to aid reconstitution. Trastuzumab may be sensitive to shear -induced 
stress, e.g., agitation or rapid expulsion from a syringe. DO NOT SHAKE.  
 
8.1.2.4  Agent Ordering  
Trastuzumab is commercially available.  
 
9. BIOMARKER, CORRELATIVE , AND SPECIAL STUDIES  
 
Given that this is a proof -of-concept phase I/II study there will be no assessment of integral 
biomarkers (essential for conducting the study) or integrated biomarkers (testing a hypothesis 
based on preexisting data).  Instead, all correlative studies for this trial will be exploratory 
and used for either hypothesis generation and/or assay development and testing.  Hypotheses 
generated from these studies will then be tested as integrated biomarkers in follow -up clinical 
studies.  
 
All analyses  will be perfo rmed in batched fashion at the end of the study.  Plasma and serum 
samples will be prepared ( Appendix E) on the same day they are drawn and stored locally.  
Biopsies will be obtained, processed, and stored as a clinical specimen by the participating 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 47 of 96 
 sites clinical pathology labs ( Appendix D ).  At the end of the study freshly cut slides will be 
requested from each site for all the appropriate biopsy specimens.  Slides will be cut for all 
specimens at the same time at the end of the study.  Pathology reports f or all samples assessed 
for the study will be entered into the clinical research form.   For the blood based biomarkers 
samples will be shipped directly to the lab performing the analysis at the end of study accrual 
and sample collection [see appendices for  shipping and labeling instructions].  
 
For patients with accessible tumor, 2 punch biopsies (for skin) or 3 core biopsies are 
recommended.  The following will be requested: 10 immunoblanks [each having 4 
micron sections on charged slides], one intervening H&E stained slide, and 12 regular 
slides each with 10 microns sections.  
 
  DNA Blood 
Biomarkers  PK IHC RNAseq RPPA 
Primary tumor biopsy (archived) *        x x x 
Biopsy upon recurrence (archived)*        x x x 
Pre-treatment biopsy (Optional)        x x x 
On-treatment biopsy (Optional)**        x x x 
Biopsy upon progression (Optional)        x x x 
Pre-treatment whole blood  x           
Pre-treatment plasma and serum    x         
On-treatment plasma and serum**    x         
Plasma and serum upon progression    x         
On-treatment plasma**      x       
 
*If available  
**On-treatment assessments will be performed on C2D1.   For PK analysis plasma will be 
drawn before the C2D1 dose and again two hours after.  
 
Transcriptional profiling  
RNA-Sequencing  will be performed by the Columbia University Genome Center using current 
best technologies with a goal of at least 40 million reads per sample.  RNAseq has been 
validated from FFPE breast cancer samples.  In addition, the quality of sequencing reads from 
FFPE has been verified  by the Columbia University Genome Center .  Data analysis will be 
performed by the Columbia University bioinformatics core under the direction of Andrea 
Califano.  Using the master regulator methodologies pioneered by Dr. Califano and  used as the 
basis for the preclinical studies, they will perform interactome modeling for JAK/SAT pathway 
dependence. In addition, intrinsic molecular subtype of each sample will be identified, as well 
as mutation assessment and pathway analysis.  
 
RPPA 
We will explore the baseline proteomic profile of patients entered on this study, the profile in 
the setting of trastuzumab resistance, and the effect on the proteomic profile with treatment 
with combined trastuzumab and ruxolitinib. We will use is the curre nt technology being used 
for proteomic profiling in the cancer genome atlas (TCGA) project. Samples will be sent to 
and analyzed by the MDA Anderson RPPA Functional Proteomics Core Facility.   
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 48 of 96 
 Protein extracts from FFPE tumor blocks (3 -8 untreated 10 micr on slides) will be prepared 
from appropriately isolated regions (as determined by an experienced pathologist).  
Following deparaffinization, at least 30 -40 micrograms of protein per sample will be 
extracted using an extraction buffer of 20 mM Tris HCl buff er at pH 9, with 2%(w/v)SDS, as 
previously described. RPPA will be conducted using a total of 161 antibodies 
(www.mdanderson.org/education -and-research/resources -for-professionals/scientific -
resources/core -facilities-and-services/functional -proteomics -rppa-core/index.html), including 
markers of proliferation (PCNA) and apoptosis (e.g., cleaved caspase -3), as well as 
antibodies against STAT3, EGFR, HER2, c -MET, IGF -1R, PI3K, PTEN, AKT, mTOR, and 
their phosphorylated isoforms.  These antibodies have been fully validated by direct 
correlation between RPPA and Western blotting results.  Specifically, tumor lysates will be 
diluted in five 2 -fold serial dilutions and arrayed on nitrocellulose -coated slides (Whatman, 
Schleicher & Schuell BioScience, Inc., Keene , NH).  Samples will be probed with validated 
primary antibodies and biotin -conjugated secondary antibodies and visualized by DAB 
colorimetric reaction.  Slides will be scanned and quantified for raw signal intensities by 
using MicroVigene automated RPPA s oftware (VigeneTech, Inc., North Billerica, MA).  
Dilution curves will be fitted to the logistic model â€œSupercurve Fittingâ€ 
(http://bioinformatics.mdanderson.org/OOMPA ).  Relative protein levels fo r each sample 
were derived from the supercurve for each lysate by curve -fitting, will be normalized for 
protein loading, and the log2 -scaled protein concentrations will be  normalized by global 
sample median normalization.  
 
IHC 
Ten freshly cut slides from  each biopsy and archived tissue will be analy zed by the Columbia 
University Molecular Pathology Lab for immunhistochemical (IHC) staining.  IHC for 
phosphorylated STAT3, Ki67, and cleaved caspase -3, as well as other potential markers 
identified through tr anscriptional and/or proteomic profiling, will be performed based on the 
standard protocol published for each antibody.  Standard protocols, institutional and from the 
antibody vender, will be assessed and modified as needed.  Phospho -Stat3 (Tyr705) (D3A7)  
XPÂ® Rabbit mAb  [CellSignaling #9145].  Phospho -Stat3 staining will be measured with an 
H score c alculated from  the percent and intensity of staining. 
 
Peripheral blood samples 
Peripheral blood  samples will be obtained from each patients prior to starting  study drug, 
prior to the observed C2D1 dose and at the time of progression.  Plasma and serum 
biomarkers will be assessed by Biomarkers Core of the Irving Institute for Clinical and 
Translational Research at Columbia University Medical Center.  At minimum,  IL-6, IL-8, 
and C-reactive protein levels will be  assessed. 
 
Pharmacokinetics  
Ruxolitinib exhibits near complete oral absorption, achieving maximal plasma concentration 
at approximately 1 -2 h post-dose with linear PK over a dose range of 5 -200 mg.  Full P K 
analyses will not be performed given the low likelihood of interactions between the 
trastuzumab and ruxolitinib.  However, steady state trough and peak levels [2 hours post 
dose] of ruxolitinb will be assessed on C2D1 for the first 10 patients  on study.  Once the 
samples from the first 10 patients have been obtained the y will be sent to Incyte for analysis.  
If the results are not within expected ranges then the protocol will be amended to include full 
PK sampling on the remaining patients.   The time the trough level is drawn, the time the 
C2D1 dose is taken, and the time the peak level is drawn must be entered into the clinical 
research form.  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 49 of 96 
  
10. STUDY CALENDAR  
 
Baseline evaluations , except for scans and x -rays, are to be conducted within 14 days prior to 
start of protocol therapy.  Scans , including CT scans and MUGA/ECHO, and x-rays must be 
done < 28 days prior to the start of therapy.   
 
  Cycle 1c Cycle 2c Cycle 3c Cycle 4+c Off Study 
Visit Day  Pre-
Study Day 
1 Day 
8 Day 
15 Day 1 Day 1 Day 1 Within 28 
days of the 
last dose 
Visit Window 
(Days)   Â± 2d Â± 2d Â± 4d Â± 4 Â± 4  
Ruxolitiniba  X X X X X X  
Trastuzumab  X   X X X  
Informed consente X        
Inclusion/  
Exclusion Criteria          
Demographics  X        
Medical history  X        
Concurrent medsf  X X X X X Xg X 
History and 
Physical exam  X X X X X X Xg X 
Vital signs  X X X X X X Xg X 
Height X  
Weight X X X X X X Xg X 
Performance status  X X X X X X Xg X 
Adverse event 
evaluation  X X X X X X Xg X 
CBC w/diff, plts  X X X X X X Xg X 
Serum chemistry, 
liver function testsh X X X X X X Xg X 
Lipid panel  Xi      Xi X 
B-HCG Xj  
Pharmacokinetics      Xk    
ECG X  Xl  Xl  Xm X 
EF Assessment 
(Echo or MUGA)  X    Xn  Xo X 
CT C/A/P or 
PET/CTp X    Xm X 
Bone Scanq Xq    Xq Xq 
Review Pill  Diary   X X X X Xg X 
Blood Biomarker  X    X   X 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 50 of 96 
   Cycle 1c Cycle 2c Cycle 3c Cycle 4+c Off Study 
Visit Day  Pre-
Study Day 
1 Day 
8 Day 
15 Day 1 Day 1 Day 1 Within 28 
days of the 
last dose 
Visit Window 
(Days)   Â± 2d Â± 2d Â± 4d Â± 4 Â± 4  
(Section 9)  
Whole blood for 
DNA X        
Tumor Analysis: 
Predictive 
Biomarker  
(Section 9)  Xr    Xs   Xs 
a. Ruxolitinib:  Dose as assigned (phase I dose level 0: 20 mg b.i.d.; phase II dose wi ll be based upon the phase I 
Maximum Tolerated Dose ).  Patients will be instructed not take ruxolitinib  until seen by study team on 
days of study visits.   Ideally, the first dose of ruxolitinib will be in the morning so that the first day allow 
for b.i.d. On D1 of every cycle prior to drug dispensation and dose administration, subjectâ€™s disease 
status/non -progression will be confirmed by the treating investigator, including clinical and radiographic 
assessment. RECIST restaging will be confirmed for the most rece nt scans received, including documentation 
of investigator sign off on calculation of percentage change from baseline and nadir and overall response, prior 
to treatment. If the new scan information becomes available mid cycle, the study team will inform th e subject 
if treatment discontinuation is required per protocol in real time, and document date of treatment 
discontinuation.  
b. Trastuzumab:  Fixed dosing.  If no t rastuzumab > 28 days from initiating t rastuzumab: load 8 mg/kg IV.  
Otherwise, 6 mg/kg IV.  If loaded, patient should remain on 6 mg/kg IV every 21 days (+/ - 3 days). 
c:    Cycle = 21 days (+/ -4 days from Day 1 of the prior cycle)  
d.    During cycle 1, patients will be seen on day 1, 8 (+/ - 2 days), 15 (+/ - 2 days).  Cycle 2 day 1 should be within 
21 days (+/ - 4 days) from Cycle 1 day 1.  
e.    Radiographic assessments and EF (ejection fraction)  testing may be done before consenting, if performed as 
part of the subject â€™s routine care/procedures, and if done within the screening window per the protocol-defined 
method time period.  
f.     Patients on strong CYP3A4 inhibitors are not eligible.  Must be off for at least 1 week prior to being deemed 
eligible. 
g.    Every 21 days (+/ - 4 days) during phase I and phase II  
h.    Albumin, alkaline phospha tase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, LDH, 
phosphorus, potassium, total protein, SGOT [AST], SGPT [ALT], sodium.  
i.     Lipids should be conducted at baseline, prior to  cycle 4, and then every 3 cycles  (~9 weeks+/ - 1 week).  
Hyperlipidemia is not an exclusion criterion.  Lipids do not need to be fasting.  If abnormalities are detected, 
fasting blood lipid levels  (at least 8 hours fasting)  should be considered and patients should be treated per 
standard of care.  
j.     Serum pregnancy test (women of childbearing potential).  
k.    Trough  (prior) and peak (2 hours post)  levels should be drawn at Cycle 2 Day 1 (+/- 2 days) during phase I 
only. 
l.     ECG prior to dose at Cycle 1 D ay 8 (+/- 2 days) and prior to C ycle 2 Day 1 during phase I only.  
m.   Every 3 cycles ( ~9 weeks of treatment +/ - 4 days) during phase I and phase II.  Scans to be conducted every 9 
weeks (+/ - 4 days) from start of study treatment.  
n.    During phase I only, EF assessment should occur prior to Cycle 2 D ay 1. 
o.    EF assessment should be performed prior to C ycle 4 Day 1.  EF assessment should be repeated 3 cycles ( ~9 
weeks+/- 4 days) prior to treatment with t rastuzumab.  
p.    If patients have known brain metastases and are eligible for this tria l, a head CT or brain MRI MUST be 
performed along with systemic imaging.  If a patient does not have known brain metastases and is asymptomatic, 
no baseline brain imaging is required.  . Scans to be conducted every 9 weeks (+/ - 4 days) from start of study 
treatment. Corresponding RECIST restaging will be conducted in real time following scans and signed 
(electronically or wet ink) by the investigator, including confirmation of overall dis ease status per RECIST v.1.1  
q.    Baseline bone scan required in all patients.  
NOTE: If bone scan done â‰¤ 6 weeks prior to registration showed no evidence suggesting bone metastases and no 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 51 of 96 
   Cycle 1c Cycle 2c Cycle 3c Cycle 4+c Off Study 
Visit Day  Pre-
Study Day 
1 Day 
8 Day 
15 Day 1 Day 1 Day 1 Within 28 
days of the 
last dose 
Visit Window 
(Days)   Â± 2d Â± 2d Â± 4d Â± 4 Â± 4  
clinical indication of skeletal pain or other evidence suggesting b one metastases, a repeat baseline bone scan is 
not required .  If there is evidence of disease on the bone scan, bone scans should be continued every 3 cycles 
(~9 weeks of treatment +/ - 4 days), as clinically indicated.  
r.    From archived primary and/or metastatic biopsy  if patient is amenable  and has accessible disease  repeat 
biopsy (optional)  
s.    If patient is amenable and has accessible tumor, repeat biopsy (optional ).  These biopsies should be considered 
in patients with accessible disease.  
 
11. MEASUREMENT OF EFFEC T 
 
11.1 Antitumor Effect â€“ Solid Tumors  
For the purposes of the phase I/II  study, patients should be re -evaluated for response every 3 
cycles (~9  weeks of treatment +/- 4 days).  In addition to a baseline scan, confirmatory scans 
should also  be obtained  9 (not less than 4) weeks (+/-  4 days) following initial 
documentation of an objective response.  
 
Response and progression will be evalua ted in this study using the international criteria 
proposed by the revised Response Evaluation Criteria i n Solid Tumors (RECIST) guideline 
(version 1.1) [ Eur J Ca 45:228-247, 2009].  Changes in the largest diameter (unidimensional 
measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph 
nodes are used in the RECIST criteria.  
 
11.1.1  Definitions  
Evaluable for toxicity :  All patients will be evaluable for toxicity from the time of their first 
treatment with  ruxolitinib and t rastuzumab . 
 
Evaluable for objective response :  Only those patients who have measurable disease present 
at baseline, have received at least one cycle of therapy, and have had their disease re -
evaluated will be considered evaluable for response.  These patients will have their response 
classified accor ding to the definitions stated below.  (Note:  Patients who exhibit objective 
disease progression prior to the end of cycle 1 will also be considered evaluable.)  
 
Evaluable Non -Target Disease Response :  Patients who have lesions present at baseline that 
are evaluable but do not meet the definitions of measurable disease, have received at least one 
cycle of therapy, and have had their disease re -evaluated will be considered evaluable for 
non-target disease.  The response assessment is based on the presence, absence, or 
unequivocal progression of the lesions.  
 
11.1.2  Disease Parameters  
Measurable disease :  Measurable lesions are defined as those that can be accurately measured 
in at least one dimension (longest diameter to be recorded) as â‰¥20 mm by chest x -ray or as 
â‰¥10 mm with CT scan, MRI, or calipers by clinical exam.  All tumor measurements must be 
recorded in millimeters  (or decimal fractions of centimeters).  
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 52 of 96 
 Note:  Tumor lesions that are situated in a previously irradiated area may  be considered 
measurable,  as long as they meet the criteria above.    
 
Malignant lymph nodes :  To be considered pathologically enlarged and measurable, a lymph 
node must be â‰¥15 mm in short axis when assessed by CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm ).  At baseline and in follow -up, only the short axis 
will be measured and followed.  
 
Non-measurable disease :  All other lesions (or sites of disease), including small lesions 
(longest diameter <10 mm or pathological lymph nodes with â‰¥10 to <15 mm short ax is), are 
considered non -measurable disease.  Bone lesions, leptomeningeal disease, ascites, 
pleural/pericardial effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and 
abdominal masses (not followed by CT or MRI), are considered as non -measurable.  
 
Note:  Cystic lesions that meet the criteria for radiographically defined simple cysts should 
not be considered as malignant lesions (neither measurable nor non -measurable) since they 
are, by definition, simple cysts.  
 
â€˜Cystic lesionsâ€™ thought to represent cystic metastases can be considered as measurable 
lesions, if they meet the definition of measurability described above. However, if non -cystic 
lesions are present in the same patient, these are preferred for selection as target lesions.  
 
Target lesions:  All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions 
in total, representative of all involved organs, should be identified as target lesions  and 
recorded and measured at baseline.  Target lesions should be selected on th e basis of their 
size (lesions with the longest diameter), be representative of all involved organs, but in 
addition should be those that lend themselves to reproducible repeated measurements.  It may 
be the case that, on occasion, the largest lesion does not lend itself to reproducible 
measurement in which circumstance the next largest lesion which can be measured 
reproducibly should be selected.  A sum of the diameters (longest for non -nodal lesions, short 
axis for nodal lesions) for all target lesions wi ll be calculated and reported as the baseline 
sum diameters.  If lymph nodes are to be included in the sum, then only the short axis is 
added into the sum.  The baseline sum diameters will be used as reference to further 
characterize any objective tumor re gression in the measurable dimension of the disease.  
 
Non-target lesions :  All other lesions (or sites of disease) including any measurable lesions 
over and above the 5 target lesions should be identified as non-target lesions and should also 
be recorded a t baseline.  Measurements of these lesions are not required, but the presence, 
absence, or in rare cases unequivocal progression of each should be noted throughout follow -
up.  
 
11.1.3  Methods for Evaluation of Measurable Disease  
All measurements should be taken and recorded in metric notation using a ruler or calipers.  
All baseline evaluations should be performed as closely as possible to the beginning of 
treatment and never more than 4 weeks before the beginning of the treatment . 
 
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow -up. Imaging -based evaluation is 
preferred to evaluation by clinical examination unless the lesion(s) be ing followed cannot be 
imaged but are assessable by clinical exam.  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 53 of 96 
  
Clinical lesions :  Clinical lesions will only be considered measurable when they are 
superficial ( e.g., skin nodules and palpable lymph nodes) and â‰¥10 mm diameter as assessed 
using calipers (e.g., skin nodules).  In the case of skin lesions, documentation by color 
photography, including a ruler to estimate the size of the lesion, is recommended.  
 
Chest x-ray:  Lesions on chest x -ray are acceptable as measurable lesions when they are  
clearly defined and surrounded by aerated lung.  However, CT is preferable.  
 
Conventional CT and MRI :  This guideline has defined measurability of lesions on CT scan 
based on the assumption that CT slice thickness is 5 mm or less.  If CT scans have slice  
thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the 
slice thickness.  MRI is also acceptable in certain situations ( e.g. for body scans).   
 
Use of MRI remains a complex issue.  MRI has excellent contrast, spatial, an d temporal 
resolution; however, there are many image acquisition variables involved in MRI, which 
greatly impact image quality, lesion conspicuity, and measurement.  Furthermore, the 
availability of MRI is variable globally.  As with CT, if an MRI is perfo rmed, the technical 
specifications of the scanning sequences used should be optimized for the evaluation of the 
type and site of disease.  Furthermore, as with CT, the modality used at follow -up should be 
the same as was used at baseline and the lesions sh ould be measured/assessed on the same 
pulse sequence.  It is beyond the scope of the RECIST guidelines to prescribe specific MRI 
pulse sequence parameters for all scanners, body parts, and diseases.  Ideally, the same type 
of scanner should be used and the  image acquisition protocol should be followed as closely as 
possible to prior scans.  Body  scans should be performed with breath -hold scanning 
techniques, if possible.  
 
PET-CT: At present, the low dose or attenuation correction CT portion of a combined PE T-
CT is not always of optimal diagnostic CT quality for use with RECIST measurements.  
However, if the site believes  that the CT performed as part of a PET -CT is of identical 
diagnostic quality to a diagnostic CT (with IV and oral contrast), then the CT po rtion of the 
PET-CT can be used for RECIST measurements and can be used interchangeably with 
conventional CT in accurately measuring cancer lesions over time.  Note, however, that the 
PET portion of the CT introduces additional data which may bias an inves tigator if it is not 
routinely or serially performed.   
 
Ultrasound :  Ultrasound is not useful in assessment of lesion size and should not be used as a 
method of measurement.  Ultrasound examinations cannot be reproduced in their entirety for 
independent r eview at a later date and, because they are operator dependent, it cannot be 
guaranteed that the same technique and measurements will be taken from one assessment to 
the next.  If new lesions are identified by ultrasound in the course of the study, confirm ation 
by CT or MRI is advised.  If there is concern about radiation exposure at CT, MRI may be 
used instead of CT in selected instances.  
 
Endoscopy, Laparoscopy :  The utilization of these techniques for objective tumor evaluation 
is not advised.  However, such techniques may be useful to confirm complete pathological 
response when biopsies are obtained or to determine relapse in trials where recurrence 
following complete response (CR) or surgical resection is an endpoint.  
 
Tumor markers :  Tumor markers alon e cannot be used to assess response.  If markers are 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 54 of 96 
 initially above the upper normal limit, they must normalize for a patient to be considered in 
complete clinical response.   
 
Cytology, Histology :  These techniques can be used to differentiate between pa rtial responses 
(PR) and complete responses (CR) in rare cases ( e.g., residual lesions in tumor types, such as 
germ cell tumors, where known residual benign tumors can remain).  
 
The cytological confirmation of the neoplastic origin of any effusion that appears or worsens 
during treatment when the measurable tumor has met criteria for response or stable disease is 
mandatory to differentiate between response or stable disease (an effusion may be a side 
effect of the treatment) and progressive disease.  
 
FDG-PET:  While FDG -PET response assessments need additional study, it is sometimes 
reasonable to incorporate the use of FDG -PET scanning to complement CT scanning in 
assessment of progression (particularly possible 'new' disease).  New lesions on the basis o f 
FDG-PET imaging can be identified according to the following algorithm:  
a. Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of 
PD based on a new lesion.  
b. No FDG-PET at baseline and a positive FDG -PET at follow -up:  If the positiv e 
FDG-PET at follow -up corresponds to a new site of disease confirmed by CT, this 
is PD.  If the positive FDG -PET at follow -up is not confirmed as a new site of 
disease on CT, additional follow -up CT  scans are needed to determine if there is 
truly progres sion occurring at that site (if so, the date of PD will be the date of the 
initial abnormal FDG -PET scan).  If the positive FDG -PET at follow -up 
corresponds to a pre -existing site of disease on CT that is not progressing on the 
basis of the anatomic images , this is not PD.  
c. FDG-PET may be used to upgrade a response to a CR in a manner similar to a 
biopsy in cases where a residual radiographic abnormality is thought to represent 
fibrosis or scarring.  The use of FDG -PET in this circumstance should be 
prospectively described in the protocol and supported by disease -specific medical 
literature for the indication.  However, it must be acknowledged that both 
approaches may lead to false positive CR due to limitations of FDG -PET and 
biopsy resolution/sensitivity.  
 
Note:  A â€˜positiveâ€™ FDG -PET scan lesion means one which is FDG avid with an 
uptake greater than twice that of the surrounding tissue on the attenuation corrected 
image. 
 
11.1.4  Response Criteria  
 
11.1.4.1  Evaluation of Target Lesions  
 
Complete Response (CR) :  Disappearance of all target lesions.  Any pathological lymph 
nodes (whether target or non -target) must have reduction in short axis to <10 mm.  
 
Partial Response (PR) :  At least a 30% decrease in the sum of the diameters of target lesions, 
taking as referen ce the baseline sum diameters.  
 
Progressive Disease (PD) :  At least a 20% increase in the sum of the diameters of target 
lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 55 of 96 
 the smallest on study).  In addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5 mm.  (Note:  the appearance of one or more 
new lesions is also considered progressions).  
 
Stable Disease (SD) :  Neither sufficient shrinkage to qualify for PR  nor sufficient increase to 
qualify for PD, taking as reference the smallest sum diameters while on study.  
 
11.1.4.2  Evaluation of Non -Target Lesions  
 
Complete Response (CR) :  Disappearance of all non -target lesions and normalization of 
tumor marker level.  All lymph nodes must be non -pathological in size (<10 mm short axis).  
 
Note:  If tumor markers are initially above the upper normal limit, they must normalize for a 
patient to be considered in complete clinical response.  
 
Non-CR/Non-PD:  Persistence of one or more non -target lesion(s) and/or maintenance of 
tumor marker level above the normal limits.  
 
Progressive Disease (PD) :  Appearance of one or more new lesions and/or unequivocal 
progression  of existing non -target lesions.  Unequivocal progression  should not  normally 
trump target lesion status.  It must be representative of overall disease status change, not a 
single lesion increase.     
 
Although a clear progression of â€œnon -targetâ€ lesions only is exceptional, the opinion of the 
treating physician should pre vail in such circumstances, and the progression status should be 
confirmed at a later time by the review panel (or Principal Investigator).  
 
11.1.4.3  Evaluation of Best Overall Response  
 
The best overall response is the best response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for progressive disease the smallest 
measurements recorded since the treatment started).  The patient's best response assignment 
will depend on the achievement of both measurement and conf irmation criteria.  
 
For Patients with Measurable Disease ( i.e., Target Disease)  
 
Target 
Lesions Non-Target 
Lesions New 
Lesions Overall 
Response  Best Overall Response when 
Confirmation is Required*  
CR CR No CR >4 wks. Confirmation**  
CR Non-CR/Non-
PD No PR 
>4 wks. Confirmation**  CR Not evaluated  No PR 
PR Non-CR/Non-
PD/not 
evaluated  No PR 
SD Non-CR/Non-
PD/not 
evaluated  No SD Documented at least once >4 
wks. from baseline**  
PD Any Yes or No  PD no prior SD, PR or CR  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 56 of 96 
 Any PD*** Yes or No  PD 
Any Any Yes PD 
ï€ª See RECIST 1.1 manuscript for further details on what is evidence of a new lesion.  
**        Only for non -randomized trials with response as primary endpoint.  
***      In exceptional circumstances, unequivocal progressi on in non -target lesions may be  
            accepted as disease progression.  
 
Note:  Patients with a global deterioration of health status requiring discontinuation of 
treatment  without objective evidence of disease progression at that time should be 
reported as â€œsymptomatic deterioratio n.â€  Every effort should be made to document the 
objective progression even after discontinuation of treatment.  
 
For Patients with Non -Measurable Disease ( i.e., Non-Target Disease)  
 
Non-Target Lesions  New Lesions  Overall Response  
CR No CR 
Non-CR/non-PD No Non-CR/non-PD* 
Not all evaluated  No not evaluated  
Unequivocal PD  Yes or No  PD 
Any Yes PD 
ï€ª â€˜Non-CR/non-PDâ€™ is preferred over â€˜stable diseaseâ€™ for non -target disease since SD is 
increasingly used as an endpoint for assessment of efficacy in some trials  so to assign 
this category when no lesions can be measured is not advised  
 
11.1.5  Duration of Response  
 
Duration of overall response :  The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (whichever is first recor ded) until the first date 
that recurrent or progressive disease is objectively documented (taking as reference for 
progressive disease the smallest measurements recorded since the treatment started).  
 
The duration of overall CR is measured from the time me asurement criteria are first met for 
CR until the first date that progressive disease is objectively documented.   
 
Duration of stable disease :  Stable disease is measured from the start of the treatment until the 
criteria for progression are met, taking as  reference the smallest measurements recorded since 
the treatment started, including the baseline measurements.  
 
11.1.6  Progression -Free Survival  
PFS is defined as the duration of time from start of treatment to time of progression or death, 
whichever occurs first.  
 
Percent progression -free at 24 weeks is defined as the proportion of patients who remain 
progression -free at 24 weeks from study entry  day #1 (binary proportion).  
 
11.1.7  Response Review  
All responses are reviewed by an expert(s) independent of the study at the studyâ€™s 
completion. Simultaneous review of the patientsâ€™ files and radiological images is the best 
approach.  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 57 of 96 
  
12. DATA REPORTING / REGULATO RY REQUIREMENTS  
 
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 7.0 
(Adverse Events: List and Reporting Requirements).  The Data Safety Monitoring Plan is 
described in Section 12.2.  
 
12.1 Data Collection  
The Herbert Irving Comprehensive Cancer Center has an electronic clinical trials and data 
management system that will be used for data collection. CRFs for the study will be built into 
Velos for data entry. The system has full auditing capabilities which i s web-based and housed 
on a server in a fully HIPAA compliant server room with restricted access and video camera 
monitoring.  All users must login with their own application username and password.  Users 
off campus must first access the Virtual Private Ne twork with their assigned campus 
username and password and then use their application credentials.  Users are only able to 
view study information if they are indicated as study personnel in our electronic IRB system, 
or an affiliate IRB system. Users are l imited to access based on the role assigned in their 
corresponding protocol.  Subject data is entered directly into the system, which (in the case of 
Columbia subjects) confirms the correct identity of patients via an interface with the 
electronic medical patient index.  Staff with the appropriate IRB defined roles can run reports 
within the system for reporting purposes.  
 
12.2 Data Reporting  
Responsibility for Data Sub mission 
Case Report Forms will be completed for each subject enrolled into the clinical study through 
Velos eResearch. It is the investigatorâ€™s responsibility for ensuring that all clinical and 
laboratory data entered on the corresponding CRFs are complete, accurate and authentic.  
 
Refer to the table below regarding the form completion and source document  submission 
guidelines.  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 58 of 96 
  
Phase I: 
 
Redacted 
Source 
Documents 
(if 
applicable)  Case Report Form  Pre-Study 
(Required 
for Central 
Registration ) Baseline Cycle 1 
Day 1 Cycle 1 
Day 8 Cycle 1 
Day 15 Cycle 2 Cycle 3 Cycle 4 Off Study  SAEs 
Required Submission Schedules  
Within 2 
business 
days of 
visit  At time of 
Central 
Registration 
submission  Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 24 
hours and 
ongoing as 
available and 
applicable  
x Registration and 
Demographics   x        
 
x Eligibility (Inclusion and 
Exclusion)   x        
 
x Medical and Surgical History   x        
 
x Breast Biopsy and Histology   x        
 
x Metastatic Breast Cancer Prior 
to Study  x        
 
x HER2 Status Prior to Study   x        
 
x Previous Therapy   x        
 
x Baseline Physical Exam   x        
 
x Baseline Cardiac Assessments   x        
 
x Baseline Laboratory & 
Biomarker Collection (Heme 
and chemistry)   x        
 
x Baseline Imaging   x        
 
x Baseline Disease Assessment   x        
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 59 of 96 
 Redacted 
Source 
Documents 
(if 
applicable)  Case Report Form  Pre-Study 
(Required 
for Central 
Registration ) Baseline Cycle 1 
Day 1 Cycle 1 
Day 8 Cycle 1 
Day 15 Cycle 2 Cycle 3 Cycle 4 Off Study  SAEs 
Required Submission Schedules  
Within 2 
business 
days of 
visit  At time of 
Central 
Registration 
submission  Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 24 
hours and 
ongoing as 
available and 
applicable  
x On Study Physical Exam    
x x x x x x  
 
x On Study Cardiac Assessment     
x  
x  
x1  
 
x On Study Hematology    
x x x x x x  
 
x On Study Biochemistry    
x x x x x x  
 
x Cycle Form    
x x x x x x  
 
x Agent Interruption Form    
x x x x x x  
 
x Phase I Observation Period       
x2    
 
x On Study Lipid Panel         
x3 x  
x Pharmacokinetics       
x    
 
x Follow Up On Study Tumor 
Assessment        
x   
 
x On Study Biomarker 
Collection       
x    
 
x Research Related Biopsies    
x   
x   
x  
x Adverse Events   x x x x x x x x x 
x Concomitant Medications, 
Supplements, Et. Al.   x x x x x x x x  
x Off Study Medical History          
x  
x Off Study Physical Exam          
x  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 60 of 96 
 Redacted 
Source 
Documents 
(if 
applicable)  Case Report Form  Pre-Study 
(Required 
for Central 
Registration ) Baseline Cycle 1 
Day 1 Cycle 1 
Day 8 Cycle 1 
Day 15 Cycle 2 Cycle 3 Cycle 4 Off Study  SAEs 
Required Submission Schedules  
Within 2 
business 
days of 
visit  At time of 
Central 
Registration 
submission  Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 24 
hours and 
ongoing as 
available and 
applicable  
x Off Study Laboratory Data 
(Hematology)          
x  
x Off Study Laboratory Data 
(Biochemistry)          
x  
x Off Study Cardiac Assessment          
x  
x Off Study Biomarkers          
x  
x Off Study          
x  
x Death Report4          
 
 Comments*           
 
 Verification           
 
x Off Schedule Imaging*           
 
x Follow Up On Study Tumor* 
Assessment           
 
 
1 On study cardiac assessments to be completed prior to C4D1 and every 3 cycles thereafter; CRF to be completed with C4D1 asses sments, C7D1 assessments, C10D1 assessments, etc.  
2 If subject does not complete entire 3 week phase I observation period, a Phase  I Observation CRF should be inserted with last day of study assessments to note time point of DLT.  
3 On study lipid panel to be completed prior to C4D1 and every 3 cycles thereafter: CRF to be completed with C4D1 assessments, C7D1 assessments, C10D1 asses sments, etc.  
4 Complete at Death Report CRF only if subject dies while on study or within 30 days of last study intervention.   
* Certain CRF pages can be inserted into any Velos eResearch calendar time point such as Comments or Off Schedule Imaging. Plea se provide applicable redacted source in these instances.  
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 61 of 96 
 Phase II:  
 
Redacted 
Source 
Documents 
(If 
applicable)  Case Report Form  Pre-Study 
(Required 
for Central 
Registration ) Baseline Cycle 1 
Day 1 Cycle 1 
Day 8 Cycle 1 
Day 15 Cycle 2 Cycle 3 Cycle 4 Off Study SAEs 
Required Submission Schedules  
Within 2 
business 
days of 
visit  At time of 
Central 
Registration 
submission  Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 24 
hours and 
ongoing as 
available and 
applicable  
x Registration and 
Demographics   x        
 
x Eligibility (Inclusion and 
Exclusion)   x        
 
x Medical and Surgical History   x        
 
x Breast Biopsy and Histology   x        
 
x Metastatic Breast Cancer Prior 
to Study  x        
 
x HER2 Status Prior to Study   x        
 
x Previous Therapy   x        
 
x Baseline Physical Exam  x        
 
x Baseline Cardiac Assessments   x        
 
x Baseline Laboratory & 
Biomarker Collection (Heme 
and chemistry)   x        
 
x Baseline Imaging   x        
 
x Baseline Disease Assessment   x        
 
x On Study Physical Exam    
x x x x x x  
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 62 of 96 
 Redacted 
Source 
Documents 
(If 
applicable)  Case Report Form  Pre-Study 
(Required 
for Central 
Registration ) Baseline Cycle 1 
Day 1 Cycle 1 
Day 8 Cycle 1 
Day 15 Cycle 2 Cycle 3 Cycle 4 Off Study SAEs 
Required Submission Schedules  
Within 2 
business 
days of 
visit  At time of 
Central 
Registration 
submission  Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 24 
hours and 
ongoing as 
available and 
applicable  
x On Study Cardiac Assessment         
x1  
 
x On Study Hematology    
x x x x x x  
 
x On Study Biochemistry    
x x x x x x  
 
x Cycle Form    
x x x x x x  
 
x Agent Interruption Form    
x x x x x x  
 
x On Study Lipid Panel         
x2 x  
x Follow Up On Study Tumor 
Assessment        
x   
 
x On Study Biomarker 
Collection       
x    
 
x Research Related Biopsies    
x   
x   
x  
x Adverse Events   x x x x x x x x x 
x Concomitant Medications, 
Supplements, Et. Al.   x x x x x x x x  
x Off Study Medical History          
x  
x Off Study Physical Exam          
x  
x Off Study Laboratory Data 
(Hematology)          
x  
x Off Study Laboratory Data 
(Biochemistry)          
x  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 63 of 96 
 Redacted 
Source 
Documents 
(If 
applicable)  Case Report Form  Pre-Study 
(Required 
for Central 
Registration ) Baseline Cycle 1 
Day 1 Cycle 1 
Day 8 Cycle 1 
Day 15 Cycle 2 Cycle 3 Cycle 4 Off Study SAEs 
Required Submission Schedules  
Within 2 
business 
days of 
visit  At time of 
Central 
Registration 
submission  Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 2 
business 
days of 
visit Within 24 
hours and 
ongoing as 
available and 
applicable  
x Off Study Cardiac Assessment          
x  
x Off Study Biomarkers          
x  
x Off Study          
x  
x Death Report3          
 
 Comments*           
 
 Verification           
 
x Off Schedule Imaging*           
 
x Follow Up On Study Tumor* 
Assessment           
 
 
1 On study cardiac assessments to be completed prior to C4D1 and every 3 cycles thereafter; CRF to be completed with C4D1 asses sments, C7D1 assessments, C10D1 assessments, etc.  
2 On study lipid panel to be completed prior to C4D1 and every 3 cycles thereaft er: CRF to be completed with C4D1 assessments, C7D1 assessments, C10D1 assessments, etc.  
3 Complete at Death Report CRF only if subject dies while on study or within 30 days of last study intervention.  
* Certain CRF pages can be inserted into any Velos eR esearch calendar time point such as Comments or Off Schedule Imaging. Please provide applicable redacted source in these inst ances. 
 
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  64 12.3 Data and Safety Monitoring Committee  
The NCI-approved Data Safety and Monitoring Committee (DSMC) of the Herbert 
Irving Comprehensive Cancer Center (HICCC) will monitor every subject who 
receives treatment on this protocol for toxicity. This protocol will adhere to the 
policies of the currently approved HICCC Data and Safety Monitoring Plan (DSM P), 
which is in accordance with NCI and CUMC -IRB policy and guidelines.  The 
committee is led by Dr. J. Gregory Mears and consists of HICCC faculty and staff 
with expertise in oncology, research pharmacy, research nursing, and data 
management. The DSMC con venes twice a month to review patient safety and the 
conduct of the trial. The PI will submit data and safety monitoring reports to the 
DSMC at a frequency to be determined by the DSMC based on risk to the subjects.  
(Appendix F ) 
 
At the time of renewal, th e study team will submit the most recent DSMC approval 
letter for safety review to the CUMC IRB. Any modifications that are required by the 
DSMC to ensure patient safety will be submitted to the IRB. All protocol deviations, 
violations, and eligibility wai vers will be submitted to and approved by the DSMC 
prior to being reported to the IRB. All study data reviewed and discussed during these 
meetings will be kept confidential.  
 
The Coordinating Site will assure that there is a mechanism in place to distribu te the 
report to all participating investigators for submission to their local IRB.  The report 
will document that a review of data and outcomes across all centers took place on a 
given date.  It will summarize the DSMCâ€™s review of the cumulative toxicitie s 
reported from all participating sites without specific disclosure by treatment arm.  It 
will also inform site investigators of the study the DSMCâ€™s conclusion with respect to 
progress or need for modification of the protocol.   
 
12.4 Quality Control and Quali ty Assurance  
Independent monitoring of the clinical study for protocol and GCP compliance will be 
conducted periodically by the CPDM Compliance Core on behalf of the HICCC 
DSMC.  Additionally, the Compliance Oversight Committee of the IRB at Columbia 
University Medical Center may audit the study at any time , per institutional policies 
and procedures.  
 
The investigator -sponsor and Columbia University Medical Center will permit direct 
access of the study monitors and appropriate regulatory authorities to the study data 
and to the corresponding source data and documents to verify the accuracy of this 
data. 
 
A risk-based approach will be used by the Compliance Core to determine the frequency, 
number of subject charts, and data elements to be monitored. The Compl iance 
Coordinator will review the study status and summarize enrollment, toxicities, 
SAEs/UPs, dose escalation, statistical endpoints (e.g., stopping rules), etc. for the full 
DSMC membership at the regularly scheduled meetings.   
 
Internal On -site Monitor ing: 
 
1. Initial, recurrent, and close -out on-site monitoring visits will also be conducted 
at remote clinical sites, as appropriate/feasible. Other sites will have 
monitoring performed remotely (see below for further details).  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  65  
a. The study Monitoring Visit Log  will be completed and signed by the 
monitor and the PI/CRNP/CRN and/or CRC and will be filed in the 
regulatory binder.  
 
2. The Compliance Coordinator will communicate with the site coordinator/Site 
Principle Investigator to schedule the monitoring visit and arrange for access 
to study materials and documentation.  
 
3. The assigned Compliance Coordinator will monitor IIT trials within 1 month 
after the first subject is enrolled and throughout the life of the study to ensure 
that the study is being conducted in acc ordance with the protocol, GCP, 
applicable federal and local regulations, and per all applicable SOPs. The 
Compliance Coordinator is responsible to notify the PI and CRNP/CRN/CRC 
of upcoming monitor visits and convey what information and documentation 
will be required for the visit(s).  The Compliance Coordinator is responsible 
for verifying that informed consent is properly obtained, eligibility is met (via 
the central registration process), and all study procedures are conducted 
according to the study pro tocol. The Compliance Coordinator will also verify 
that the data reported in the CRFâ€™s accurately reflect source documents, that 
all toxicities have been reported to date, and that all 
SAEâ€™s/UPs/deviations/violations have been reported according to local I RB 
and HICCC DSMC requirements. The Compliance Coordinator will issue 
queries and ensure resolution in a timely and efficient manner.  The 
Compliance Coordinator will also monitor for applicable regulatory 
compliance and research pharmacy compliance (if ap plicable) and 
communicate any deficiencies as appropriate.  
 
12.5 Confidentiality  
Information about study subjects will be kept confidential and managed according to 
the requirements of the Health Insurance Portability and Accountability Act (HIPAA).  
Those regu lations require a signed subject authorization informing the subject of the 
following:  
1. What protected health information (PHI) will be collected from subjects in this 
study 
2. Who will have access to that information and why  
3. Who will use or disclose that inf ormation 
4. The rights of a research subject to revoke their aut horization for use of their 
PHI  
In the event that a subject revokes authorization to collect or use PHI, the investigator, 
by regulation, retains the ability to use all information collected pri or to the revocation 
of subject authorization.  For subjects who have revoked authorization to collect or 
use PHI, attempts should be made to obtain permission to collect at least vital status 
(i.e. that the subject is alive) at the end of their scheduled study period.  
12.6 Source Documents  
Source data is all information, original records of clinical findings, observations, or 
other activities in a clinical trial necessary for the reconstruction and evaluation of the 
trial.  Source data are contained in source d ocuments   Examples of these original 
documents, and data records include: hospital records, clinical and office charts, 
laboratory notes, memoranda, subjectsâ€™ diaries or evaluation checklists, pharmacy 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  66 dispensing records, recorded data from automated inst ruments, copies or transcriptions 
certified after verification as being accurate and complete, microfiches, photographic 
negatives, microfilm or magnetic media, x -rays, subject files, and records kept at the 
pharmacy, at the laboratories, and at medico -technical departments involved in the 
clinical trial.  
 
12.7 Reporting to Incyte Corporation  
The Overall Principal Investigator will send complete Data transfers every six months 
during the course of the study to Incyte Corporation. Incyte Corporation may request 
additional data transfers over the course of the study. The data will be provided in a 
readable format for all study participants. The data will not include any protected health 
information as defined under HIPAA.  
 
Additionally, Incyte Corporation will be provide monthly study status updates 
including a summary of:  
ï‚· Recruitment (screened, enrolled, discontinued and on -going with dates and 
study drug dosing regimens,  
ï‚· SAEs and safety reports to regulatory authorities  
ï‚· Regulatory correspondence include IRB appro val letters, IRB approved 
protocol, informed consent documents, and documents related to Inycte.  
ï‚· Investigational product Inventory  
ï‚· Payment milestones.  
 
12.8 Records Retention  
Records relating to a specific research activity, including research records collect ed 
by investigators, must be maintained for at least three years after completion of the 
research (45 CFR 46.115(b); 21 CFR 56.115(b); 21 CFR 312.62). This minimum 
retention period applies whether or not any subjects were enrolled in the study.  
If the rese arch is FDA regulated, records should be retained for at least two years after 
approval of the investigational agent by FDA; if it is not approved, records should be 
retained at least two years after the study is terminated and FDA is notified (note the 
additional requirement below for clinical research studies);  
Clinical records, including consent forms that document clinical intervention or 
clinical diagnostic procedure research -related procedures, must be retained in medical 
records by the institution f or at least seven years, per CUMC and NYP policy , which 
is based on state law.  
 
Guidelines for Processing IND Safety Reports  
The U.S. Food and Drug Administration (FDA) regulations require sponsors of 
clinical studies to notify the FDA and all participating investigators of any serious and 
unexpected adverse experiences that are possibly related to the investigational agent. 
The CUMC Principal Investigator will review all applicable IND Safety Reports and 
has the responsible for forwarding the I ND Safety Reports to the Affiliate Institutions. 
The Affiliate Institution investigators are to review, send a copy to their IRB 
according to their local IRBâ€™s policies and procedures, and file a copy with their 
regulatory documents. All Affiliate site IND SR submissions, along with IRB 
acknowledgment (per local policies and procedures) are to be forwarded to CUMC for 
placement within the trial master file.  
 
13. STATISTICAL CONSIDER ATIONS  
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  67 13.1 Study Design/ Primary Endpoint  (Sample Size)  
 
Phase I (n=10 patients) :  
The objective of the phase I portion of this  study is to determine an acceptable dose of 
ruxolitinib in combination with trastuzumab.  The dose of t rastuzumab will be fixed at 
6 mg/kg every 3 weeks IV for all patients.  If patients have not received t rastuzumab 
for > 28 days prior to the initiation of study drugs, a loading of 8 mg/kg IV should be 
used.  After this dose, patients should remain on 6 mg/kg every 21 days (+/ - 4 days).  
We evaluate four doses of ruxolitinib  PO during the phase I. The ordering o f these 
doses is as follows:  
 
The maximum tolerated dose (MTD) combination is defined as the dose combination 
associated with a target probability of dose limiting toxicity of 0.25. A dose -limiting 
toxicity is defined as the MTD with DLTs defined as any grade 3 non -hematologic 
toxicities despite maximal supportive care or any grade 4 hematologic toxicity  directly 
related to study drug .  In order for a patient to be evaluable for DLT assessments, the 
patient must incur a DLT during the first 21 days of actively taking  ruxolitinib plus 
trastuzumab.  If , for instance,  the patient temporarily stops ruxolitinib due to 
uncomplicated hematologic toxicities, the patient can resume ruxolitinib at the same 
dose and the DLT period will remain defined as the first 21 days of acti vely taking the 
study medication.  In order to be considered eligible, the DLT period (i.e. 21 days of 
actively taking ruxolitinib plus trastuzumab) must be completed within 30 days of the 
first dose of ruxolitinib.  
 
The MTD will be estimated using the tim e to event continual reassessment method 
(TITE-CRM).  The TITE -CRM will use an empirical dose -toxicity model, with a 
sample size of 10.  The dose -toxicity model is calibrated such that the method will 
eventually select a dose that yields between 16% and 34 % DLT (Lee and Cheung 2009, 
Cheung and Chappell 2002).  The advantage of the TITE -CRM is that it uses the 
patientâ€™s partial information before a complete follow -up is achieved.  As a result, we 
can conduct the trial in a continuous fashion without having p atients being turned away 
due to waiting time.  However, since the MTD will be estimated from partial data, final 
data may show that patients will have been treated with a dose exceeding the MTD. 
Given the toxicities reported on previous studies using this  drug, we anticipate very low 
rates of DLTs at 10 and 15 mg.  Most likely the MTD will be 25mg or 20mg.  In addition, 
another advantage is an increased likelihood of getting the true MTD with this 
methodology, as opposed to utilizing a 3+3 dose -finding desi gn.  We will start the trial 
with a dose of 20mg based on the Incyte Investigatorâ€™s Brochure and assess the 
performance of the TITE -CRM under two most likely scenarios.  
 
To evaluate the performance of the method, 2000 simulations under the two mostly 
likely scenarios of toxicity profiles were done.  The operating characteristics of our 
design under these scenarios are displayed in the  Table 8.  With 10 patients, the design Dose Level  Dose 
1 25 mg bid  
0 (starting dose level)  20 mg bid  
-1 15 mg bid  
-2 10 mg bid  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  68 selects the correct MTD with probabilities over 50%.   These simulations assume that 
the patients arrive at a rate of 2 patients every 3 weeks, especially at the initiation of the 
clinical trial, and that a DLT occurs randomly and uniformly within the observation 
window.  
Table 8: Selection Probabilities of the TITE -CRM  
Doses of 
Ruxolitinib   10mg 15mg 20mg 25mg 
Scenario 1      
DLT rate 1% 5% 5% 25% 
P(Selection)  0% 2% 20% 78% 
     
Scenario 2      
DLT rate 1% 5%   25% 40% 
P(Selection)  1% 21% 51% 27% 
 
Table 9 displays a simulation of a sample design using the method where the 
MTD is at dose level 1 (i.e. 25 mg po b.i.d.)    Given the low likelihood of 
overlapping toxicities with ruxolitinib plus t rastuzumab and fa vorable side effect 
profile of r uxolitinib, we anticipate that the table below is the most likely 
scenario.  
 
Table 9: Sample simulated design with n=10  
Patient Arrival Time  Dose Level 
Assigned  Toxicity (Y/N)  Time of Toxicity  
1 1.5 weeks  0 N - 
2 3 weeks 0 N - 
3 4.5 weeks  1 N - 
4 6 weeks 1 N - 
5 7.5 weeks 1 N - 
6 9 weeks 1 N - 
7 10.5 weeks  1 Y 1.11 weeks  
8 12 weeks  1 N - 
9 13.5 weeks  1 N - 
10 15 weeks  1 N - 
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  69 Phase II (n=30 patients â€“ evaluable patients from phase I at the recommended 
phase II trial may be included) :  
The primary endpoint of the phase II portion of this study is to define the progression 
free surviv al (PFS) of the combination of ruxolitinib plus t rastuzumab in patients with 
HER2+ metastatic breast cancer who have previously received HER2 targeted 
therapy.  PFS will be defined as the time from patient registration  until objective or 
disease progression or death from any cause. Assuming a historical PFS of 8 weeks 
with single -agent agent HER2 -targeted therapy in metastatic HER2+ brea st cancer 
after progressing on t rastuzumab -based therapy (Blackwell JCO 2010), we predict 
that patients receiving the combination of ruxolitinib at the MTD dose] plus 
trastuzumab will have a PFS of at least 13 weeks.  With a 2 -sided alpha of 0.05, we 
have 80% power to detect a difference  with 30 pts.   
 
The PFS distribution of the treatment arm will be estimated by Kaplan -Meier survival 
analysis. Ninety -five percent confidence intervals for the Kaplan -Meier PFS estimates 
will be calculated using Greenwoodâ€™s formulae.  Patients will be anal yzed regardless 
of therapy initiation or compliance for this analysis. A secondary analysis will be 
performed comparing â€œevaluableâ€ patients. We will define â€œevaluableâ€ patients as 
patients who met eligibility requirements, have initiated therapy, and were  not 
removed from the study for non -compliance or patient withdrawal.  Evaluation of 
disease will be made according to RECIST criteria (version 1.1) in patients with 
measurable disease. Patients with hormone receptor positive metastatic breast cancer 
may not have easily measurable disease as defined by RECIST criteria, in particular 
bone and soft tissue metastases. In these patients CR or PR are not easily assessed. 
Thus, we have chosen Progression Free Survival as our primary endpoint. The 
Clinical Benefit  Rate (CBR), defined as complete response, partial response or stable 
disease for > 24 weeks, is our secondary endpoint. In addition, overall response rate, 
CR and PR will be analyzed in evaluable patients.  
 
13.2 Accrual Rate  
Four centers will accrue patients t o the phase I/II portions of this trial.   These centers 
are: New York Presbyterian Hospital â€“ Columbia University, Albert Einstein College 
of Medicine, New York Presbyterian Hospital - Cornell University, and Mount Sinai 
Medical Center.  We anticipate that  each site will be able to accrue 5 patients per year 
and believe that the accrual period will be 2 years.  If the accrual is lower than 
expected within the first 6 months, we will consider expanding the study.  
 
13.3 Stratification Factors  
Patients will be stra tified by hormone receptor status (binary: positive or negative).  
Positivity will be defined as estrogen receptor and/or progesterone receptor status > 
1% by immunohistochemistry.  
 
13.4 Analysis of Secondary Endpoints  
 
13.4.1  Clinical Benefit Rate, Percent Progression -Free at 24 weeks, Objective 
Response Rate:  
Secondary endpoints include clinical benefit rate (CR + PR + SD > 24 weeks) 
(estimated via binomial proportions) and percent progression -free at 24 weeks.  
Ninety-five percent confidence intervals wil l be calculated for the clinical benefit 
response proportion and the percent progression -free at 24 weeks via binomial 
proportions. The analysis of objective response rate will be conducted on the 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  70 Measurable Disease at baseline analysi s set. Exact binomial  2-sided 95% confidence 
intervals will be generated for the objective response rate.    
 
13.4.2  Toxicity Evaluation  
The frequency of subjects experiencing toxicities will be tabulated.  
The CTEP Active Version of the NCI Common Terminology Criteria for Adverse 
Events (CTCAE) will be utilized for AE reporting. The CTEP Version 4.0 of the 
CTCAE is identified and  located on the CTEP website at 
(http://ctep.cancer.gov/protocolDe velopment/electronic_applications/ctc.htm ). 
All appropriate treatment areas should have access to a copy of the CTEP Active 
Version of CTCAE.  All patients will be evaluable for toxicity from the tim e of their 
first treatment with the  study drugs.  
 
13.4.3  Correlative Studies  
Transcriptional profiling will be assessed by our bioinformatics core under the 
direction of Dr. Califano using standard analyses, as well as Interactome modeling.  
Comparisons between pre -treatment to on -treatment will be assessed for  significance 
and trend using the paired t -tests. 
 
13.5 Reporting and Exclusions  
  
13.5.1  Evaluation of toxicity.  
All patients included in the study must be assessed for response to treatment, even if 
there are major protocol treatment deviations or if they are ineli gible. Each patient 
will be assigned one of the following categories: 1) complete response, 2) partial 
response, 3) stable disease, 4) progressive disease, 5) early death from malignant 
disease, 6) early death from toxicity, 7) early death because of other  cause, or 9) 
unknown (not assessable, insufficient data). [Note: By arbitrary convention, category 
9 usually designates the â€œunknownâ€ status of any type of data in a clinical database.]  
 
All of the patients who met the eligibility criteria (with the possible exception of those 
who received no study medication) should be included in the main analysis of the 
response rate. Patients in response categories 4 -9 should be considered to have a 
treatment failure (disease progression). Thus, an incorrect treatment schedule or drug 
administration does not result in exclusion from the analysis of the response rate.  
 
14. PROTECTION OF HUMAN SUBJECTS  
This study is to be conducted in accordance with applicable government regulations 
and Institutional research policies and procedures.  AN IND annual report will be 
submitted to the FDA in accordance with 21.CFR 312.33.  
 
This protocol and any amendments will be submitted to a properly cons tituted 
Institutional Review Board (IRB), in agreement with local legal prescriptions, for 
formal approval of the study conduct.  The decision of the IRB concerning the 
conduct of the study will be made in writing to the investigator and a copy of this 
decision will be provided to the sponsor before commencement of this study.  
 
All subjects for this study will be provided a consent form describing this study and 
providing sufficient information for subjects to make an informed decision about their 
participation in this study. This consent form will be submitted with the protocol for 
review and approval by the IRB for the study.  The formal consent of a subject, using 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  71 the IRB-approved consent form, must be obtained before that subject is submitted to 
any study procedure.  This consent form must be signed by the subject or legally 
acceptable surrogate, and the investigator -designated research professional obtaining 
the consent.  
 
 
15. REFERENCES  
1. Parkin DM, Bray F,  Ferlay J, Pisani P. Global cancer statistics, 2002. CA 
Cancer J Clin 2005;55(2):74 â€“108.  
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 
2008;58(2):71 â€“96.  
3. Revillion F, Bonneterre J, Peyrat JP.  ERBB2 oncogene in human br east cancer 
and its clinical significance. European Journal of Cancer 1998;34(6):791 â€“808.  
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human 
breast cancer: correlation of relapse and survival with amplification of the 
HER-2/neu oncoge ne. Science 1987;235(4785):177 â€“82.  
5. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National 
Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB -2 
protein overexpression in primary breast cancer. J Clin Oncol 1990 ;8(1):103â€“
12.  
6. Hudis CA. Trastuzumab --mechanism of action and use in clinical practice. 
NEJM 2007;357(1):39 â€“51.  
7. Slamon DJ, Leyland -Jones B, Shak S, et al. Use of chemotherapy plus a 
monoclonal antibody against HER2 for metastatic breast cancer that 
overexpresses HER2. NEJM 2001;344(11):783 â€“92.  
8. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant 
chemotherapy for operable HER2 -positive breast cancer. NEJM 
2005;353(16):1673 â€“84.  
9. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy 
and safety of humanized anti -HER2 monoclonal antibody in women who have 
HER2-overexpressing metastatic breast cancer that has progressed after 
chemotherapy for metastatic disease. J Clin Oncol 1999;17(9):2639 â€“48.  
10. Seidman AD, Forn ier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel 
therapy for metastatic breast cancer with analysis of efficacy by HER2 
immunophenotype and gene amplification. J Clin Oncol 2001;19(10):2587 â€“95.  
11. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and 
trastuzumab for patients with HER -2â€“overexpressing metastatic breast cancer. 
J Clin Oncol 2002;20(7):1800 â€“8.  
12. Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinor elbine or 
taxane chemotherapy for HER2 -overexpressing metastatic breast cancer: the 
trastuzumab and vinorelbine or taxane study. Cancer 2007;110(5):965 â€“72.  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  72 13. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing 
doxorubicin and cyc lophosphamide followed by docetaxel (ACâ†’ T) with 
doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab 
(ACâ†’ TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 
positive early breast cancer patients: BCIRG 006 study. Breast Cancer  Res 
Treat 2005;94(Suppl 1):S5.  
14. Fridman JS, Scherle PA, Collins R, et al. Preclinical evaluation of local JAK1 
and JAK2 inhibition in cutaneous inflammation. J Investig Dermatol 
2011;131(9):1838 â€“44.  
15. QuintÃ¡s-Cardama A, Vaddi K, Liu P, et al. Precl inical characterization of the 
selective JAK1/2 inhibitor INCB018424: therapeutic implications for the 
treatment of myeloproliferative neoplasms. Blood 2010;115(15):3109 â€“17.  
16. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted 
inhibitors. Nat Rev Cancer 2005;5(5):341 â€“54.  
17. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla Favera R, Califano A. 
Reverse engineering of regulatory networks in human B cells. Nat Genet 
2005;37(4):382 â€“90.  
18. Carro MS, Lim WK, Alvarez MJ, et al. The transcriptional network for 
mesenchymal transformation of brain tumours. Nature 2009;463(7279):318 â€“
25.  
19. Margolin AA, Nemenman I, Basso K, et al. ARACNE: an algorithm for the 
reconstruction of gene regulatory networks in a mammalian cellular context. 
BMC Bioinformatics 2006;7 Suppl 1:S7.  
20. Wang K, Saito M, Bisikirska BC, Alvarez MJ, al E. Genome -wide 
identification of post -translational modulators of transcription factor activity in 
human B cells. Nature 2009;  
21. Silva JM, Mizuno H, Brady A, Lucito R , Hannon GJ. RNA interference 
microarrays: high -throughput loss -of-function genetics in mammalian cells. 
Proc Natl Acad Sci USA 2004;101(17):6548 â€“52.  
22. Silva JM, Marran K, Parker JS, et al. Profiling essential genes in human 
mammary cells by multiplex R NAi screening. Science 2008;319(5863):617 â€“
20.  
23. Silva JM, Ezhkova E, Silva J, et al. Cyfip1 is a putative invasion suppressor in 
epithelial cancers. Cell 2009;137(6):1047 â€“61.  
24. Paddison PJ, Silva JM, Conklin DS, et al. A resource for large -scale RNA -
interference -based screens in mammals. Nature 2004;428(6981):427 â€“31.  
25. Akca H, Tani M, Hishida T, Matsumoto S, Yokota J. Activation of the AKT 
and STAT3 pathways and prolonged survival by a mutant EGFR in human 
lung cancer cells. Lung Cancer 2006;54(1): 25â€“33.  
26. Byers LA, Sen B, Saigal B, et al. Reciprocal regulation of c -Src and STAT3 in 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  73 non-small cell lung cancer. Clin Cancer Res 2009;15(22):6852 â€“61.  
27. Weerasinghe P, Garcia GE, Zhu Q, et al. Inhibition of Stat3 activation and 
tumor growth suppress ion of non -small cell lung cancer by G -quartet 
oligonucleotides. Int J Oncol 2007;31(1):129 â€“36.  
28. Zhang X, Guo A, Yu J, et al. Identification of STAT3 as a substrate of receptor 
protein tyrosine phosphatase T. Proc Natl Acad Sci USA 2007;104(10):4060 â€“
4.  
29. Darnell JE. Validating Stat3 in cancer therapy. Nat Med 2005;11(6):595 â€“6.  
30. Sansone P, Bromberg J. Targeting the interleukin -6/Jak/stat pathway in human 
malignancies. Journal of Clinical Oncology 2012;30(9):1005 â€“14.  
31.     Guo, H., W. Liu, Z. Ju, P. Tamboli, E. Jonasch, G. Mills, Y. Lu, B. Hennessy 
and D.  Tsavachidou (2012). "An efficient procedure for protein extraction 
from formalin -fixed,  paraffi n-embedded tissues for reverse phase protein 
arrays." Proteome Science  10(1): 56. 
32.      Guo, T., W. Wang, P. Rudnick, T. Song, J. Li, Z. Zhuang, R. Weil, D. DeVoe,  
C. Lee and  B. Balgley (2007). "Proteome analysis of microdissected formalin -
fixed and paraffin -embedded tissue specimens." J Histochem Cytochem  55(7): 
763 - 772. 
 
33. Mackey JR, Clemons M, CÃ´tÃ© MA, et al. Cardiac management during adjuvant 
trastuzumab therapy: recommendations of the Canadian Trastuzumab Working 
Group. Curr Oncol 2008;15(1):24 â€“35.  
34. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation  criteria 
in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 
2009;45(2):228 â€“47.  
  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  74 APPENDIX A :  PERFORMANCE STATUS  CRITERIA  
 
ECOG Performance Status Scale  Karnofsky Performance Scale  
Grade Descriptions  Percent Description  
0 Normal activity.  Fully active, able 
to carry on all pre -disease 
performance without restriction.  100 Normal, no complaints, no 
evidence of disease.  
90 Able to carry on normal activity; 
minor signs or symptoms of 
disease. 
1 Symptoms, but ambulatory.  
Restricted in physically strenuous 
activity, but ambulatory and able 
to carry out work of a light or 
sedentary nature ( e.g., light 
housework, office work).  80 Normal activity with effort; 
some signs or symptoms of 
disease. 
70 Cares for self, unable to carry on 
normal activity or to do active 
work. 
2 In bed <50% of the time.  
Ambulatory and capable of all 
self-care, but unable to carry out 
any work activities.  Up and about 
more than 50% of waking hours.  60 Requires occasional assistance, 
but is able to  care for most of 
his/her needs.  
50 Requires considerable assistance 
and frequent medical care.  
3 In bed >50% of the time.  Capable 
of only limited self -care, confined 
to bed or chair more than 50% of 
waking hours.  40 Disabled, requires special care 
and assistance.  
30 Severely disabled, 
hospitalization indicated.  Death 
not imminent.  
4 100% bedridden.  Completely 
disabled.  Cannot carry on any 
self-care.  Totally confined to bed 
or chair. 20 Very sick, hospitalization 
indicated. Death not imminent.  
10 Moribund, fatal processes 
progressing rapidly.  
5 Dead. 0 Dead. 
 
 
 
 
 
 
 
 
 
  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  75 APPENDIX B : SUBJECTâ€™S  MEDICATION DIARY  
 
SUBJECTâ€™S  MEDICATION DIARY  
 
Todayâ€™s date  _____________________  Agent:  Ruxolitinib  ______ mg  
 
Subject Name____________________ _ (initials acceptable)     
Subject Study ID  __________________________  
 
 
Cycle   
Day  
Date  
Time of 
dose  
(AM)   
Number 
of Pills 
(AM)  
Time of 
dose  
(PM)  
Number 
of Pills 
(PM) Comments  
Side effects  
 1       
 2       
 3       
 4       
 5       
 6       
 7       
 8       
 9       
 10       
 11       
 12       
 13       
 14       
 15       
 16       
 17       
 18       
 19       
 20       
 21       
 22       
 23       
 24       
 25       
 
 
____________________ __                       ____________________ _                  
SUBJECT SIGNATURE   DATE       
 
 
 
 
 
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  76 APPENDIX C: STRONG KNOWN CYP 3A4 INHIBI TORS AND INDUCERS.  
Inhibitors  
boceprevir  
clarithromycin  
chloramphenicol  
conivaptan  
indinavir 
itraconazole  
ketoconazole  
lopinavir/ritonavir  
mibefradil  
nefazodone  
nelfinavir  
posaconazole  
ritonavir 
saquinavir  
telaprevir  
telithromycin  
voriconazole  
 
Patients should limit grapefruit juice intake  
 
Source: Jakafi prescribing information, 2013.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  77 APPENDIX D : ARCHIVED TISSUE AND BIOPSY COLLECTION AN D 
SHIPMENT   
 
All formalin -fixed paraffin embedded (FFPE) from archived tumor and study -related 
biopsies will be stored onsite until requested by the coordinating center. Ideally, all 
slides will be cut at the same time, within 6 weeks of time of request , and sent to th e 
coordinating center to distribute for analysis at the Columbia University Genome 
Center, Columbia University Molecular Pathology Core, and MD Anderson 
Functional Proteomics Core Facility.  
Ship to: 
Kevin Kalinsky, MD, MS  
Attn: Stephanie Aguilar  
Columbia University Medical Center  
161 Fort Washington Ave â€“ Mezzanine  
New York, NY 10032  
Phone: 212-342-4591 
Complete these forms separately for each subject; enclose with shipment along with 
accompanying pathology report.  
 
I. Archived Diagnostic Tissue  
Subject ID: ______________________  
Archival tissue, diagnostic biopsy                                                                               
 Not available  
Number of 
slides Slide preparation  Slide IDs  
  10 immunoblanks [each having 4 micron sections on 
charged slides]  
 1 intervening H&E stained  
 12 regular slides each with 10 microns sections   
Enclose redacted accompanying pathology report. 
Archival tissue, biopsy at recurrence                                                            Not 
available/applicable  
Number of 
slides Slide preparation  Slide IDs  
  10 immunoblanks [each having 4 micron sections on 
charged slides]  
 1 intervening H&E stained  
 12 regular slides each with 10 microns sections   
Enclose redacted accompanying pathology report . 
Date  Name of person responsible for this shipment  
  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  78 II.  Optional study -related biopsies 
For patients with accessible tumor, 2 punch biopsies (for skin) or 3 core biopsies are 
recommended.  The following will be requested: 10 immunoblanks [each having 4 
micron sections on charged slides], one intervening H&E stained slide, and 12 regu lar 
slides each with 10 microns sections.  
Subject ID: ______________________  
FFPE tissue, Pre -treatment biopsy   
 Core biopsies (3 preferred)   Punch biopsies  (2 preferred)                                                                       
Number 
of slides Slide preparation  Date 
Collected  Slide IDs 
  10 immunoblanks [each having 4 micron sections on 
charged slides]  
 1 intervening H&E stained  
 12 regular slides each with 10 microns sections    
Enclose redacted accompanying pathology report (if available) . 
FFPE tissue, On -treatment biopsy from C2D1 (prior to treatment)  
 Core biopsies (3 preferred)   Punch biopsies  (2 preferred)                                                  
Number 
of slides Slide preparation  Date 
Collected  Slide IDs 
  10 immunoblanks [each having 4 micron sections on 
charged slides]  
 1 intervening H&E stained  
 12 regular slides each with 10 microns sections    
Enclose redacted accompanying pathology report (if available).  
Date  Name of person responsible for this shipment  
  
 
III. Optional biopsy upon progression  
For agreeable patients with accessible tumor upon progression, 2 punch biopsies (for 
skin) or 3 core biopsies are recommended.  The following will be requested: 10 
immunoblanks [each having 4 micron sections on charged slides], one intervening 
H&E stained slide, and 12 regular slides each with 10 microns sections.  
Subject ID: ______________________  
FFPE tissue, biopsy upon progression  
 Core biopsies (3 preferred)   Punch biopsies  (2 preferred)                                                  
Number 
of slides Slide preparation  Date 
Collected  Slide IDs  
  10 immunoblanks [each having 4 micron 
sections on charged slides]  
 1 intervening H&E stained  
 12 regular slides each with 10 microns 
sections   
Date  Name of person responsible for this shipment  
  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  79 APPENDIX E :  BLOOD BIOMARKER C OLLECTION  
 
I.  Plasma and Serum Biospecimen Collection  
Samples should be obtained at protocol specified time points, using supplies available 
onsite. All specimens will be stored onsite and shipped out when requested (usually at 
inception of analysis). Samples are collected according to the calendar in section  9.  
I. Whole Blood  
Collect Invert Store 
   
At least 3 ml whole blood  
in EDTA tube (lavender 
top) Invert 8 to 10 times.  Freeze in -80 freezer 
until ready to ship; 
alternatively, freeze in -
20 freezer up to 4 weeks 
prior to transferring to -
80 freezer for long -term 
storage.  
 
Whole blood is collected pre -study only for all subjects.  
ï‚· Be sure to label tube with subject ID, date and time point  
ï‚· When requested, ship to:  
Regina Santella Laboratory  
Attn: Irina Gurvich  
Columbia University Medical Center  
630 West 168th St Room 16 -410 
New York, NY 10032  
Phone: 212 -305-8158 
ï‚· Ship on dry ice for overnight delivery; FedEx airbill can b e supplied by study 
team. 
ï‚· Email m1906@columbia.edu  and ig112@columbia.edu  to inform study team 
and Irina of incoming samples  

Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  80 II. Plasma PK â€“ C2D1 only  
Plasma PK is collected C2D1 prior to treatment only for all phase I subjects. 
Trough (prior) and peak (2 hours post) levels should be drawn at Cycle 2 Day 1.  
Collect Invert Ice/Water 
Bath Centrifuge  Aliquot & 
label Store 
  
 
    
4 ml whole 
blood in 
K2EDTA 
tube 
(lavender 
top) Invert â‰¥ 5 
times. Place tube on 
ice or in 
water bath.  Within 45 
min. of 
collection, 
centrifuge 
2000 x g for 
15 minutes at 
~5á´C. With pipette, 
aliquot equal 
amounts 
plasma into 2 
cryotubes.  Ship Plasma 
aliquot A 
same day as 
collection or 
store both in -
20 to -80 
freezer until 
ready for 
shipment.  
 
ï‚· Label the cryotubes with protocol number, patient ID, time of collection and 
Plasma aliquot A or Plasma aliquot B.  Place transparent tape over the cryotube 
labels. 
ï‚· When prepared, ship Plasma aliquot A  samples to:  
Incyte Corporation  
Attn: Tom Emm  
Route 141 & Henry Clay Rd  
Building 400 -3431 
Wilmington, DE 19880  
Phone: 302-498-6775 
ï‚· Ship on plenty of dry ice for overnight delivery; FedEx airbill can be supplied 
by study team.  
ï‚· Plasma aliquot B samples will remain in frozen storage at the site until 
specified by Incyte or the study PI to ship  
ï‚· Email temm@incyte.com  and smalhotra@incyte.com  with tracking 
information to inform them of incoming samples  
  

Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  81 III. Plasma (C -reactive protein, et. al)  
Collect Invert Centrifuge  Aliquot Store 
     
At least 4 ml 
whole blood  
in lithium 
heparin tube 
(dark green top);  
alternatively, 
sample can be 
collected in pink 
top K2EDTA 
tube. Invert 8 to 10 
times (do not 
shake). Keep 
at room 
temperature or 
on regular ice 
after inverted.  Within 1 hour 
of collection, 
centrifuge 
2000 x g for 15 
minutes at 4á´C. With pipette, 
aliquot ~1.0 ml 
of plasma  into 3 
to 5 cryovials. 
(max. volume of 
cryovials should 
be 2 ml) Freeze in -80 
freezer until ready 
to ship.  
 
Plasma is collected pre -study, C2D1 prior to treatment , and at progression  for all 
subjects.  
ï‚· Be sure to label cryovials with subject ID, date, specimen type and time point  
ï‚· When requested, ship to:  
Regina Santella Laboratory  
Attn: Irina Gurvich  
Columbia University Medical Center  
630 West 168th St Room 16 -410 
New York, NY 10032  
Phone: 212 -305-8158 
ï‚· Ship on dry ice for overnight delivery; FedEx airbill can be supplied by study 
team. 
ï‚· Email m1906@columbia.edu  and ig112@columbia.edu  to inform study team 
and Irina of incoming samples  
 
 
 
 
 
  

Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  82 IV. Serum (IL6, IL8 cytokines & additional serum biomarkers)  
Collect Invert Centrifuge  Aliquot Store 
     
Up to 10 ml 
whole blood  
in serum tube 
(red top, no gel 
separator); 
alternatively, 
sample can be 
collected in 
multiple serum 
tubes less than 10 
ml. to have 
adequate 
aliquots. Invert 8 to 10 
times. Keep at 
room 
tempature until 
adequately 
clotted (at least 
30 minutes).  Within 1 hour 
of collection, 
centrifuge 
2000 x g for 15 
minutes at 4á´C. With pipette, 
aliquot ~1.0 ml 
of serum into 4 
to 6 cryovials. 
(max. volume of 
cryovials should 
be 2 ml) Freeze in -80 
freezer until ready 
to ship.  
 
Serum Plasma is collected pre -study, C2D1 prior to treatment, and at progression for 
all subjects.  
ï‚· Be sure to label cryovials with subject ID, date, specimen type and time point  
ï‚· When requested, ship to:  
Regina Santella Laboratory  
Attn: Irina Gurvich  
Columbia University Medical Center  
630 West 168th St Room 16 -410 
New York, NY 10032  
Phone: 212 -305-8158 
ï‚· Ship on dry ice for overnight delivery; FedEx airbill can be supplied by study 
team. 
ï‚· Email m1906@columbia.edu  and ig112@columbia.edu  to inform study team 
and Irina of incoming samples  
  

Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  83 V. Plasma (Additional plasma biomarkers)  
Collect Invert Centrifuge  Aliquot Store 
     
At least 4 ml 
whole blood  
in EDTA tube 
(lavender top)  Invert 8 to 10 
times.  Within 1 hour 
of collection, 
centrifuge 
2000 x g for 15 
minutes at 4á´C. With pipette, 
aliquot ~1.0 ml 
of plasma into 3 
to 5 cryovials. 
(max. volume of 
cryovials should 
be 2 ml) Freeze in -80 
freezer until ready 
to ship.  
 
Plasma for biomakers is collected pre -study and C2D1 prior to treatment for all 
subjects.  
ï‚· Be sure to label cryovials with subject ID, date, specimen type and time point  
ï‚· When requested, ship to:  
Regina Santella Laboratory  
Attn: Irina Gurvich  
Columbia University Medical Center  
630 West 168th St Room 16 -410 
New York, NY 10032  
Phone: 212 -305-8158 
ï‚· Ship on dry ice for overnight delivery; FedEx airbill can be supplied by study 
team. 
ï‚· Email m1906@columbia.edu  and ig112@columbia.edu  to inform study team 
and Irina of incoming samples  
  

Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  84 VI. Shipping Document for Biospecimens  
Store all biospecimens onsite until they are requested from the coordinating site.  
Enclose this document with all biospecmen shipments. You may ship multiple 
specimen types and subjects together, but keep time points and subjects grouped 
together (i.e. all pre -treatment samples grouped  together for one subject; all C2D1 
samples for one subject grouped together).  
All biospecimens will be shipped to:  
Regina Santella Laboratory  
Attn: Irina Gurvich  
Columbia University Medical Center  
630 West 168th St Room 16 -410 
New York, NY 10032  
Phone: 212-305-8158 
Keep a copy or multiples copies of this document on site with study subject records.  
Send shipments on dry ice for overnight delivery.  
 
Subject 
ID Whole 
Blood Plasma 
CRP Serum Plasma Total # of 
cryovials Comments  
  Pre-
treatment   Pre-
treatment  
 C2D1  Pre-
treatment  
 C2D1  Pre-
treatment  
 C2D1   
  Pre-
treatment   Pre-
treatment  
 C2D1  Pre-
treatment  
 C2D1  Pre-
treatment  
 C2D1   
  Pre-
treatment   Pre-
treatment  
 C2D1  Pre-
treatment  
 C2D1  Pre-
treatment  
 C2D1   
  Pre-
treatment   Pre-
treatment  
 C2D1  Pre-
treatment  
 C2D1  Pre-
treatment  
 C2D1   
  Pre-
treatment   Pre-
treatment  
 C2D1  Pre-
treatment  
 C2D1  Pre-
treatment  
 C2D1   
Use additional shipping documents if needed.  
Date  Name of person responsible for this shipment  
  
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  85 VII. Shipping Document for PKâ€™s  
 
Ship PKâ€™s directly to Incyte for processing.  
Ship same day if possible on dry ice or store in -80 freezer until ready for shipment.  
All PKâ€™s will be shipped to:  
Thomas Emm  
Sr. Director, Drug Metabolism and Biopharmaceutics  
Incyte Corporation  
1801 August ine Cut Off  
Wilmington, DE 19803  
 
Email temm@incyte.com and smalhotra@incyte.com with tracking information to 
inform them of incoming samples  
Keep a copy of this document on site with study subject records.  
Sites should use th eir own courier services for this activity.  
Send shipments on dry ice for overnight delivery; shipments may be completed 
Monday to Thursday only as Saturday delivery is not available.  
 
Subject 
ID Plasma PK  
 Number of tubes 
being sent  Comments  
  C2D1 only prior to 
treatment   
  C2D1 only prior to 
treatment   
  C2D1 only prior to 
treatment   
Use additional shipping documents if needed.  
Date  Name of person responsible for this shipment  
  
 
 
 
 
 
 
 
 
 
 
 
  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  86  HERBERT IRVING COMPREHENSIVE 
CANCER CENTER  
Data and Safety Monitoring Committee  
 
SERIOUS ADVERSE EVENT REPORTING FORM  
 
1 â€“ Trial Information  
SPONSOR   
OVERALL PRINCIPAL INVESTIGATOR   
LOCAL  PRINCIPAL INVESTIGATOR    
IRB NUMBER   
STUDY TITLE   
Study team member reporting event   
 
 
2 â€“ Type of event   
Are you reporting a UP ? (Unanticipated Problem ) Yes  No  
 
3 â€“ SAE report type   
Report type  Initial notification   Follow up   
 
 
4 â€“ Timeline of the event  
Date Investigator informed   Date of report   
Date of Onset   Date Resolved     
 
5 â€“ Participant information  
SUBJECT  ID NUMBER   Age  Gender  Male   Female   
 
6 â€“ Description of the Event (s)  
Seriousness  Causality  Expectedness  
Death   Not related   Expected   
Life threatening   Unlikely   Not expected   
Hospitalization or prolongation of hospital stay   Possibly    
Persistent or significant disability or incapacity   Probably    
Congenital abnormality or birth defect   Definitely    
Otherwise considered serious    
Primary Diagnosis  
CTCAE term for Primary SAE   Grade  Attribution  
Start date of Primary SAE   End date of Primary AE   
Secondary SAEs during hospitalization/prolongation of hospitalization (if applicable)  
CTCAE term  Grade  Start date of AE  End date of AE  Attribution  Comments  
      
      
      
      

Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  87 Brief description and treatment of events  
 
 
 
Outcome  
Fatal   On-going   Recovered with 
sequelae   Recovered   
If recovered  (or recovered with sequelae ) selected, enter date of recovery   
If fatal  enter date of death   
Cause of death:  
 
 
 
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
v. 6/16/15  88  
 
 7 â€“ Medication details  
Information about the CHEMOTHERAPY / STUDY DRUG  
Drug  (please specify action taken next to the agent) Legend is in the last column  Dose  Route  Start date  Stop date  Action  Taken  
     
1- Dose stopped  
2- Dose reduced  
3- Dose unchanged  
4- Dose increased       
     
     
Relevant Concomitant Medication  
Drug  (please specify action taken)  Indication  Dose  Route  Start date  Stop date  Action  Taken  
      1- Dose stopped  
2- Dose reduced  
3- Dose unchanged  
4- Dose increased  
5- N/A 
       
      
      
Other clinical information, including relevant tests (laboratory, CT, ECG etc.) **Please include relevant redacted source documentation.  
 
 
 
 
 
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
 89  
 
 
 
 
 CONTACT DETAILS  
Clinical Research Coordinato r or 
Research Nurse   
Signature  and date   
Email   
Fax  
Telephone   
CONTACT DETAILS  
CUMC Principal Investigator  or  
Co-Investigator providing 
coverage   
Signature  and date   
Email   
Fax  
Telephone   
CONTACT DETAILS  
Sub-Site Principal Investigator   
Signature  and date   
Email   
Fax  
Telephone   
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 90 of 96 
 APPENDIX G : GUIDELEINES FOR AFFI LIATE INSTITUTIONS I N MULTICENTER 
STUDIES  
 
 
1. Multi-site Communication:  
The CPDM office at CUMC provides administration, data management, and organizational 
support for the affiliate sites in the conduct of a multicenter clinical trial.  The CPDM office will 
coordinate  regularly scheduled  conference calls with affiliate sites.  
The following issues will be discussed as appropriate:  
ï‚· Enrollment information  
ï‚· Cohort updates (i.e. DLTs)  
ï‚· Adverse events (i.e. new adverse events and updates on unresolved adverse events and 
new safety information)  
ï‚· Protocol violations  
ï‚· Other issues affecting the conduct of the study  
 
2. New Protoc ol Distribution, IRB Submission, Modifications and Annual Renewals  
ï‚· Protocol specific documents are distributed to affiliate sites once CUMC IRB approval 
has been obtained.  
ï‚· The affiliate site must submit a draft of site specific revisions to protocol and/o r consent 
form documents for review and approval by the sponsor -investigator prior to submission 
to the local IRB. Draft documents should be sent to the study specific email address. The 
site will be provided confirmation that they are approved to submit t o their local IRB.  
ï‚· Protocol amendments must be approved by the affiliate siteâ€™s local IRB within 90 days of 
distribution to the site by the sponsor -investigator.  
 
3. Regulatory Documents:  
3.1 Prior to Site Initiation:  
Sponsor-Investigator will ensure that proper requests are made of sites and that the following 
documentation is collected prior to the initiation of an affiliate site.   
ï‚· CV of PI, Sub -Iâ€™s and other research staff listed on FDA 1572 (signed and dated copy 
within 2 years)  
ï‚· Medical Licenses of PI and Sub -Iâ€™s (current copy)  
ï‚· Human subjects training certificates for PI and Sub -Iâ€™s 
ï‚· CLIA/Laboratory  Certifications for Local Laboratories listed on FDA 1572  
ï‚· Local Laboratory Directorâ€™s CV and License  
ï‚· Local Laboratory R eference Ranges  
ï‚· IRB roster or statement of compliance  
ï‚· FDA Form 1572, if applicable (wet ink originals required)  
ï‚· Financial Disclosure forms for all members listed on FDA 1572 (wet ink originals 
required) 
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 91 of 96 
 3.2 Ongoing Regulatory Documentation:  Sponsor -Investigator will ensure that proper requests 
are made of sites and that the following documentation is collected throughout the course of the 
study. 
ï‚· IRB approval letters for all protocol modifications and all renewals  
ï‚· IRB-approved consent forms  
ï‚· Current IRB ro ster, if statement of compliance is not provided as part of site initiation  
ï‚· FDA Form 1572, if applicable as updates are required  
ï‚· Updated investigator and site information where relevant (e.g., CV, medical licensure 
and Financial Disclosure for new sub-investigator, local laboratory information)  
 
Regulatory documents may be sent to M1906@columbia.edu  or to the following address if wet 
ink originals are required:  
 
Clinical Protocol & Data Management Office  
161 Fort Washington Ave.  
Herbert Irving Pavilion  
Mezzanine Level, M -203 
New York, NY 10032  
 
4. Protocol Deviation/Subject Waiver request for Affiliate Sites:  
The Affiliate site MUST submit a prospective deviation request to the CUMC lead PI for review 
and submis sion to the HICCC DSMC and CUMC IRB. Approvals must be obtained from all 
entities prior to implementation at the Affiliate site.  If a prospective protocol deviation request is 
submitted for review (from an Affiliate site), the PI/site memo(s), HICCC DSMC approval(s) and 
correspondence and CUMC IRB eligibility deviation approval letter(s) should be forwarded to the 
Affiliate site for documentation. The Affiliate site is also required to obtain prospective local IRB 
approval as per institutional policies/pro cedures prior to implementing the proposed deviation and 
registering/enrolling the subject via CUMC Central Registration. All documents and 
determinations must be clearly documented in the study subjectâ€™s medical record, research chart 
and regulatory binde r, as described.  
 
 
5. Guidelines for Affiliate Site Monitoring  
 
6.1 On-Site MCT Monitoring:  
1. Initial, recurrent, and close -out on-site monitoring visits will also be conducted at 
Affiliate sites, as appropriate/feasible. Other sites will have monitoring performed 
remotely (see below for further details).  
ï‚· The study Monitoring Visit Log will be completed and signed by the 
monitor and the PI/CRNP/CRN and/or CRC and will be filed in the 
regulatory binder.  
 
2. The Compliance Coordinator will communicate with the Affiliate site coordinator/Site  
 Principle Investigator to schedule the monitoring visit and arrange for access to study 
materials and documentation.  
 
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 92 of 96 
 3. The Compliance Coordinator will monitor IIT trials within 1 month after the first subject 
is enrolled at the Affiliate site and throughout the life of the study to ensure that the study 
is being conducted in accordance with the protocol, GCP, applicable federal and local 
regulations, and per all applicable SOPs. The Compliance Coordinator is responsible to 
notify the participating site PI and CRNP/CRN/CRC of upcoming monitor visits and 
convey what information and documentation will be required for the visit(s).  The 
Compliance Coordinator is responsible for verifying that informed consent is properly 
obtained, eligibility is met (via the central registration process), and all study procedures 
are conducted according to the study protocol. The Compliance Coordinator will also 
verify that the data reported in the CRFâ€™s accurately reflect source documents, that al l 
toxicities have been reported to date, and that all SAEâ€™s/UPs/deviations/violations have 
been reported according to Coordinating Center, local IRB and HICCC DSMC 
requirements. The Compliance Coordinator will issue queries and ensure resolution in a 
timely and efficient manner.  The Compliance Coordinator will also monitor for 
applicable regulatory compliance and research pharmacy compliance (if applicable) and 
communicate any deficiencies as appropriate.  
 
4. An SIV (or) teleconference will be scheduled and c onducted prior to study drug being 
made available (if applicable) and before any subjects are enrolled on a study at the 
Affiliate site.  
 
6.2 MCT Remote Monitoring:  
 
1. When necessary (due to logistical constraints), Affiliate sites will be monitored 
remotely by a designated Compliance Coordinator. Sites will be informed of this remote 
monitoring process on a site by site basis.  
 
2. Affiliate sites will be monitored by the Compliance Coordinator on both a regulatory 
level, as well as a clinical data/so urce documentation review level.  
 
3. Redacted source documents (applicable to supporting the protocol specific CRF data 
requirements) will be sent to the designated Compliance Coordinator via fax or secure email 
for all subjects enrolled at Affiliate sites . Timelines for submission procedures will be 
defined on a case -by-case basis.   
 
4. The Compliance Coordinator will review all submitted redacted source documents 
against the data entered on the protocol specific CRFs. The Compliance Coordinator will 
issue queries when/if necessary.  
 
5. The Affiliate site research staff will respond to queries within 30 days. If queries remain  
outstanding, the Compliance Coordinator will send a delinquent query reminder for the 
outstanding items.  
 
3. The remote monitoring proced ures will include review of applicable redacted source 
documentation and supporting applicable documents to determine compliance regarding:  
ï‚· Informed consent procedures  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 93 of 96 
 ï‚· Eligibility criteria  
ï‚· Protocol specific treatment compliance  
ï‚· Protocol specific toxicity/o utcome documentation/compliance  
ï‚· Protocol specific schedule of events (e.g., baseline visits, pre -treatment, on 
study, follow -up) 
ï‚· Participating site IRB documents (e.g., IRB amendment approvals, annual 
renewals, SAE/UP submissions, violation/deviation submi ssions, INDSR 
submissions, etc).  
ï‚· Required specimen submissions (e.g., tissue specimens, research blood 
specimens, etc.)  
ï‚· Pharmacy accountability records  
ï‚· Adherence to the CRF submission timeframes to CUMC (within the 
protocol specified timeframes)  
 
4. Affiliate site remote monitoring reports will be sent to the lead PI, HICCC DSMC, and 
Affiliate sites after each remote monitoring review. Reports will include information 
regarding data submission timeliness/accuracy, protocol adherence items, query 
resolution sta tus, regulatory status, and overall Affiliate site performance. These reports 
will be generated by the Compliance Coordinator and reviewed with the Compliance 
Core Manager prior to dissemination.  
 
 
6. Dose Level Determinations:  
 
The sponsor -investigator will review enrollment for each dose level cohort during the regularly 
scheduled conference call with the affiliate sites.  
 
The dose level for newly enrolled subjects will be determined by the study statistician upon 
notification that a subject has signed informed consent to participate in the study. The assigned 
dose level for any subject to begin study treatment will be commu nicated to the affiliate site 
along with the determination by Central Registration that the subject is eligible for enrollment in 
the study.  
 
If a Dose Limiting Toxicity (DLT) is identified in a subject, the affiliate site must notify the 
sponsor-investigator via email at the study specific email address within 1 business day of 
identification. The lead site will communicate that a DLT has been experienced within 1 
business day.  
 
 
7. Confidentiality  
Each affiliate site will be assigned a site number. Each su bject that signs consent should be 
assigned a unique code number consisting of site number followed by a number with each new 
subject being assigned the next sequential number (e.g. 04 -10). All sites will be required to enter 
their data in the Velos eResea rch, the Clinical Trial Management System used for all Cancer -
related clinical research at CUMC. All users must login with their own application username and 
password.  Users off campus must first access the Virtual Private Network with their assigned 
campus username and password and then use their application credentials.   
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 94 of 96 
  
Subject confidentiality must be maintained accordi ng to HIPAA regulations and GCP 
recommendations.  
 
Except when required by law, study information shared with persons and organizations outside 
of Columbia University Medical Center must not identify the patient by name, social security 
number, address, telephone number, or any other direct personal identifier.  
If the results of this research project are published or presente d at a scientific or medical meeting, 
the patient not be identified. Otherwise, all results will be kept confidential and will not be 
divulged (except as required by law) without permission.  
 
Data Reporting Plan  
Columbia University Medical Center (CUMC) i s deeply committed to research integrity and 
strong credibility when it comes to the discovery of new treatment concepts, implementation of 
new clinical research techniques, and acceptance of its researcher's findings by the medical 
establishment. In accor d with these ethics, CUMC encourages and supports its investigators in 
the sharing of final research data and/or details of newly developed clinical treatments.  
 
CUMC's policies that pertain to patient data sharing conform to CUMC IRB rules, local and stat e 
laws, and HIPAA privacy regulations. The primary reason for this is to protect the privacy of 
patients who participate in clinical trials. The data can be made available for continuing review 
by federal agencies upon request and for ongoing study safety reviews by the Principal 
Investigator, Statistician, Data Safety and Monitoring Board (DSMC), and, in other instances, 
the CUMC IRB.  
 
Data collected during the course of this clinical trial will primarily be shared with other 
investigators and University s taff, the IRB, FDA, and other reporting agencies, and/or transferred 
to other collaborators.  Prior to transfer, the data collected must comply with, and must be 
limited by, the CUMC's guidelines for Protecting the Rights and Privacy of Human Subjects.   
 
Data Acquisition and Submission  
Informed consent, including HIPPA authorization, must be obtained on all subjects prior to their 
participation. Always keep the original signed and dated consent form, with the redacted source 
documents and eligibility check list. Velos eResearch will be used as the electronic clinical trials 
and data management system. Affiliate sites will enter data directly into Velos eResearch via 
customized case report forms for the study. The research staff will generate reports from Vel os 
eResearch to ensure timely submission of data by affiliate sites. This resource allows for the 
timely analysis of particular data sets for safety analysis.  
 
  
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 95 of 96 
 APPENDIX H: DRUG ORDER FORM  
 
Completed Form should be e -mailed to: gmb-pci-clinicalrequests@catalent.com  and cc: 
Evyonne.Shands@catalent.com   or fax to (215)613 -3360.  
INVESTIGATIONAL SUPPLIES SHIPMENT AND RECEI PT VERIFICATION FORM  
Incyte: Protocol: I-RUX -13-02 (Site Protocol  # AAAM1906)  
Section I : (PRINT/TYPE)  
Authorized 
Requestor:  Sales Order #:  9015870  Todayâ€™s Date:  
 
 
Date needed on site:  
 Domestic Carrier: Catalent 
Preferred Carrier  
Site No.: 1  Investigator Information:  
Full Ship To Address: (No P.O. Boxes ) Name:  
 Attention to:   
  
  Telephone:    
Authorized Requestor:  Date:  
  
Description    Catalent  Part # Quantity  
Requested  to 
Ship  
I-RUX-13-02 5MG 60CT BT  
LABELED  CLR-FG-9015870-001  
       
1.0 Attachment 3  Shipment Checklist  Section II:  (to be completed by Pharmacy, Site Coordinator or Investigator)  
 
Date Shipment 
Received:  
  Inventoried By:   
Discrepancies:    
Authorized Site 
Signature:  
  Date:   
Upon Receipt, please conduct an inventory of the above shipment and file a 
copy  of this form with the drug accountability records.  
      
Local Protocol#:  AAAM1906  
Version Date: September  19, 2019 
 
Page 96 of 96 
    
Incyte Corporation  
 I-RUX -13-02 
Pack Slip#:  SO#: 9015870  Consign#  
Shipment Condition: Ambient  
 Carrier: FedEx  
 
Documents Included w/shipment:  
ï‚† Packing Slip  
ï‚† Shipment Request Form  
  
International Requirements: N/A  
 
Shipping Timelines:  
ï‚· 48 hour turnaround unless expedited services requested by client.  
 
Special Instructions:  
 
Study Material is CL1  
 
 
 
Packout: Standard Corrugated Shipper  
 
 
 
 
 
 
 
 
